0001628280-23-027203.txt : 20230803 0001628280-23-027203.hdr.sgml : 20230803 20230803160728 ACCESSION NUMBER: 0001628280-23-027203 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 231139921 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 10-Q 1 abt-20230630.htm 10-Q abt-20230630
000000180012-312023Q2falseP12M42600000018002023-01-012023-06-300000001800exch:XCHI2023-01-012023-06-300000001800exch:XNYS2023-01-012023-06-3000000018002023-06-30xbrli:shares00000018002023-04-012023-06-30iso4217:USD00000018002022-04-012022-06-3000000018002022-01-012022-06-30iso4217:USDxbrli:shares00000018002022-12-310000001800us-gaap:CommonStockMember2023-03-310000001800us-gaap:CommonStockMember2022-03-310000001800us-gaap:CommonStockMember2023-04-012023-06-300000001800us-gaap:CommonStockMember2022-04-012022-06-300000001800us-gaap:CommonStockMember2023-06-300000001800us-gaap:CommonStockMember2022-06-300000001800us-gaap:TreasuryStockCommonMember2023-03-310000001800us-gaap:TreasuryStockCommonMember2022-03-310000001800us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000001800us-gaap:TreasuryStockCommonMember2022-04-012022-06-300000001800us-gaap:TreasuryStockCommonMember2023-06-300000001800us-gaap:TreasuryStockCommonMember2022-06-300000001800us-gaap:RetainedEarningsMember2023-03-310000001800us-gaap:RetainedEarningsMember2022-03-310000001800us-gaap:RetainedEarningsMember2023-04-012023-06-300000001800us-gaap:RetainedEarningsMember2022-04-012022-06-300000001800us-gaap:RetainedEarningsMember2023-06-300000001800us-gaap:RetainedEarningsMember2022-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000001800us-gaap:NoncontrollingInterestMember2023-03-310000001800us-gaap:NoncontrollingInterestMember2022-03-310000001800us-gaap:NoncontrollingInterestMember2023-04-012023-06-300000001800us-gaap:NoncontrollingInterestMember2022-04-012022-06-300000001800us-gaap:NoncontrollingInterestMember2023-06-300000001800us-gaap:NoncontrollingInterestMember2022-06-300000001800us-gaap:CommonStockMember2022-12-310000001800us-gaap:CommonStockMember2021-12-310000001800us-gaap:CommonStockMember2023-01-012023-06-300000001800us-gaap:CommonStockMember2022-01-012022-06-300000001800us-gaap:TreasuryStockCommonMember2022-12-310000001800us-gaap:TreasuryStockCommonMember2021-12-310000001800us-gaap:TreasuryStockCommonMember2023-01-012023-06-300000001800us-gaap:TreasuryStockCommonMember2022-01-012022-06-300000001800us-gaap:RetainedEarningsMember2022-12-310000001800us-gaap:RetainedEarningsMember2021-12-310000001800us-gaap:RetainedEarningsMember2023-01-012023-06-300000001800us-gaap:RetainedEarningsMember2022-01-012022-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000001800us-gaap:NoncontrollingInterestMember2022-12-310000001800us-gaap:NoncontrollingInterestMember2021-12-310000001800us-gaap:NoncontrollingInterestMember2023-01-012023-06-300000001800us-gaap:NoncontrollingInterestMember2022-01-012022-06-3000000018002021-12-3100000018002022-06-30abt:segment0000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMembercountry:US2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMembercountry:US2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:OtherEmergingMarketsMember2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:OtherEmergingMarketsMember2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2023-04-012023-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2022-04-012022-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2023-04-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2022-04-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-04-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-04-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:CoreLaboratoryMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:CoreLaboratoryMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMembercountry:US2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMembercountry:US2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMembercountry:US2023-04-012023-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMembercountry:US2022-04-012022-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMembercountry:US2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMembercountry:US2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800abt:ElectrophysiologyMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800abt:ElectrophysiologyMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800us-gaap:NonUsMemberabt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800us-gaap:NonUsMemberabt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800abt:StructuralHeartMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800abt:StructuralHeartMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800abt:NeuromodulationMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800abt:NeuromodulationMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800abt:DiabetesCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800abt:DiabetesCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-04-012023-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-04-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-04-012022-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800us-gaap:CorporateNonSegmentMembercountry:US2023-04-012023-06-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-04-012023-06-300000001800us-gaap:CorporateNonSegmentMember2023-04-012023-06-300000001800us-gaap:CorporateNonSegmentMembercountry:US2022-04-012022-06-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2022-04-012022-06-300000001800us-gaap:CorporateNonSegmentMember2022-04-012022-06-300000001800country:US2023-04-012023-06-300000001800us-gaap:NonUsMember2023-04-012023-06-300000001800country:US2022-04-012022-06-300000001800us-gaap:NonUsMember2022-04-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMembercountry:US2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMembercountry:US2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMember2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:OtherEmergingMarketsMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:OtherEmergingMarketsMember2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMember2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:CoreLaboratoryMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:USabt:CoreLaboratoryMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMembercountry:US2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMembercountry:US2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMembercountry:US2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMembercountry:US2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMemberabt:RapidDiagnosticsMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800abt:DiagnosticProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800abt:ElectrophysiologyMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800abt:ElectrophysiologyMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800us-gaap:NonUsMemberabt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800us-gaap:NonUsMemberabt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:VascularMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800abt:StructuralHeartMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800abt:StructuralHeartMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:StructuralHeartMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800abt:NeuromodulationMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800abt:NeuromodulationMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:NeuromodulationMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800abt:DiabetesCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800abt:DiabetesCareMemberus-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:DiabetesCareMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-01-012023-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2022-01-012022-06-300000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800us-gaap:CorporateNonSegmentMembercountry:US2023-01-012023-06-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-01-012023-06-300000001800us-gaap:CorporateNonSegmentMember2023-01-012023-06-300000001800us-gaap:CorporateNonSegmentMembercountry:US2022-01-012022-06-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2022-01-012022-06-300000001800us-gaap:CorporateNonSegmentMember2022-01-012022-06-300000001800country:US2023-01-012023-06-300000001800us-gaap:NonUsMember2023-01-012023-06-300000001800country:US2022-01-012022-06-300000001800us-gaap:NonUsMember2022-01-012022-06-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:HeartFailureMemberabt:MedicalDevicesMember2022-04-012022-06-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2022-04-012022-06-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2022-01-012022-06-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:HeartFailureMemberabt:MedicalDevicesMember2022-01-012022-06-300000001800abt:DiagnosticProductsMember2023-06-300000001800abt:MedicalDevicesMember2023-06-3000000018002023-07-012023-01-012023-06-30xbrli:pure00000018002023-07-012023-06-3000000018002025-07-012023-01-012023-06-3000000018002025-07-012023-06-300000001800us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-06-300000001800us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-06-300000001800us-gaap:EquitySecuritiesMember2023-06-300000001800us-gaap:EquitySecuritiesMember2022-12-310000001800us-gaap:OtherInvestmentsMember2023-06-300000001800us-gaap:OtherInvestmentsMember2022-12-310000001800us-gaap:EquitySecuritiesMemberabt:StJudeMedicalMember2023-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-012023-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-04-012022-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-012022-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-06-300000001800abt:CardiovascularSystemsIncMember2023-04-270000001800abt:CardiovascularSystemsIncMember2023-04-272023-04-270000001800abt:CardiovascularSystemsIncMember2023-01-012023-06-300000001800abt:EstablishedPharmaceuticalProductsMember2023-06-300000001800abt:NutritionalProductsMember2023-06-300000001800abt:CardiovascularSystemsIncMember2023-04-012023-06-300000001800abt:MedicalDevicesMember2023-04-012023-06-300000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2023-01-012023-06-300000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMemberabt:CostOfGoodsAndServicesSoldMember2023-01-012023-06-300000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300000001800us-gaap:SellingGeneralAndAdministrativeExpensesMemberabt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2023-01-012023-06-300000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2022-12-310000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2023-06-300000001800us-gaap:EmployeeStockOptionMember2023-01-012023-06-300000001800abt:RestrictedStockAwardsMember2023-01-012023-06-300000001800us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300000001800us-gaap:EmployeeStockOptionMember2023-06-300000001800abt:A255LongTermNotesDue2022Member2022-03-152022-03-150000001800abt:A255LongTermNotesDue2022Member2022-03-150000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-06-300000001800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-06-300000001800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800abt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-12-310000001800abt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-06-300000001800abt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2023-06-300000001800abt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberabt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberabt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberabt:PrepaidExpensesAndOtherReceivablesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberabt:PrepaidExpensesAndOtherReceivablesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800us-gaap:NondesignatedMemberabt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMember2023-06-300000001800us-gaap:NondesignatedMemberabt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800us-gaap:NondesignatedMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMember2023-06-300000001800us-gaap:NondesignatedMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800us-gaap:DebtMemberabt:LongTermDebtExcludingCurrentMaturitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2023-06-300000001800us-gaap:DebtMemberabt:LongTermDebtExcludingCurrentMaturitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-12-310000001800us-gaap:ForeignExchangeForwardMemberabt:CostOfGoodsAndServicesSoldMember2023-04-012023-06-300000001800us-gaap:ForeignExchangeForwardMemberabt:CostOfGoodsAndServicesSoldMember2022-04-012022-06-300000001800us-gaap:ForeignExchangeForwardMemberabt:CostOfGoodsAndServicesSoldMember2023-01-012023-06-300000001800us-gaap:ForeignExchangeForwardMemberabt:CostOfGoodsAndServicesSoldMember2022-01-012022-06-300000001800us-gaap:DebtMember2023-04-012023-06-300000001800us-gaap:DebtMember2022-04-012022-06-300000001800us-gaap:DebtMember2023-01-012023-06-300000001800us-gaap:DebtMember2022-01-012022-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-04-012023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2022-04-012022-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-01-012023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2022-01-012022-06-300000001800us-gaap:ForeignExchangeForwardMember2023-04-012023-06-300000001800us-gaap:ForeignExchangeForwardMember2022-04-012022-06-300000001800us-gaap:ForeignExchangeForwardMember2023-01-012023-06-300000001800us-gaap:ForeignExchangeForwardMember2022-01-012022-06-300000001800us-gaap:EquitySecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000001800us-gaap:EquitySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000001800us-gaap:EquitySecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000001800us-gaap:EquitySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2023-06-300000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2022-12-310000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeForwardMember2023-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800us-gaap:ForeignExchangeForwardMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:FairValueMeasurementsRecurringMember2023-06-300000001800us-gaap:FairValueInputsLevel1Member2023-06-300000001800us-gaap:FairValueInputsLevel2Member2023-06-300000001800us-gaap:FairValueInputsLevel3Member2023-06-300000001800us-gaap:FairValueMeasurementsRecurringMember2022-12-310000001800us-gaap:FairValueInputsLevel1Member2022-12-310000001800us-gaap:FairValueInputsLevel2Member2022-12-310000001800us-gaap:FairValueInputsLevel3Member2022-12-310000001800srt:MinimumMemberabt:LegalProceedingsAndEnvironmentalExposuresMember2023-06-300000001800abt:LegalProceedingsAndEnvironmentalExposuresMembersrt:MaximumMember2023-06-300000001800abt:LegalProceedingsAndEnvironmentalExposuresMember2023-06-300000001800us-gaap:PensionPlansDefinedBenefitMember2023-04-012023-06-300000001800us-gaap:PensionPlansDefinedBenefitMember2022-04-012022-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-04-012023-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-04-012022-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-06-300000001800us-gaap:OperatingSegmentsMember2023-04-012023-06-300000001800us-gaap:OperatingSegmentsMember2022-04-012022-06-300000001800us-gaap:OperatingSegmentsMember2023-01-012023-06-300000001800us-gaap:OperatingSegmentsMember2022-01-012022-06-300000001800us-gaap:MaterialReconcilingItemsMember2023-04-012023-06-300000001800us-gaap:MaterialReconcilingItemsMember2022-04-012022-06-300000001800us-gaap:MaterialReconcilingItemsMember2023-01-012023-06-300000001800us-gaap:MaterialReconcilingItemsMember2022-01-012022-06-300000001800abt:NutritionalProductsMember2022-04-012022-06-300000001800abt:NutritionalProductsMember2022-01-012022-06-300000001800abt:AndreaFWainerMember2023-01-012023-06-300000001800abt:AndreaFWainerMember2023-04-012023-06-300000001800abt:AndreaFWainerTradingArrangementCommonStockMemberabt:AndreaFWainerMember2023-06-300000001800abt:AndreaFWainerTradingArrangementStockOptionsMemberabt:AndreaFWainerMember2023-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation
I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABT
New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer x
Accelerated Filer o
Non-Accelerated Filer o
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of June 30, 2023, Abbott Laboratories had 1,735,357,980 common shares without par value outstanding.


Abbott Laboratories
Table of Contents
2



Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended Six Months Ended
June 30June 30
2023202220232022
Net sales$9,978 $11,257 $19,725 $23,152 
Cost of products sold, excluding amortization of intangible assets4,483 4,933 8,814 9,920 
Amortization of intangible assets498 507 989 1,019 
Research and development715 684 1,369 1,381 
Selling, general and administrative2,740 2,757 5,502 5,544 
Total operating cost and expenses8,436 8,881 16,674 17,864 
Operating earnings1,542 2,376 3,051 5,288 
Interest expense159 132 312 263 
Interest (income)(98)(26)(199)(40)
Net foreign exchange (gain) loss21  27 (3)
Other (income) expense, net(176)(82)(287)(160)
Earnings before taxes1,636 2,352 3,198 5,228 
Taxes on earnings261 334 505 763 
Net Earnings$1,375 $2,018 $2,693 $4,465 
Basic Earnings Per Common Share$0.79 $1.15 $1.54 $2.53 
Diluted Earnings Per Common Share$0.78 $1.14 $1.53 $2.51 
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share1,740,359 1,753,865 1,741,051 1,757,858 
Dilutive Common Stock Options9,889 11,598 9,933 12,115 
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options1,750,248 1,765,463 1,750,984 1,769,973 
Outstanding Common Stock Options Having No Dilutive Effect5,474 5,419 5,474 2,655 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months EndedSix Months Ended
June 30June 30
2023202220232022
Net Earnings$1,375 $2,018 $2,693 $4,465 
Foreign currency translation gain (loss) adjustments(52)(315)87 (421)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(3) and $(3) in 2023 and $12 and $25 in 2022
(6)54 (4)116 
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $4 and $(54) in 2023 and $61 and $46 in 2022
26 29 (103)(27)
Other comprehensive income (loss)(32)(232)(20)(332)
Comprehensive Income$1,343 $1,786 $2,673 $4,133 
June 30,
2023
December 31,
2022
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments$(6,646)$(6,733)
Net actuarial (losses) and prior service (costs) and credits(1,497)(1,493)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other72 175 
Accumulated other comprehensive income (loss)$(8,071)$(8,051)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4

Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
June 30,
2023
December 31,
2022
Assets
Current Assets:
Cash and cash equivalents$7,835 $9,882 
Short-term investments320 288 
Trade receivables, less allowances of $485 in 2023 and $500 in 2022
6,172 6,218 
Inventories:
Finished products4,004 3,805 
Work in process845 680 
Materials2,022 1,688 
Total inventories6,871 6,173 
Prepaid expenses and other receivables2,307 2,663 
Total Current Assets23,505 25,224 
Investments799 766 
Property and equipment, at cost20,926 20,212 
Less: accumulated depreciation and amortization11,477 11,050 
Net property and equipment9,449 9,162 
Intangible assets, net of amortization9,834 10,454 
Goodwill23,258 22,799 
Deferred income taxes and other assets6,509 6,033 
$73,354 $74,438 
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable$4,211 $4,607 
Salaries, wages and commissions1,362 1,556 
Other accrued liabilities5,334 5,845 
Dividends payable886 887 
Income taxes payable273 343 
Current portion of long-term debt2,284 2,251 
Total Current Liabilities14,350 15,489 
Long-term debt14,562 14,522 
Post-employment obligations, deferred income taxes and other long-term liabilities7,038 7,522 
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
  
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2023: 1,987,181,491; 2022: 1,986,519,278
24,612 24,709 
Common shares held in treasury, at cost — Shares: 2023: 251,823,511; 2022: 248,724,257
(15,722)(15,229)
Earnings employed in the business36,355 35,257 
Accumulated other comprehensive income (loss)(8,071)(8,051)
Total Abbott Shareholders’ Investment37,174 36,686 
Noncontrolling Interests in Subsidiaries230 219 
Total Shareholders’ Investment37,404 36,905 
$73,354 $74,438 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended June 30
20232022
Common Shares:
Balance at March 31
Shares: 2023: 1,986,904,170; 2022: 1,985,525,053
$24,488 $24,304 
Issued under incentive stock programs  
Shares: 2023: 277,321; 2022: 151,682
14 10 
Share-based compensation119 125 
Issuance of restricted stock awards(9)(10)
Balance at June 30  
Shares: 2023: 1,987,181,491; 2022: 1,985,676,735
$24,612 $24,429 
Common Shares Held in Treasury:
Balance at March 31
Shares: 2023: 247,957,371; 2022: 234,582,764
$(15,307)$(13,726)
Issued under incentive stock programs  
Shares: 2023: 157,305; 2022: 135,663
10 7 
Purchased  
Shares: 2023: 4,023,445; 2022: 9,891
(425)(1)
Balance at June 30  
Shares: 2023: 251,823,511; 2022: 234,456,992
$(15,722)$(13,720)
Earnings Employed in the Business:
Balance at March 31$35,868 $33,295 
Net earnings1,375 2,018 
Cash dividends declared on common shares (per share — 2023: $0.51; 2022: $0.47)
(889)(827)
Effect of common and treasury share transactions1 1 
Balance at June 30$36,355 $34,487 
Accumulated Other Comprehensive Income (Loss):
Balance at March 31$(8,039)$(8,474)
Other comprehensive income (loss)(32)(232)
Balance at June 30$(8,071)$(8,706)
Noncontrolling Interests in Subsidiaries:
Balance at March 31$222 $230 
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases8 (4)
Balance at June 30$230 $226 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
6

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Six Months Ended June 30
20232022
Common Shares:
Balance at January 1
Shares: 2023: 1,986,519,278; 2022: 1,985,273,421
$24,709 $24,470 
Issued under incentive stock programs
Shares: 2023: 662,213; 2022: 403,314
30 24 
Share-based compensation415 449 
Issuance of restricted stock awards(542)(514)
Balance at June 30
Shares: 2023: 1,987,181,491; 2022: 1,985,676,735
$24,612 $24,429 
Common Shares Held in Treasury:
Balance at January 1
Shares: 2023: 248,724,257; 2022: 221,191,228
$(15,229)$(11,822)
Issued under incentive stock programs
Shares: 2023: 4,090,470; 2022: 4,280,139
252 230 
Purchased
Shares: 2023: 7,189,724; 2022: 17,545,903
(745)(2,128)
Balance at June 30
Shares: 2023: 251,823,511; 2022: 234,456,992
$(15,722)$(13,720)
Earnings Employed in the Business:
Balance at January 1$35,257 $31,528 
Net earnings2,693 4,465 
Cash dividends declared on common shares (per share — 2023: $1.02; 2022: $0.94)
(1,779)(1,653)
Effect of common and treasury share transactions184 147 
Balance at June 30$36,355 $34,487 
Accumulated Other Comprehensive Income (Loss):
Balance at January 1$(8,051)$(8,374)
Other comprehensive income (loss)(20)(332)
Balance at June 30$(8,071)$(8,706)
Noncontrolling Interests in Subsidiaries:
Balance at January 1$219 $222 
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases11 4 
Balance at June 30$230 $226 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
7

Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Six Months Ended June 30
20232022
Cash Flow From (Used in) Operating Activities:
Net earnings$2,693 $4,465 
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation617 626 
Amortization of intangible assets989 1,019 
Share-based compensation413 447 
Trade receivables37 (939)
Inventories(667)(1,030)
Other, net(1,736)(113)
Net Cash From Operating Activities2,346 4,475 
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment(887)(700)
Acquisitions of businesses and technologies, net of cash acquired(826) 
Proceeds from business dispositions40 48 
Sales (purchases) of other investment securities, net(7)18 
Other5 10 
Net Cash From (Used in) Investing Activities(1,675)(624)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other(29)13 
Proceeds from issuance of long-term debt1 6 
Repayments of long-term debt(2)(752)
Purchases of common shares(966)(2,312)
Proceeds from stock options exercised77 69 
Dividends paid(1,780)(1,660)
Net Cash From (Used in) Financing Activities(2,699)(4,636)
Effect of exchange rate changes on cash and cash equivalents(19)(77)
Net Increase (Decrease) in Cash and Cash Equivalents(2,047)(862)
Cash and Cash Equivalents, Beginning of Year9,882 9,799 
Cash and Cash Equivalents, End of Period$7,835 $8,937 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
8

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.


Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
9

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended June 30, 2023Three Months Ended June 30, 2022
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$ $990 $990 $ $946 $946 
Other 297 297  277 277 
Total 1,287 1,287  1,223 1,223 
Nutritionals —    
Pediatric Nutritionals507 517 1,024 413 512 925 
Adult Nutritionals374 678 1,052 348 680 1,028 
Total881 1,195 2,076 761 1,192 1,953 
Diagnostics —     
Core Laboratory311 982 1,293 287 934 1,221 
Molecular43 98 141 71 141 212 
Point of Care99 43 142 101 38 139 
Rapid Diagnostics508 233 741 1,982 740 2,722 
Total961 1,356 2,317 2,441 1,853 4,294 
Medical Devices —    
Rhythm Management269 314 583 264 284 548 
Electrophysiology245 308 553 226 260 486 
Heart Failure226 69 295 207 62 269 
Vascular264 451 715 228 425 653 
Structural Heart219 279 498 207 233 440 
Neuromodulation185 42 227 157 40 197 
Diabetes Care 505 919 1,424 399 793 1,192 
Total1,913 2,382 4,295 1,688 2,097 3,785 
Other3  3 2  2 
Total$3,758 $6,220 $9,978 $4,892 $6,365 $11,257 


10

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 3 — Revenue (Continued)
Six Months Ended June 30, 2023Six Months Ended June 30, 2022
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$ $1,902 $1,902 $ $1,852 $1,852 
Other 574 574  518 518 
Total 2,476 2,476  2,370 2,370 
Nutritionals —    
Pediatric Nutritionals966 982 1,948 751 1,021 1,772 
Adult Nutritionals727 1,368 2,095 687 1,388 2,075 
Total1,693 2,350 4,043 1,438 2,409 3,847 
Diagnostics —
Core Laboratory600 1,875 2,475 555 1,850 2,405 
Molecular90 198 288 243 389 632 
Point of Care192 84 276 192 75 267 
Rapid Diagnostics1,414 552 1,966 4,163 2,084 6,247 
Total2,296 2,709 5,005 5,153 4,398 9,551 
Medical Devices —
Rhythm Management529 581 1,110 512 560 1,072 
Electrophysiology483 575 1,058 442 529 971 
Heart Failure444 132 576 403 116 519 
Vascular482 850 1,332 437 835 1,272 
Structural Heart429 530 959 397 454 851 
Neuromodulation340 83 423 300 76 376 
Diabetes Care984 1,753 2,737 742 1,576 2,318 
Total3,691 4,504 8,195 3,233 4,146 7,379 
Other6  6 5  5 
Total$7,686 $12,039 $19,725 $9,829 $13,323 $23,152 

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $28 million of sales in the second quarter of 2022 and $57 million in the first six months of 2022 were moved from Rapid Diagnostics to Heart Failure.

Remaining Performance Obligations

As of June 30, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.2 billion in the Diagnostics segment and approximately $475 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

11

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 3 — Revenue (Continued)
Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2022$500 
Unearned revenue from cash received during the period243 
Revenue recognized related to contract liability balance(192)
Balance at June 30, 2023$551 

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended June 30, 2023 and 2022 were $1.370 billion and $2.009 billion, respectively, and for the six months ended June 30, 2023 and 2022 were $2.682 billion and $4.447 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2023 includes $290 million of pension contributions and the payment of cash taxes of approximately $837 million. The first six months of 2022 includes $348 million of pension contributions and the payment of cash taxes of approximately $657 million.

The following summarizes the activity for the first six months of 2023 related to the allowance for doubtful accounts as of June 30, 2023:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022$262 
Provisions/charges to income16 
Amounts charged off and other deductions(12)
Balance at June 30, 2023$266 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
12

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
The components of long-term investments as of June 30, 2023 and December 31, 2022 are as follows:

(in millions)June 30,
2023
December 31,
2022
Long-term Investments:
Equity securities$574 $558 
Other225 208 
Total$799 $766 

The increase in Abbott’s long-term investments as of June 30, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.

Abbott’s equity securities as of June 30, 2023 include $305 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of June 30, 2023 with a carrying value of $164 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $95 million that do not have a readily determinable fair value.

Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202320222023202220232022
Balance at March 31$(6,594)$(5,945)$(1,491)$(2,608)$46 $79 
Other comprehensive income (loss) before reclassifications(52)(315)1 13 80 45 
Amounts reclassified from accumulated other comprehensive income  (7)41 (54)(16)
Net current period comprehensive income (loss)(52)(315)(6)54 26 29 
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 
13

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)
Six Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20232022202320222023 2022
Balance at January 1$(6,733)$(5,839)$(1,493)$(2,670)$175 $135 
Other comprehensive income (loss) before reclassifications87 (421)3 30 38 11 
Amounts reclassified from accumulated other comprehensive income   (7)86 (141)(38)
Net current period comprehensive income (loss)87 (421)(4)116 (103)(27)
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.

Note 6 — Business Acquisition

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complimentary technologies to Abbott's portfolio of vascular device offerings.

The preliminary allocation of the purchase price of the acquisition resulted in the recording of a non-deductible developed technology intangible asset of $290 million; non-deductible in-process research and development of $60 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $340 million; net deferred tax assets of approximately $18 million and other net assets of approximately $143 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts.

Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $23.3 billion at June 30, 2023 and $22.8 billion at December 31, 2022. The acquisition of CSI increased goodwill by approximately $340 million and foreign currency translation adjustments increased goodwill by approximately $120 million in the first six months of 2023. The amount of goodwill related to reportable segments at June 30, 2023 was $2.7 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.7 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first six months of 2023.

14

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 7 — Goodwill and Intangible Assets (continued)
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.7 billion and $27.2 billion as of June 30, 2023 and December 31, 2022, respectively. The gross amount of amortizable intangible assets increased by $290 million due to the CSI acquisition. Accumulated amortization was $18.7 billion and $17.6 billion as of June 30, 2023 and December 31, 2022, respectively. Foreign currency translation adjustments increased intangible assets by $47 million in the first six months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026 and $1.3 billion in 2027.

Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were approximately $822 million as of June 30, 2023 and $807 million as of December 31, 2022. In the second quarter of 2023, the acquisition of CSI increased IPR&D by $60 million. This increase was partially offset by $45 million of charges recorded on the Research and development line of the Condensed Consolidated Statement of Earnings for the impairment of certain indefinite-lived intangible assets related to the Medical Devices reportable segment.

Note 8 — Restructuring Plans

In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the six months ended June 30, 2023, Abbott recorded employee related severance and other charges of approximately $49 million, of which approximately $17 million was recorded in Cost of products sold, approximately $5 million was recorded in Research and development, and approximately $27 million was recorded in Selling, general and administrative expenses. In addition, Abbott recognized fixed asset impairment charges of approximately $17 million related to these restructuring plans.

The following summarizes the activity related to these restructuring actions and the status of the related accruals as of June 30, 2023:

(in millions)Total
Accrued balance at December 31, 2022$228 
Restructuring charges in 202349 
Payments and other adjustments(120)
Accrued balance at June 30, 2023$157 


Note 9 — Incentive Stock Programs

In the first six months of 2023, Abbott granted 1,973,371 stock options, 460,447 restricted stock awards and 4,854,027 restricted stock units under its incentive stock program. At June 30, 2023, approximately 74 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at June 30, 2023 is as follows:

OutstandingExercisable
Number of shares 29,508,026 24,819,977 
Weighted average remaining life (years)
5.24.5
Weighted average exercise price $73.66 $66.04 
Aggregate intrinsic value (in millions)
$1,107 $1,101 

The total unrecognized share-based compensation cost at June 30, 2023 amounted to approximately $660 million which is expected to be recognized over the next three years.

15

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 10 — Debt and Lines of Credit

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.

Note 11 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.1 billion at June 30, 2023 and $7.7 billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At June 30, 2023 and December 31, 2022, Abbott held the gross notional amounts of $12.3 billion and $12.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $446 million as of June 30, 2023 and December 31, 2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.9 billion at June 30, 2023 and December 31, 2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

16

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2023 and December 31, 2022:

Fair Value - AssetsFair Value - Liabilities
(in millions)June 30,
2023
December 31, 2022Balance Sheet CaptionJune 30,
2023
December 31, 2022Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current$ $ Deferred income taxes and other assets$142 $136 Post-employment obligations, deferred income taxes and other long-term liabilities
Current  Prepaid expenses and other receivables11 20 Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments147 304 Prepaid expenses and other receivables129 96 Other accrued liabilities
Others not designated as hedges78 108 Prepaid expenses and other receivables62 130 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a413 446 Long-term debt
$225 $412 $757 $828 

17

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2023 and 2022.

Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023202220232022Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$90 $141 $27 $92 $63 $43 $189 $70 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary38 54 33 84 — — — — n/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(6)(47)3 (168)Interest expense

Gains of $39 million and $303 million were recognized in the three months ended June 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. A loss of $64 million and a gain of $252 million were recognized in the first six months ended June 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of June 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

June 30, 2023December 31, 2022
(in millions)Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
Long-term Investment Securities:
Equity securities$574 $574 $558 $558 
Other225 225 208 208 
Total Long-term Debt(16,846)(16,555)(16,773)(16,313)
Foreign Currency Forward Exchange Contracts:   
Receivable position225 225 412 412 
(Payable) position(191)(191)(226)(226)
Interest Rate Hedge Contracts:    
Receivable position    
(Payable) position(153)(153)(156)(156)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
18

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances
Quoted
Prices in
Active
Markets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
June 30, 2023:
Equity securities$315 $315 $ $ 
Foreign currency forward exchange contracts225  225  
Total Assets$540 $315 $225 $ 
Fair value of hedged long-term debt$2,697 $ $2,697 $ 
Interest rate swap derivative financial instruments153  153  
Foreign currency forward exchange contracts191  191  
Contingent consideration related to business combinations84   84 
Total Liabilities$3,125 $ $3,041 $84 
December 31, 2022:
Equity securities$307 $307 $ $ 
Foreign currency forward exchange contracts412  412  
Total Assets$719 $307 $412 $ 
Fair value of hedged long-term debt$2,691 $ $2,691 $ 
Interest rate swap derivative financial instruments156 156 
Foreign currency forward exchange contracts226  226  
Contingent consideration related to business combinations130   130 
Total Liabilities$3,203 $ $3,073 $130 

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The change in fair value from December 31, 2022 reflects changes in the projected timelines for events that will trigger payment of contingent consideration.

19

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)

Note 12 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $25 million to $35 million. The recorded accrual balance at June 30, 2023 for these proceedings and exposures was approximately $30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 13 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023202220232022
Service cost - benefits earned during the period$58 $94 $118 $190 $10 $12 $19 $25 
Interest cost on projected benefit obligations114 75 228 151 16 8 30 18 
Expected return on plan assets(243)(234)(485)(470)(6)(8)(12)(15)
Curtailment gain(14) (14)     
Net amortization of:
Actuarial loss, net3 57 6 116 (1)1 (1)6 
Prior service cost (credit) 1  1 (4)(6)(7)(12)
Net cost (credit)$(82)$(7)$(147)$(12)$15 $7 $29 $22 

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first six months of 2023 and 2022, $290 million and $348 million, respectively, were contributed to defined benefit plans. In the first six months of 2023 and 2022, $28 million was contributed, in each year, to the post-employment medical and dental plans.

20

Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 14 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2023 and 2022, taxes on earnings include approximately $9 million and $32 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of 2023 and 2022, taxes on earnings also include approximately $62 million and $27 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

Note 15 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.



Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2023
(Unaudited)
Note 15 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023 2022 2023 2022
Established Pharmaceutical Products$1,287 $1,223 $2,476 $2,370 $307 $258 $607 $500 
Nutritional Products2,076 1,953 4,043 3,847 308 230 688 481 
Diagnostic Products2,317 4,294 5,005 9,551 437 1,705 1,088 4,269 
Medical Devices4,295 3,785 8,195 7,379 1,385 1,160 2,463 2,243 
Total Reportable Segments9,975 11,255 19,719 23,147 2,437 3,353 4,846 7,493 
Other 3 2 6 5 
Net sales$9,978 $11,257 $19,725 $23,152 
Corporate functions and benefit plan costs(71)(123)(148)(237)
Net interest expense (61)(106)(113)(223)
Share-based compensation (a) (132)(142)(413)(447)
Amortization of intangible assets(498)(507)(989)(1,019)
Other, net (b)(39)(123)15 (339)
Earnings before taxes$1,636 $2,352 $3,198 $5,228 
______________________________________
Notes:Three and six months ended June 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three and six months ended June 30, 2023 includes costs associated with the acquisition of CSI, charges related to restructurings, and income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and six months ended June 30, 2022 includes $42 million and $162 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment as well as integration costs related to the acquisition of Alere Inc.
22

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review — Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

The following tables detail sales by reportable segment for the three and six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.

Net Sales to External Customers
(in millions)Three Months Ended
June 30, 2023
Three Months Ended
June 30, 2022
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products$1,287 $1,223 5.2 %(7.4)%12.6 %
Nutritional Products2,076 1,953 6.3 (3.0)9.3 
Diagnostic Products2,317 4,294 (46.0)(1.3)(44.7)
Medical Devices4,295 3,785 13.5 (1.9)15.4 
Total Reportable Segments9,975 11,255 (11.4)(2.5)(8.9)
Othern/mn/mn/m
Net Sales$9,978 $11,257 (11.4)(2.5)(8.9)
Total U.S.$3,758 $4,892 (23.2)— (23.2)
Total International$6,220 $6,365 (2.3)(4.4)2.1 

Net Sales to External Customers
(in millions)Six Months Ended
June 30, 2023
Six Months Ended
June 30, 2022
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products$2,476 $2,370 4.4 %(7.5)%11.9 %
Nutritional Products4,043 3,847 5.1 (3.4)8.5 
Diagnostic Products5,005 9,551 (47.6)(1.6)(46.0)
Medical Devices8,195 7,379 11.0 (2.9)13.9 
Total Reportable Segments19,719 23,147 (14.8)(2.9)(11.9)
Othern/mn/mn/m
Net Sales$19,725 $23,152 (14.8)(2.9)(11.9)
Total U.S.$7,686 $9,829 (21.8)— (21.8)
Total International$12,039 $13,323 (9.6)(5.0)(4.6)
______________________________________
Notes:The Acelis Connected Health business was internally transferred from Diagnostic Products to Medical Devices on January 1, 2023. As a result, $28 million of sales in the second quarter of 2022 and $57 million in the first six months of 2022 were moved from Diagnostic Products to Medical Devices.
In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful
23

The 8.9 percent decrease in total net sales during the second quarter of 2023, excluding the impact of foreign exchange, reflected the decrease in demand for Abbott’s rapid diagnostic tests to detect COVID-19, partially offset by higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $263 million during the second quarter of 2023 and approximately $2.3 billion during the second quarter of 2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 8.8 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 11.9 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the second quarter as the relatively stronger U.S. dollar decreased total international sales by 4.4 percent and total sales by 2.5 percent.

The 11.9 percent decrease in total net sales during the first six months of 2023, excluding the impact of foreign exchange, reflected lower demand for Abbott’s COVID-19 tests, partially offset by higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $993 million during the first six months of 2023 and approximately $5.6 billion during the first six months of 2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 6.9 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 10.6 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first six months as the relatively stronger U.S. dollar decreased total international sales by 5.0 percent and total sales by 2.9 percent.

Due to the unpredictability of demand for COVID-19 tests, the future extent to which COVID-19 will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.

The table below provides detail by sales category for the six months ended June 30, 2023. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)June 30,
2023
June 30,
2022
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products —
Key Emerging Markets$1,902 $1,852 2.7 %(8.0)%10.7 %
Other Emerging Markets574 518 10.8 (5.5)16.3 
Nutritionals —
International Pediatric Nutritionals982 1,021 (3.8)(4.5)0.7 
U.S. Pediatric Nutritionals966 751 28.6 — 28.6 
International Adult Nutritionals1,368 1,388 (1.4)(6.2)4.8 
U.S. Adult Nutritionals727 687 5.8 — 5.8 
Diagnostics —
Core Laboratory2,475 2,405 2.9 (4.4)7.3 
Molecular288 632 (54.4)(1.1)(53.3)
Point of Care276 267 3.2 (0.8)4.0 
Rapid Diagnostics1,966 6,247 (68.5)(0.6)(67.9)
Medical Devices —
Rhythm Management1,110 1,072 3.4 (2.8)6.2 
Electrophysiology1,058 971 9.0 (3.8)12.8 
Heart Failure576 519 10.9 (0.8)11.7 
Vascular1,332 1,272 4.7 (3.2)7.9 
Structural Heart959 851 12.8 (2.7)15.5 
Neuromodulation423 376 12.4 (1.4)13.8 
Diabetes Care2,737 2,318 18.1 (3.1)21.2 
Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $57 million of sales for the first six months of 2022 were moved from Rapid Diagnostics to Heart Failure.
24

Excluding the unfavorable effect of foreign exchange, sales in Key Emerging Markets for Established Pharmaceutical Products increased 10.7 percent in the first six months of 2023, led by growth in several countries, including India, China, and Brazil, and across several therapeutic areas, including women's health, respiratory, and central nervous system/pain management. Other Emerging Markets, excluding the effect of foreign exchange, increased by 16.3 percent in the first six months of 2023.

Excluding the impact of foreign exchange, total Nutritional Products sales in the first six months of 2023 increased 8.5 percent. The 28.6 percent increase in U.S. Pediatric Nutritional sales in the first six months of 2023 reflects the unfavorable impact of the voluntary recall of certain infant formula products in the first quarter of 2022 as well as progress in recovering market share in this business following the voluntary recall, partially offset by a decrease in 2023 Pedialyte® sales. Excluding the effect of foreign exchange, the 0.7 percent increase in International Pediatric Nutritional sales in the first six months of 2023 primarily reflects growth in various markets offset by the impact of exiting the pediatric nutrition business in China.

Excluding the effect of foreign exchange, the increases of 5.8 percent in U.S. Adult Nutritionals and 4.8 percent in International Adult Nutritionals in the first six months of 2023 were led by growth of Ensure® products.

The 46.0 percent decrease in Diagnostic Products sales in the first six months of 2023, excluding the impact of foreign exchange, was driven by lower demand for COVID-19 tests. In Rapid Diagnostics, sales decreased 67.9 percent in the first six months of 2023, excluding the effect of foreign exchange, due to lower demand for COVID-19 tests. In the first six months of 2023 and 2022, Rapid Diagnostics COVID-19 testing-related sales were $954 million and $5.3 billion, respectively. In the first six months of 2023, Rapid Diagnostics sales increased 3.3 percent, excluding COVID-19 testing-related sales, and increased 5.7 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

In Core Laboratory Diagnostics, sales increased 7.3 percent in the first six months of 2023, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing performed in hospitals and other laboratories, partially offset by lower test sales for the detection of COVID-19 IgG and IgM antibodies. In the first six months of 2023 and 2022, Core Laboratory Diagnostics COVID-19 testing-related sales were $11 million and $40 million, respectively. In the first six months of 2023, Core Laboratory Diagnostics sales increased 4.2 percent, excluding COVID-19 testing-related sales, and increased 8.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

The 53.3 percent decrease in Molecular Diagnostics sales in the first six months of 2023, excluding the effect of foreign exchange, was driven by lower demand for laboratory-based molecular tests for COVID-19 as well as lower demand for respiratory testing compared to significantly higher-than-usual demand in the first six months of 2022. In the first six months of 2023 and 2022, Molecular Diagnostics COVID-19 testing-related sales were $28 million and $321 million, respectively. In the first six months of 2023, Molecular Diagnostics sales decreased 16.5 percent, excluding COVID-19 testing-related sales, and decreased 14.5 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

Excluding the effect of foreign exchange, total Medical Devices sales grew 13.9 percent in the first six months of 2023, led by double-digit growth in Diabetes Care, Structural Heart, Heart Failure, Neuromodulation and Electrophysiology. Higher Diabetes Care sales were driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $2.5 billion in the first six months of 2023, which reflected a 25.1 percent increase, excluding the effect of foreign exchange, over the first six months of 2022 when FreeStyle Libre sales totaled $2.1 billion.

During the first six months of 2023, procedure volumes increased across the cardiovascular and neuromodulation businesses. In Structural Heart, the 15.5 percent increase in sales, excluding the effect of foreign exchange, reflects continued growth of the MitraClip® product along with contributions from recently launched products, including Amulet®, Navitor®, and TriClip®. In Vascular, the 7.9 percent increase in sales, excluding the impact of foreign exchange, during the first six months of 2023 reflects the acquisition of Cardiovascular Systems, Inc. (CSI) on April 27, 2023 as well as double-digit growth in endovascular sales.

In Electrophysiology, the 12.8 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher procedure volumes in the U.S., China, and various European countries. In Neuromodulation, the 13.8 percent increase in sales, excluding the effect of foreign exchange, was driven by the recent launch of the Eterna® rechargeable spinal cord stimulation system for the treatment of chronic pain along with market growth compared to the prior year period.

25

In the first six months of 2023, Medical Devices received various product approvals. In January 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) had approved Navitor, Abbott's second-generation transcatheter aortic valve implantation system to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. In March 2023, Abbott's Freestyle Libre continuous glucose monitoring system received U.S. FDA clearance for integration with automated insulin delivery systems. In March 2023, the U.S. FDA approved Abbott's Epic® Max stented tissue valve to treat people with aortic regurgitation or stenosis. In May 2023, Abbott received U.S. FDA approval of its TactiFlex® Ablation Catheter, Sensor Enabled™, the world's first ablation catheter with a flexible electrode tip and contact force sensing technology to treat patients with atrial fibrillation. In June 2023, Abbott received U.S. FDA approval of its AVEIR® dual chamber leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.

The gross profit margin percentage was 50.1 percent for the second quarter of 2023 compared to 51.7 percent for the second quarter of 2022 and 50.3 percent for the first six months of 2023 compared to 52.8 percent for the first six months of 2022. The decrease in the quarter and first six months of 2023 reflects the unfavorable effects of lower sales of COVID-19 tests, foreign exchange, and higher costs for various manufacturing inputs, partially offset by the impact in 2022 of the voluntary product recall in the Nutritional business and the impact in 2023 of gross margin improvement initiatives.

Research and development (R&D) expenses increased $31 million, or 4.5 percent, in the second quarter of 2023 and decreased $12.0 million, or 0.9 percent, in the first six months of 2023 compared to the prior year. The increase in R&D expense in the second quarter of 2023 was primarily driven by impairment charges related to in-process R&D assets acquired in previous business combinations, partially offset by the favorable impact of foreign exchange. The decrease in R&D expense in the first six months of 2023 was primarily driven by the favorable impact of foreign exchange and the level of spending on various projects, partially offset by the impairment charges recorded in the second quarter of 2023.

Selling, general and administrative expenses decreased $17 million, or 0.6 percent, in the second quarter of 2023, and decreased $42 million, or 0.8 percent, in the first six months of 2023 compared to the prior year. Higher selling and marketing spending to drive growth across various businesses was offset by the favorable impact of foreign exchange. The decrease during the first six months of 2023 also reflects the nonrecurrence of 2022 expenses related to the voluntary product recall in the Nutritional segment.

Other (Income) Expense, net

Other income, net increased from $82 million of income in the second quarter of 2022 to $176 million of income in the second quarter of 2023 and from $160 million of income in the first six months of 2022 to $287 million of income in the first six months of 2023. The increases in the second quarter and the first six months of 2023 reflect higher income in 2023 related to the non-service cost components of net pension and post-retirement medical benefit costs, as well as favorable changes in the fair value of contingent consideration liabilities related to previous business combinations.

Interest Expense, net

Interest expense, net declined $45 million in the second quarter of 2023 and $110 million in the first six months of 2023 versus 2022 due to the favorable impact of higher interest rates on interest income, partially offset by the negative impact of interest rate hedge contracts related to certain fixed-rate debt.

Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2023 and 2022, taxes on earnings include approximately $9 million and $32 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of 2023 and 2022, taxes on earnings also include approximately $62 million and $27 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

26

Liquidity and Capital Resources June 30, 2023 Compared with December 31, 2022

The decrease in cash and cash equivalents from $9.9 billion at December 31, 2022 to $7.8 billion at June 30, 2023 primarily reflects the payment of dividends, share repurchases, the cost of a business acquisition and capital expenditures, partially offset by the cash generated from operations in the first six months of 2023. Working capital was $9.2 billion at June 30, 2023 and $9.7 billion at December 31, 2022. The decrease in working capital in 2023 primarily reflects a decrease in cash and cash equivalents, partially offset by an increase in inventory and decreases in accounts payable and other accrued liabilities.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first six months of 2023 totaled approximately $2.3 billion, a decrease of $2.1 billion from the prior year. The decrease is primarily due to the decline in operating earnings and an increase in cash taxes paid. Net cash from operating activities in 2023 includes $290 million of pension contributions and the payment of cash taxes of approximately $837 million. Net cash from operating activities in 2022 includes $348 million of pension contributions and the payment of cash taxes of approximately $657 million.

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. As of June 30, 2023, $2.15 billion of the $5 billion authorization remains available.

At June 30, 2023, Abbott’s long-term debt rating was AA- by Standard & Poor’s Corporation and Aa3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.

In the first six months of 2023, Abbott repurchased approximately 7 million of its common shares for $725 million. As of June 30, 2023, $1.709 billion remains available for repurchase under the share repurchase program authorized by the board of directors in December 2021.

In each of the first two quarters of 2023, Abbott declared a quarterly dividend of $0.51 per share on its common shares, which represents an increase of 8.5 percent over the $0.47 per share dividend declared in each of the first two quarters of 2022.

Business Acquisition

On April 27, 2023, Abbott completed the acquisition of CSI for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complimentary technologies to Abbott's portfolio of vascular device offerings.

The preliminary allocation of the purchase price of the acquisition resulted in the recording of a non-deductible developed technology intangible asset of $290 million; non-deductible in-process research and development of $60 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $340 million; net deferred tax assets of approximately $18 million and other net assets of approximately $143 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts.


27

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2022 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
28

PART I. FINANCIAL INFORMATION

Item 4.     Controls and Procedures

(a)Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b)Changes in internal control over financial reporting. During the quarter ended June 30, 2023, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.     Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities

Period(a) Total
Number of
Shares (or
Units)
Purchased
(b) Average
Price Paid per
Share (or
Unit)
(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
April 1, 2023 - April 30, 2023— 
(1)
$— — $2,134,092,391 
(2)
May 1, 2023 - May 31, 20233,300,000 
(1)
106.225 3,300,000 1,783,549,041 
(2)
June 1, 2023 - June 30, 2023723,439 
(1)
102.920 723,439 1,709,092,863 
(2)
Total4,023,439 
(1)
$105.631 4,023,439 $1,709,092,863 
(2)
______________________________________
1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.
29

Item 5.    Other Information

On May 1, 2023, Andrea F. Wainer, Executive Vice President, Rapid and Molecular Diagnostics, adopted a plan for the sale of securities of Abbott that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Ms. Wainer's Rule 10b5-1 plan provides for the sale of 5,400 shares and the exercise of up to 111,606 stock options until June 30, 2024.

The Illinois Department of Commerce and Economic Opportunity designated Abbott as an Illinois High Impact Business (HIB) through June 2043. Dividends paid by a corporation that is designated as a HIB and conducts business in a foreign trade zone may be eligible for a subtraction from base income for Illinois income tax purposes.

Item 6.     Exhibits
Exhibit No.Exhibit
10.1
31.1
31.2
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1
32.2
101The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and six months ended June 30, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).
30

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By:/s/ ROBERT E. FUNCK, JR.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer
Date: August 3, 2023
31
EX-10.1 2 amendmentno1fiveyearcredit.htm EX-10.1 Document
Exhibit 10.1
EXECUTION COPY
AMENDMENT NO. 1
THIS AMENDMENT NO. 1 (this “Agreement”), dated as of May 12, 2023, is among ABBOTT LABORATORIES (the “Borrower”), the banks, financial institutions and other institutional lenders parties to the Credit Agreement referred to below (collectively, the “Lenders”) and JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”).
RECITALS
WHEREAS, the Borrower, the Lenders and the Administrative Agent are parties to that certain Five Year Credit Agreement, dated as of November 12, 2020 (as amended, modified, extended, restated, replaced, or supplemented from time to time prior to the date hereof, the “Credit Agreement”); and
WHEREAS, the Borrower has requested certain amendments to the Credit Agreement, and the parties hereto agree to such amendments as set forth in, and in accordance with the terms and conditions of, this Amendment (the Credit Agreement as so amended, the “Amended Credit Agreement”).
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1.     Defined Terms. Capitalized terms used herein but not otherwise defined herein shall have the meanings provided to such terms in the Amended Credit Agreement.
2.    Agreement. As of the Amendment Effective Date (as defined below), subject to the satisfaction of the conditions precedent set forth in Section 3 below, the Lenders and the Borrower hereby agree to amend the Credit Agreement to delete the stricken text (indicated textually in the same manner as the following example: stricken text) and to add the double-underlined text (indicated textually in the same manner as the following example: double-underlined text) as set forth in the pages of the Amended Credit Agreement attached as Exhibit A hereto.
3.     Conditions of Effectiveness. This Amendment shall become effective on and as of the date (the “Amendment Effective Date”) on which the Administrative Agent shall have received counterparts of this Amendment executed by the Borrower, each of the Lenders and the Administrative Agent.
4.     Reaffirmation; Reference to and Effect on the Loan Documents.

(a)    From and after the Amendment Effective Date, each reference in the Credit Agreement to “hereunder,” “hereof,” “this Agreement” or words of like import and each reference in the other Loan Documents to “Credit Agreement,” “thereunder,” “thereof” or words of like import shall, unless the context otherwise requires, mean and be a reference to the Amended Credit Agreement. This Amendment is a Loan Document.
(b)    The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Loan Documents, nor constitute a waiver of any provision of any of the Loan Documents.



5.    Governing Law; Jurisdiction; Consent to Service of Process; Waiver of Jury Trial, Etc.

(a)    This Amendment shall be construed in accordance with and governed by the law of the State of New York.

(b)    SECTIONS 8.08, 8.11, 8.12 AND 8.18 OF THE CREDIT AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, AS IF SUCH SECTIONS WERE SET FORTH IN FULL HEREIN.
6.     Notices. All notices hereunder shall be given in accordance with the provisions of Section 8.02 of the Amended Credit Agreement.

7.    Transition to Adjusted Term SOFR. Notwithstanding any other provision herein or in the Amended Credit Agreement, the interest on any Eurodollar Rate Advances outstanding as of immediately prior to the occurrence of the Amendment Effective Date will continue to be determined in accordance with the Credit Agreement by reference to the Eurodollar Rate, until the end of the then current Interest Period of such Eurodollar Rate Advances, at which time interest shall be determined giving effect to the Amended Credit Agreement.

[Signature Pages Follow]
2


IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above written.
ABBOTT LABORATORIES
By: /s/ John A. McCoy Jr.    
Name: John A. McCoy Jr.
Title: Vice President, Treasurer
JPMORGAN CHASE BANK, N.A.,
as Administrative Agent
By:     
Name:
Title:

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above written.
JPMORGAN CHASE BANK, N.A., as Administrative Agent and as a Lender
By: /s/ Gregory T. Martin    
Name: Gregory T. Martin
Title: Executive Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


BANK OF AMERICA, N.A., as a Lender
By: /s/ Darren Merten        
Name: Darren Merten
Title: Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


Barclays Bank PLC, as a Lender
By: /s/ Warren Veech    
Name: Warren Veech
Title: Vice President

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


Morgan Stanley Bank, N.A., as a Lender
By: /s/ Tim Kok    
Name: Tim Kok
Title: Authorized Signatory

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


BNP PARIBAS, as a Lender
By: /s/ Reid Hill    
Name: Reid Hill
Title: Managing Director
By: /s/ Michael Pearce    
Name: Michael Pearce
Title: Managing Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


Citibank, N.A., as a Lender
By: /s/ Kevin Ciok    
Name: Kevin Ciok
Title: Vice President

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


DEUTSCHE BANK AG NEW YORK BRANCH, as a Lender
By: /s/ Ming K. Chu    
Name: Ming K. Chu
Title: Director
By: /s/ Annie Chung    
Name: Annie Chung
Title: Managing Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


MUFG BANK LTD., as a Lender
By: /s/ Jack Lonker    
Name: Jack Lonker
Title: Authorized Signatory

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


SOCIETE GENERALE, as a Lender
By: /s/ Kimberly Metzger    
Name: Kimberly Metzger
Title: Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


BANCO SANTANDER, S.A., NEW YORK BRANCH, as a Lender
By: /s/ Andres Barbosa    
Name: Andres Barbosa
Title: Managing Director
By: /s/ Rita Walz-Cuccioli    
Name: Rita Walz-Cuccioli
Title: Executive Director
Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


HSBC Bank USA. National Association, as a Lender
By: /s/ Dennis Tybor    
Name: Dennis Tybor
Title: Senior Vice President #23307
Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES
INTERNAL


STANDARD CHARTERED BANK, as a Lender
By: /s/ Kristopher Tracy        
Name: Kristopher Tracy
Title: Director, Financing Solutions

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


Goldman Sachs Bank USA,
as a Lender
By: /s/ Keshia Leday        
Name: Keshia Leday
Title: Authorized Signatory

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


The Northern Trust Company, as a Lender
By: /s/ Lisa DeCristofaro    
Name: Lisa DeCristofaro
Title: SVP

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


BANCO BILBAO VIZCAYA ARGENTARIA, S.A. NEW YORK BRANCH, as a Lender
By: /s/ Brian Crowley    
Name: Brian Crowley
Title: Managing Director
By: /s/ Miriam Trautmann    
Name: Miriam Trautmann
Title: Managing Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


ING BANK N.V., DUBLIN BRANCH, as a Lender
By: /s/ Cormac Langford    
Name: Cormac Langford
Title: Director
By: /s/ Sean Hassett    
Name: Sean Hassett
Title: Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


INTESA SANPAOLO S.p.A.
New York Branch, as a Lender
By: /s/ Alessandro Toigo    
Name: Alessandro Toigo
Title: Head of Corporate Desk
By: /s/ Neil Derfler    
Name: Neil Derfler
Title: Global Relationship Manager

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


MIZUHO BANK, LTD., as a Lender
By: /s/ Tracy Rahn    
Name: Tracy Rahn
Title: Executive Director

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


ROYAL BANK OF CANADA, as a Lender
By: /s/ Scott MacVicar    
Name: Scott MacVicar
Title: Authorized Signatory

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


Svenska Handelsbanken AB (publ), New York Branch, as a Lender
By: /s/ Mark Emmett    
Name: Mark Emmett
Title: Vice President
By: /s/ Andre Bergqvist    
Name: Andre Bergqvist
Title: Vice President

Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES


U.S. BANK NATIONAL ASSOCIATION,
as a Lender
By: /s/ Michael West    
Name: Michael West
Title: Senior Vice President
Signature Page to Amendment No.1 to
Credit Agreement dated as of November 12, 2020
ABBOTT LABORATORIES

Execution Version
EXHIBIT A TO AMENDMENT NO. 1 DATED AS OF MAY 15, 2023
U.S. $5,000,000,000
FIVE YEAR CREDIT AGREEMENT
Dated as of November 12, 2020
among
ABBOTT LABORATORIES,
as Borrower,
and
VARIOUS FINANCIAL INSTITUTIONS,
as Lenders,
and
JPMORGAN CHASE BANK, N.A.,
as Administrative Agent,
and
BARCLAYS BANK PLC
BANK OF AMERICA, N.A.
and
MORGAN STANLEY SENIOR FUNDING, INC.
as Syndication Agents
JPMORGAN CHASE BANK, N.A.
BARCLAYS BANK PLC
BOFA SECURITIES, INC.
and
MORGAN STANLEY SENIOR FUNDING, INC.
Joint Lead Arrangers and Joint Book Runners




TABLE OF CONTENTS
Page
ARTICLE I
DEFINITIONS AND ACCOUNTING TERMS
SECTION 1.01    Certain Defined Terms    1
SECTION 1.02    Computation of Time Periods    24
SECTION 1.03    Accounting Terms; Interpretative Provisions    2524
SECTION 1.04    Interest Rates; LIBORBenchmark Notification    2524
SECTION 1.05    Divisions    2625
ARTICLE II
AMOUNTS AND TERMS OF THE ADVANCES
SECTION 2.01    The Advances    2625
SECTION 2.02    Making the Advances    2625
SECTION 2.03    [Reserved]    2827
SECTION 2.04    Fees    2827
SECTION 2.05    Termination, Reduction or Increase of the Commitments; Extension of the Commitment Termination Date    2827
SECTION 2.06    Repayment of Advances    30
SECTION 2.07    Interest on Advances    3130
SECTION 2.08    Interest Rate Determination    31
SECTION 2.09    Interest Elections    32
SECTION 2.10    Optional Prepayments of Advances    33
SECTION 2.11    Increased Costs; Reserves on Eurodollar Rate Loans    33
SECTION 2.12    Illegality    3534
SECTION 2.13    Payments and Computations    35
SECTION 2.14    Taxes    36
SECTION 2.15    Sharing of Payments, Etc.    4140
SECTION 2.16    Use of Proceeds    41
SECTION 2.17    Evidence of Debt    41
SECTION 2.18    Alternate Rate of Interest    42
SECTION 2.19    Defaulting Lenders    43
SECTION 2.20    Mitigation    45
ARTICLE III
CONDITIONS TO EFFECTIVENESS AND LENDING
SECTION 3.01    Conditions Precedent to Closing Date    45
SECTION 3.02    Conditions Precedent to Each Borrowing    47
i



ARTICLE IV
REPRESENTATIONS AND WARRANTIES
SECTION 4.01    Representations and Warranties of the Borrower    4847
ARTICLE V
COVENANTS OF THE BORROWER
SECTION 5.01    Affirmative Covenants    52
SECTION 5.02    Negative Covenants    55
SECTION 5.03    Financial Covenant    58
ARTICLE VI
EVENTS OF DEFAULT
SECTION 6.01    Events of Default    58
ARTICLE VII
THE AGENTS
SECTION 7.01    Authorization and Action    6160
SECTION 7.02    Administrative Agent Individually    61
SECTION 7.03    Duties of Administrative Agent; Exculpatory Provisions    61
SECTION 7.04    Reliance by Administrative Agent    62
SECTION 7.05    Delegation of Duties    63
SECTION 7.06    Resignation of Administrative Agent    63
SECTION 7.07    Non-Reliance on Administrative Agent and OtherAcknowledgments of Lenders    64
SECTION 7.08    Indemnification    6465
SECTION 7.09    Other Agents    6566
SECTION 7.10    ERISA    6566
ARTICLE VIII
MISCELLANEOUS
SECTION 8.01    Amendments, Etc.    6668
SECTION 8.02    Notices, Etc.    6769
SECTION 8.03    No Waiver; Remedies    6970
SECTION 8.04    Expenses; Indemnity    6971
SECTION 8.05    Right of Setoff    7273
SECTION 8.06    Binding Effect    7273
SECTION 8.07    Assignments and Participations    7274
SECTION 8.08    Confidentiality    7778
SECTION 8.09    Governing Law    7879
SECTION 8.10    Execution in Counterparts    7879
SECTION 8.11    Electronic Execution of Assignments and Certain Other Documents    7879
ii



SECTION 8.12    Jurisdiction, Etc.    7880
SECTION 8.13    Patriot Act Notice    7980
SECTION 8.14    No Advisory or Fiduciary Responsibility    7981
SECTION 8.15    Termination of Credit Documents    8081
SECTION 8.16    Acknowledgment and Consent to Bail-In of Affected Financial Institutions    8081
SECTION 8.17    Integration    8082
SECTION 8.18    Waiver of Jury Trial    8182

SCHEDULES

Schedule I    –        Commitments
Schedule II    –        Administrative Agent’s Office; Certain Addresses for Notices
Schedule 4.01(f)    –        Litigation

EXHIBITS

Exhibit A            –    Form of Notice of Borrowing
Exhibit B            –    Form of Assignment and Acceptance
Exhibits C-1 – C-4    –    Forms of U.S. Tax Compliance Certificate
iii



FIVE YEAR CREDIT AGREEMENT
Dated as of November 12, 2020
ABBOTT LABORATORIES, a corporation organized and existing under the Laws of the State of Illinois (the “Borrower”), the Lenders (as defined below) that are parties hereto, and JPMorgan Chase Bank, N.A. (“JPMorgan”), as administrative agent (together with any successor thereto appointed pursuant to Article VII, the “Administrative Agent”) for the Lenders, agree as follows:
ARTICLE I
DEFINITIONS AND ACCOUNTING TERMS
SECTION 1.01    Certain Defined Terms.
As used in this Five Year Credit Agreement (as amended, restated, supplemented or otherwise modified and in effect from time to time, this “Agreement”), the following terms shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined):
2018 Credit Agreement” means the Five Year Credit Agreement, dated as of November 30, 2018, by and among the Borrower, JPMorgan, as administrative agent, and the lenders party thereto.
Additional Lender” has the meaning specified in Section 2.05(c).
“Adjusted Daily Simple SOFR Rate” means an interest rate per annum equal to (a) the Daily Simple SOFR Rate, plus (b) the applicable SOFR Adjustment; provided that if the Adjusted Daily Simple SOFR Rate as so determined would be less than the Floor, such rate shall be deemed to be equal to the Floor for the purposes of this Agreement.
“Adjusted Term SOFR Rate” means for any Interest Period, an interest rate per annum equal to (a) the Term SOFR Rate for such Interest Period, plus (b) the applicable SOFR Adjustment; provided that if the Adjusted Term SOFR Rate as so determined would be less than the Floor, such rate shall be deemed to be equal to the Floor for the purposes of this Agreement.
Administrative Agent” has the meaning specified in the recital of parties to this Agreement.
Administrative Agent’s Office” means the Administrative Agent’s address and, as appropriate, account as set forth on Schedule II, or such other address or account as the Administrative Agent may from time to time notify the Borrower and the Lenders.
Administrative Questionnaire” means an administrative questionnaire in the form supplied by the Administrative Agent.



Advance” means any advance made by a Lender to the Borrower as part of a Borrowing and refers to a Base Rate Advance or a Eurodollar RateTerm Benchmark Advance or a RFR Advance (each of which shall be a “Type” of Advance).
Affected Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial Institution.
Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with such Person or is a director or officer of such Person. For purposes of this definition, the term “control” (including the terms “controlling”, “controlled by” and “under common control with”) of a Person means the possession, direct or indirect, of the power to vote 10% or more of the Voting Stock of such Person or to direct or cause the direction of the management and policies of such Person, whether through the ownership of Voting Stock, by contract or otherwise.
Agent Parties” has the meaning specified in Section 8.02(c).
Agents” means, collectively, the Administrative Agent, the Syndication Agents and the Arrangers.
Agreement Value” means, with respect to any Hedge Agreement at any date of determination, the amount, if any, that would be payable to any bank thereunder in respect of the “agreement value” under such Hedge Agreement if such Hedge Agreement were terminated on such date, calculated as provided in the International Swap Dealers Association, Inc. Code of Standard Wording, Assumptions and Provisions for Swaps, 1986 Edition.
Applicable Lending Office” means, with respect to each Lender, such Lender’s Domestic Lending Office in the case of a Base Rate Advance and such Lender’s Eurodollar Lending Office in the case of a Eurodollar Rate Advance.any Lender, the office of such Lender specified as its “Lending Office” in its Administrative Questionnaire or in the Assignment and Acceptance, pursuant to which it became a Lender, or such other office of such Lender as such Lender may from time to time specify to the Borrower and the Administrative Agent.
Applicable Margin” means, as of any date, a percentage per annum determined by reference to the Public Debt Rating in effect on such date as set forth below:
Public Debt Rating S&P/Moody’s
Applicable Margin for Eurodollar RateTerm Benchmark Advances and RFR Advances
Applicable Margin for Base Rate Advances
Level 1:AA-/Aa3 or above0.625%0.000%
Level 2:Less than Level 1 but at least A+/A10.750%0.000%
Level 3:Less than Level 2 but at least A/A20.875%0.000%
Level 4:Less than Level 3 but at least A-/A31.000%0.000%
Level 5:Less than Level 4 but at least Baa1/BBB+1.125%0.125%
Level 6:Less than Level 5 but at least Baa2/BBB1.250%0.250%
Level 7:Less than Level 61.500%0.500%
2




Applicable Percentage” means, in the case of the commitment fee paid pursuant to Section 2.04(a), as of any date, a percentage per annum determined by reference to the Public Debt Rating in effect on such date as set forth below:
Public Debt Rating S&P/Moody’sApplicable Percentage
Level 1:AA-/Aa3 or above0.045%
Level 2:Less than Level 1 but at least A+/A10.050%
Level 3:Less than Level 2 but at least A/A20.070%
Level 4:Less than Level 3 but at least A-/A30.090%
Level 5:Less than Level 4 but at least Baa1/BBB+0.100%
Level 6:Less than Level 5 but at least Baa2/BBB0.125%
Level 7:Less than Level 60.175%

Arrangers” means JPMorgan, Barclays Bank PLC, BofA Securities, Inc., and Morgan Stanley Senior Funding, Inc.
Assignment and Acceptance” means an assignment and acceptance entered into by a Lender and an Eligible Assignee, and accepted by the Administrative Agent, in substantially the form of Exhibit B hereto.
Attributable Debt” means (except as otherwise provided in this paragraph), as to any particular lease under which any Person is at the time liable for a term of more than 12 months, at any date as of which the amount thereof is to be determined (the “determination date”), the total net amount of rent required to be paid by such Person under such lease during the remaining term thereof (excluding any subsequent renewal or other extension options held by the lessee), discounted from the respective due dates thereof to the determination date at the rate of 8% per annum, compounded monthly. The net amount of rent required to be paid under any such lease for any such period shall be the aggregate amount of the rent payable by the lessee with respect to such period after excluding amounts required to be paid on account of maintenance and repairs, services, insurance, Taxes, assessments, water rates and similar charges and contingent rents (such as those based on sales or monetary inflation). If (a) any such lease is terminable by the lessee upon the payment of a penalty, (b) the terms of such lease provide that the termination right is not exercisable until after the determination date and (c) the amount of such penalty discounted to the determination date at the rate of 8% per annum compounded monthly is less than the net amount of rentals payable after the time as of which such termination could occur (the “termination time”) discounted to the determination date at the rate of 8% per annum compounded monthly, then such discounted penalty amount shall be used instead of such discounted amount of net rentals payable after the termination time in calculating the Attributable Debt for such lease. If (i) any such lease is terminable by the lessee upon the payment of a penalty, (ii) such termination right is exercisable on the determination date and (iii) the amount of the net rentals payable under such lease after the
3



determination date discounted to the determination date at the rate of 8% per annum compounded monthly is greater than the amount of such penalty, the Attributable Debt for such lease as of such determination date shall be equal to the amount of such penalty.
Available Tenor” means, as of any date of determination and with respect to the then-current Benchmark, as applicable, any tenor for such Benchmark (or component thereof) or payment period for interest calculated with reference to such Benchmark (or component thereof), as applicable, that is or may be used for determining the length of an Interest Period for any term rate or otherwise, for determining any frequency of making payments of interest calculated pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to clause (ed) of Section 2.18.

Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.
Bail-In Legislation” means, (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing Law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act of 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).
Base Rate” means, for any day, a fluctuating rate per annum equal to the highest of (a) the Federal Funds Rate plus 1/2 of 1%, (b) the rate of interest last quoted by The Wall Street Journal as the “Prime Rate” in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the “bank prime loan” rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as reasonably determined by the Administrative Agent) or any similar release by the Federal Reserve Board (as reasonably determined by the Administrative Agent), and (c) the EurodollarAdjusted Term SOFR Rate for a one monthone-month Interest Period (but not less than 0.00%) plus 1.00%as published two (2) U.S. Government Securities Business Days prior to such day (or if such day is not a U.S. Government Securities Business Day, the immediately preceding U.S. Government Securities Business Day) plus 1.00%, provided that, for the purpose of this definition, the Adjusted Term SOFR Rate for any day shall be based on the Term SOFR Reference Rate at approximately 5:00 a.m. Chicago time on such day (or any amended publication time for the Term SOFR Reference Rate, as specified by the CME Term SOFR Administrator in the Term SOFR Reference Rate methodology); provided, further, that if the Base Rate as determined pursuant to the foregoing would be less than zero, such rate shall be deemed to be zero for purposes of this Agreement. If the Base Rate is being used as an alternate rate of interest pursuant to Section 2.18 (for the avoidance of doubt, only until the Benchmark Replacement has been
4



determined pursuant to Section 2.18(a)), then the Base Rate shall be the greater of clauses (a) and (b) above and shall be determined without reference to clause (c) above.
Base Rate Advance” means an Advance denominated in Dollars that bears interest as provided in Section 2.07(a)(i).
Benefit Plan” means any of (a) an “employee benefit plan” (as defined in ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in Section 4975 of the Internal Revenue Code or (c) any Persons whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Internal Revenue Code) the assets of any such “employee benefit plan” or “plan”.
Benchmark” means, initially, LIBORwith respect to any (i) RFR Advance, the Daily Simple SOFR Rate or (ii) Term Benchmark Advance, the Term SOFR Rate; provided that if a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, as applicable, and its and the related Benchmark Replacement Date have occurred with respect to LIBORthe Daily Simple SOFR Rate or Term SOFR Rate, as applicable, or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to clause (a) or clause (b) of Section 2.18.
Benchmark Replacement” means, for any Available Tenor, the first alternative set forth in the order below that can be determined by the Administrative Agent for the applicable Benchmark Replacement Date:
(1) the sum of: (a) Term SOFR and (b) the related Benchmark Replacement Adjustment;
(1)    (2) the sum of: (a)Adjusted Daily Simple SOFR and (b) the related Benchmark Replacement AdjustmentRate; or
(2)    (3) the sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower as the replacement for the then-current Benchmark for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement for the then-current Benchmark for dollar-denominated syndicated credit facilities at such time in the United States and (b) the related Benchmark Replacement Adjustment;
provided that, in the case of clause (1), such Unadjusted Benchmark Replacement is displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion; provided further that, notwithstanding anything to the contrary in this Agreement or in any other Loan Document, upon the occurrence of a Term SOFR Transition Event, and the delivery of a Term SOFR Notice, on the applicable Benchmark Replacement Date the “Benchmark Replacement” shall revert to and shall be deemed to be the sum of (a) Term SOFR and
5



(b) the related Benchmark Replacement Adjustment, as set forth in clause (1) of this definition (subject to the first proviso above).
If the Benchmark Replacement as determined pursuant to clause (1), or (2) or (3) above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.
Benchmark Replacement Adjustment” means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement for any applicable Interest Period and Available Tenor for any setting of such Unadjusted Benchmark Replacement:
(1) , the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by for purposes of clauses (1) and (2) of the definition of “Benchmark Replacement,” the first alternative set forth in the order below that can be determined by the Administrative Agent:
(a) the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) as of the Reference Time such Benchmark Replacement is first set for such Interest Period that has been selected or recommended by the Relevant Governmental Body for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for the applicable Corresponding Tenor;
(b) the spread adjustment (which may be a positive or negative value or zero) as of the Reference Time such Benchmark Replacement is first set for such Interest Period that would apply to the fallback rate for a derivative transaction referencing the ISDA Definitions to be effective upon an index cessation event with respect to such Benchmark for the applicable Corresponding Tenor; and
(2) for purposes of clause (3) of the definition of “Benchmark Replacement,” the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by thethe Administrative Agent and the Borrower for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body on the applicable Benchmark Replacement Date or (ii) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for dollar-denominated syndicated credit facilities;.
6



provided that, in the case of clause (1) above, such adjustment is displayed on a screen or other information service that publishes such Benchmark Replacement Adjustment from time to time as selected by the Administrative Agent in its reasonable discretion.
Benchmark Replacement Conforming Changes” means, with respect to any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of “Base Rate,” the definition of “Business Day,” the definition of “Interest Period,” timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, length of lookback periods, the applicability of breakage provisions, and other technical, administrative or operational matters) that the Administrative Agent decides, following consultation with the Borrower, in its reasonable discretion may be appropriate to reflect the adoption and implementation of such Benchmark Replacement and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of such Benchmark Replacement exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).
Benchmark Replacement Date” means the earliest to occur of the following events with respect to the then-current Benchmark:
(1)    in the case of clause (1) or (2) of the definition of “Benchmark Transition Event,” the later of (a) the date of the public statement or publication of information referenced therein and (b) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof); or
(2)    in the case of clause (3) of the definition of “Benchmark Transition Event,” the first date of the publicon which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be no longer representative; provided, that such non-representativeness will be determined by reference to the most recent statement or publication of information referenced therein; in such clause (3) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.
(3) in the case of a Term SOFR Transition Event, the date that is thirty (30) days after the date a Term SOFR Notice is provided to the Lenders and the Borrower pursuant to Section 2.18(b); or
(4) in the case of an Early Opt-in Election, the sixth (6th) Business Day after the date notice of such Early Opt-in Election is provided to the Lenders, so long as
7



the Administrative Agent has not received, by 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Early Opt-in Election is provided to the Lenders, written notice of objection to such Early Opt-in Election from Lenders comprising the Required Lenders.
For the avoidance of doubt, (i) if the event giving rise to the Benchmark Replacement Date occurs on the same day as, but earlier than, the Reference Time in respect of any determination, the Benchmark Replacement Date will be deemed to have occurred prior to the Reference Time for such determination and (ii) the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (1) or (2) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).
Benchmark Transition Event” means the occurrence of one or more of the following events with respect to the then-current Benchmark:
(1)    a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);
(2)    a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, the CME Term SOFR Administrator, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), in each case, which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or
(3)    a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are no longer, or as of a specified future date will no longer be, representative.
8



For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).
Benchmark Unavailability Period” means the period (if any) (x) beginning at the time that a Benchmark Replacement Date pursuant to clauses (1) or (2) of that definition has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any other Loan Document in accordance with Section 2.18 and (y) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any other Loan Document in accordance with Section 2.18.
Beneficial Ownership Certification” means a certification regarding beneficial ownership required by the Beneficial Ownership Regulation.
Beneficial Ownership Regulation” means 31 C.F.R. § 1010.230.
“Benefit Plan” means any of (a) an “employee benefit plan” (as defined in ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in Section 4975 of the Internal Revenue Code or (c) any Persons whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Internal Revenue Code) the assets of any such “employee benefit plan” or “plan”.
Borrowed Debt” means any Debt for money borrowed represented by notes, bonds, debentures or other similar evidences of Debt for money borrowed.
Borrower” has the meaning specified in the recital of parties to this Agreement.
Borrower Materials” has the meaning specified in Section 5.01(i).
Borrowing” means a borrowing consisting of Advances of the same Type made, Converted or continued on the same date and, in the case of Eurodollar RateTerm Benchmark Advances, as to which a single Interest Period is in effect.
Borrowing Minimum” means $10,000,000.
Borrowing Multiple” means $1,000,000.
Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, New York City or Chicago and, if such day relates to any Eurodollar Rate Advance, means any such day on which dealings in Dollar deposits are conducted by and between banks in the London interbank Eurodollar market.; provided that, in addition to the foregoing, a Business Day shall be (a) in relation to RFR Advances and any interest rate settings, fundings, disbursements, settlements or payments of any such RFR Advance, or any other dealings of such RFR Advance and (b) in relation to Advances referencing the Adjusted Term SOFR Rate and any interest rate settings, fundings, disbursements, settlements or
9



payments of any such Advances referencing the Adjusted Term SOFR Rate or any other dealings of such Advances referencing the Adjusted Term SOFR Rate, any such day that is only a U.S. Government Securities Business Day.
CERCLIS” means the Comprehensive Environmental Response, Compensation and Liability Information System maintained by the U.S. Environmental Protection Agency.
Closing Date” means the date on which each of the conditions set forth in Section 3.01 have been satisfied (or waived in accordance with Section 8.01).
“CME Term SOFR Administrator” means CME Group Benchmark Administration Limited as administrator of the forward-looking term SOFR (or a successor administrator).
Commitment” means as to any Lender (a) the Dollar amount set forth opposite such Lender’s name on Schedule I hereto, or (b) if such Lender has entered into any Assignment and Acceptance or Lender Joinder Agreement, the Dollar amount set forth for such Lender in the Register maintained by the Administrative Agent pursuant to Section 8.07(d), in each case as such commitment may be increased or reduced from time to time pursuant to the terms hereof. The aggregate amount of the Commitments as of the Closing Date is $5,000,000,000 as such commitment may be reduced thereafter in accordance with Section 2.05 or 6.01 or increased thereafter in accordance with Section 2.05(d).
Commitment Termination Date” means the earlier of (i) the date that is the fifth anniversary of the Closing Date, as such date may be extended with respect to any Consenting Lender pursuant to Section 2.05(d), and (ii) the date on which the Commitments are terminated. Following such extension, unless otherwise specified herein, the term “Commitment Termination Date” shall mean the Commitment Termination Date as so extended.
Consenting Lender” has the meaning specified in Section 2.05(d).
Consolidated” refers to the consolidation of accounts in accordance with GAAP.
Consolidated Group” means the Borrower and its Subsidiaries.
Consolidated Net Assets” means the aggregate amount of assets (less applicable reserves and other properly deductible items) after deducting therefrom all current liabilities, as set forth on the Consolidated balance sheet of the Consolidated Group most recently furnished to the Lenders pursuant to Section 5.01(i)(ii) prior to the time as of which Consolidated Net Assets shall be determined.
Consolidated Net Worth” means, at any date of determination, (a) total assets of the Borrower and its Subsidiaries (including, without limitation, all items that are treated as intangibles in accordance with GAAP) at such date less (b) total liabilities of the Borrower and its Subsidiaries (including, without limitation, all deferred Taxes) at such date, in each case determined in accordance with GAAP on a Consolidated basis.
10



Continuing Director” means, for any period, an individual who is a member of the board of directors of the Borrower on the first day of such period or whose election to the board of directors of the Borrower is approved by a majority of the other Continuing Directors.
Conversion”, “Convert”, or “Converted” each refers to a conversion of Advances of one Type into Advances of the other Type pursuant to Section 2.08 or 2.09.
Corresponding Tenor” with respect to any Available Tenor means, as applicable, either a tenor (including overnight) or an interest payment period having approximately the same length (disregarding business day adjustment) as such Available Tenor.
Daily Simple SOFR Rate” means, for any day, (a “SOFR, with the conventions for this rate (which will include a lookback) being established by the Administrative Agent in accordance with the conventions for this rate selected or recommended by the Relevant Governmental Body for determining “Daily Simple SOFR” for business loans; provided, that if the Administrative Agent decides that any such convention is not administratively feasible for the Administrative Agent, then the Administrative Agent may establish another convention in its reasonable discretion. Rate Day”), a rate per annum equal to SOFR for the day (such day “SOFR Determination Date”) that is three (3) U.S. Government Securities Business Days prior to (i) if such SOFR Rate Day is a U.S. Government Securities Business Day, such SOFR Rate Day or (ii) if such SOFR Rate Day is not a U.S. Government Securities Business Day, the U.S. Government Securities Business Day immediately preceding such SOFR Rate Day, in each case, as such SOFR is published by the SOFR Administrator on the SOFR Administrator’s Website. Any change in Daily Simple SOFR Rate due to a change in SOFR shall be effective from and including the effective date of such change in SOFR without notice to the Borrower.
Debt” of any Person means, without duplication, (a) all indebtedness of such Person for borrowed money, (b) all obligations of such Person for the deferred purchase price of property or services (other than trade payables incurred in the ordinary course of such Person’s business), (c) all obligations of such Person evidenced by notes, bonds, debentures or other similar instruments, (d) all obligations of such Person created or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person (even though the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property), (e) all obligations of such Person as lessee under leases that have been or should be, in accordance with GAAP, recorded as finance leases, (f) all obligations, contingent or otherwise, of such Person in respect of acceptances, letters of credit or similar extensions of credit, (g) all obligations of such Person in respect of Hedge Agreements, (h) all Debt of others referred to in clauses (a) through (g) above or clause (i) below directly guaranteed in any manner by such Person, or the payment of which is otherwise provided for by such Person, and (i) all Debt referred to in clauses (a) through (h) above secured by (or for which the holder of such Debt has an existing right, contingent or otherwise, to be secured by) any Lien on property (including, without limitation, accounts and contract rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such Debt.
11



Debtor Relief Laws” means the Bankruptcy Code of the United States of America, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions from time to time in effect.
Declining Lender” has the meaning specified in Section 2.05(d).
Default” means any Event of Default or any event that would constitute an Event of Default but for the requirement that notice be given or time elapse or both.
Default Interest” has the meaning specified in Section 2.07(b).
Defaulting Lender” means, subject to Section 2.19(b), any Lender that (a) has failed to (i) fund all or any portion of its Advances within two Business Days of the date such Advances were required to be funded hereunder unless such Lender notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender’s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent or any other Lender any other amount required to be paid by it hereunder within two Business Days of the date when due, (b) has notified the Borrower or the Administrative Agent in writing that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to fund an Advance hereunder and states that such position is based on such Lender’s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three Business Days after written request by the Administrative Agent or the Borrower, to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding obligations hereunder (provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent and the Borrower), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity, (iii) become an Embargoed Lender or (iv) become the subject of a Bail-In Action; provided that for the avoidance of doubt, a Lender shall not be a Defaulting Lender solely by virtue of (A) the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority or (B) in the case of a solvent Person, the precautionary appointment of an administrator, guardian or custodian or similar official by a Governmental Authority under or based on the Law of the country where such Person is organized if the applicable Law of such jurisdiction requires that such appointment not be publicly disclosed, in any such case, where such ownership or action, as applicable, does not result in or provide such Lender with immunity from the jurisdiction of courts within
12



the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of clauses (a) through (d) above shall be conclusive and binding as to such Lender absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.19(b)) upon delivery of written notice of such determination to the Borrower and each Lender.
Designated Jurisdiction” means any country, region or territory that is, or has a government that is, subject to comprehensive country-wide economic or financial sanctions or trade embargoes imposed, administered or enforced by any Person listed in the definition of “Sanction(s)”.
Division” means the division of the assets, liabilities and/or obligations of a Person (the “Dividing Person”) among two or more Persons (whether pursuant to a “plan of division” or similar arrangement), which may or may not include the Dividing Person and pursuant to which the Dividing Person may or may not survive.
Dollars” and the “$” sign each means lawful currency of the United States.
Domestic Lending Office” means, with respect to any Lender, the office of such Lender specified as its “Domestic Lending Office” in its Administrative Questionnaire or in the Assignment and Acceptance, pursuant to which it became a Lender, or such other office of such Lender as such Lender may from time to time specify to the Borrower and the Administrative Agent.
Domestic Subsidiary” means any Subsidiary of the Borrower substantially all the property of which is located, or substantially all of the business of which is carried on, within the United States (excluding its territories and possessions and Puerto Rico), provided, however, that the term shall not include any Subsidiary of the Borrower which (a) is engaged principally in the financing of operations outside of the United States or in leasing personal property or financing inventory, receivables or other property or (b) does not own a Principal Domestic Property.
Early Opt-in Election” means, if the then-current Benchmark is LIBOR, the occurrence of:
(1) a notification by the Administrative Agent to (or the request by the Borrower to the Administrative Agent to notify) each of the other parties hereto that at least five currently outstanding dollar-denominated syndicated credit facilities at such time contain (as a result of amendment or as originally executed) a SOFR-based rate (including SOFR, a term SOFR or any other rate based upon SOFR) as a benchmark rate (and such syndicated credit facilities are identified in such notice and are publicly available for review), and
13



(2) the joint election by the Administrative Agent and the Borrower to trigger a fallback from LIBOR and the provision by the Administrative Agent of written notice of such election to the Lenders.
EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.
EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.
EEA Resolution Authority” means any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.
Eligible Assignee” means (a) a Lender; (b) an Affiliate of a Lender; (c) a commercial bank organized under the Laws of the United States, or any State thereof, and having total assets in excess of $10,000,000,000; (d) a commercial bank organized under the Laws of any other country that is a member of the Organization for Economic Cooperation and Development or has concluded special lending arrangements with the International Monetary Fund associated with its General Arrangements to Borrow, or a political subdivision of any such country, and having total assets in excess of $10,000,000,000, so long as such bank is acting through a branch or agency located in the country in which it is organized or another country that is described in this clause (d); and (e) any other Person approved by the Administrative Agent and, so long as no Event of Default has occurred and is continuing, by the Borrower, such approval not to be unreasonably withheld or delayed; provided, however, that no Defaulting Lender (or Person who would be a Defaulting Lender upon becoming a Lender) nor the Borrower nor any Affiliate of the Borrower shall qualify as an Eligible Assignee.
Embargoed Lender” means any Lender (a) that is the subject of any Sanctions or (b) that is located, organized or resident in any Designated Jurisdiction.
Environmental Action” means any action, suit, demand, demand letter, claim, notice of noncompliance or violation, notice of liability or potential liability, investigation, proceeding, consent order or consent agreement relating in any way to any Environmental Law, Environmental Permit or Hazardous Materials or arising from alleged injury or threat of injury to health, safety or the environment, including, without limitation, (a) by any governmental or regulatory authority for enforcement, cleanup, removal, response, remedial or other actions or damages and (b) by any governmental or regulatory authority or any third party for damages, contribution, indemnification, cost recovery, compensation or injunctive relief.
14



Environmental Law” means any federal, state, local or foreign statute, Law, ordinance, rule, regulation, code, order, judgment, decree or judicial or agency interpretation, policy or guidance relating to pollution or protection of the environment, health, safety or natural resources, including, without limitation, those relating to the use, handling, transportation, treatment, storage, disposal, release or discharge of Hazardous Materials.
Environmental Liability” means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Borrower or any of its Subsidiaries directly or indirectly resulting from or based upon (a) violation of any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.
Environmental Permit” means any permit, approval, identification number, license or other authorization required under any Environmental Law.
ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time, and the regulations promulgated and rulings issued thereunder.
ERISA Affiliate” means any Person that for purposes of Title IV of ERISA is a member of the Borrower’s controlled group, or under common control with the Borrower, within the meaning of Section 414 of the Internal Revenue Code.
ERISA Event” means:
(a)    (i) the occurrence of a reportable event, within the meaning of Section 4043 of ERISA, with respect to any Plan unless the 30-day notice requirement with respect to such event has been waived by the PBGC, or (ii) the requirements of subsection (1) of Section 4043(b) of ERISA (without regard to subsection (2) of such Section) are being met with a contributing sponsor, as defined in Section 4001(a)(13) of ERISA, of a Plan, and an event described in paragraph (9), (10), (11), (12) or (13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such Plan within the following 30 days;
(b)    the application for a minimum funding waiver with respect to a Plan;
(c)    the provision by the administrator of any Plan of a notice of intent to terminate such Plan pursuant to Section 4041(a)(2) of ERISA (including any such notice with respect to a plan amendment referred to in Section 4041(e) of ERISA);
(d)    the cessation of operations at a facility of the Borrower or any ERISA Affiliate in the circumstances described in Section 4062(e) of ERISA;
(e)    the withdrawal by the Borrower or any ERISA Affiliate from a Multiple Employer Plan during a plan year for which it was a substantial employer, as defined in Section 4001(a)(2) of ERISA;
15



(f)    the conditions for the imposition of a lien under Section 303(k) of ERISA shall have been met with respect to any Plan; or
(g)    the institution by the PBGC of proceedings to terminate a Plan pursuant to Section 4042 of ERISA, or the occurrence of any event or condition described in Section 4042 of ERISA that could constitute grounds for the termination of, or the appointment of a trustee to administer, a Plan.
EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.
Eurocurrency Liabilities” has the meaning specified in Regulation D of the Board of Governors of the Federal Reserve System, as in effect from time to time.
Eurodollar Lending Office” means, with respect to any Lender, the office of such Lender specified as its “Eurodollar Lending Office” in its Administrative Questionnaire or in the Assignment and Acceptance pursuant to which it became a Lender (or, if no such office is specified, its Domestic Lending Office), or such other office, branch, subsidiary or affiliate of such Lender as such Lender may from time to time specify to the Borrower and the Administrative Agent.
Eurodollar Rate” means,
(a) for any Interest Period with respect to a Eurodollar Rate Advance, the rate per annum equal to the London Interbank Offered Rate (“LIBOR”) as published on the applicable Bloomberg screen page (or other comparable commercially available source providing quotations of LIBOR as may be designated by the Administrative Agent from time to time), at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period, for Dollar deposits (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period (the “Screen Rate”);
(b) for any interest rate calculation with respect to a Base Rate Advance on any date, the rate per annum equal to LIBOR, at approximately 11:00 a.m., London time determined two Business Days prior to such date for Dollar deposits being delivered in the London interbank market for a term of one month commencing that date; and
(c) if the Eurodollar Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement.
Eurodollar Rate Advance” means an Advance denominated in Dollars that bears interest as provided in Section 2.07(a)(ii).
Events of Default” has the meaning specified in Section 6.01.
Excluded Taxes” means any of the following Taxes imposed on or with respect to any Lender or the Administrative Agent or required to be withheld or deducted from a payment to any Lender or the Administrative Agent: (a) Taxes imposed on or measured by
16



net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Lender or the Administrative Agent being organized under the laws of, or having its principal office or, in the case of any Lender, its Applicable Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender pursuant to a law in effect on the date such Lender becomes a party to this Agreement (or designates a new Applicable Lending Office), except to the extent that such Lender (or its assignor, if any) was entitled, on the date of designation of a new Applicable Lending Office (or assignment), to receive additional amounts from the Borrower with respect to such withholding Tax pursuant to 0Section 2.14(a)(ii) or Error! Reference source not found.Section 2.14(c), (c) Taxes attributable to a failure by such Lender or the Administrative Agent to comply with Error! Reference source not found.Section 2.14(e) and (d) any U.S. federal withholding Taxes imposed pursuant to FATCA.
Existing Commitment Termination Date” has the meaning specified in Section 2.05(ed).
Extension Date” has the meaning specified in Section 2.05(d).
FATCA” means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code, any published intergovernmental agreement entered into in connection with the implementation of such Sections of the Internal Revenue Code and any fiscal or regulatory legislation adopted pursuant to such published intergovernmental agreements.
Federal Funds Effective Rate” means, for any day, the rate calculated by the Federal Reserve Bank of New York based on such day’s federal funds transactions by depositary institutions, as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time, and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the effective federal funds rate; provided that if the Federal Funds Effective Rate as so determined would be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.
Federal Funds Rate” means, for any day, the greater of (a) the Federal Funds Effective Rate in effect on such day and (b) the Overnight Bank Funding Rate in effect on such day (or for any day that is not a Business Day, for the immediately preceding Business Day); provided that if none of such rates are published for any day that is a Business Day, the term “Federal Funds Rate” means the rate for a federal funds transaction quoted at 11:00 a.m. on such day received by the Administrative Agent from a federal funds broker of recognized standing selected by it; provided, further, that if any of the aforesaid rates as so determined shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.
17



Fee Letter” means the Fee Letter dated as of October 21, 2020 among the Borrower, the Arrangers and the Administrative Agent.
Floor” means the benchmark rate floor, if any, provided in this Agreement initially (as of the execution of this Agreement, the modification, amendment or renewal of this Agreement or otherwise) with respect to the Eurodollar Rate.Adjusted Term SOFR Rate or the Adjusted Daily Simple SOFR Rate, as applicable. For the avoidance of doubt, the initial Floor for each of the Adjusted Term SOFR Rate and the Adjusted Daily Simple SOFR Rate shall be zero.
Foreign Lender” means a Lender that is not a U.S. Person.
Funded Debt” means Debt of the Borrower (other than Debt in respect of the Advances or Debt subordinated in right of payment to the Advances) or Debt of any wholly-owned Domestic Subsidiary, for money borrowed, having a stated maturity of more than 12 months from the date of application of sale/leaseback proceeds or which is extendible at the option of the obligor thereon to a date more than 12 months from the date of such application.
GAAP” has the meaning specified in Section 1.03.
Governmental Authority” means any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, administrative tribunal, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank).
Hazardous Materials” means (a) petroleum and petroleum products, byproducts or breakdown products, radioactive materials, asbestos-containing materials, polychlorinated biphenyls and radon gas and (b) any other chemicals, materials or substances designated, classified or regulated as “hazardous” or “toxic” or as a “pollutant” or “contaminant” under any Environmental Law.
Hedge Agreements” means interest rate swap, cap or collar agreements, interest rate future or option contracts, currency swap agreements, currency future or option contracts and other similar agreements.
Increase Effective Date” has the meaning specified in Section 2.05(c).
Increasing Lender” has the meaning specified in Section 2.05(c).
Indemnified Party” has the meaning specified in Section 8.04(b).
Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (b) to the extent not otherwise described in clause (a), Other Taxes.
18



Information” has the meaning specified in Section 8.08.
Information Memorandum” means the information memorandum dated October 2020 used by the Arrangers in connection with the syndication of the Commitments.
Initial Lenders” has the meaning specified in the definition of “Lenders”.
Interest Election Request” means a request by the Borrower to Convert or continue a Borrowing in accordance with Section 2.09.
Interest Period” means, for each Eurodollar RateTerm Benchmark Advance comprising part of the same Borrowing, the period commencing on the date of such Eurodollar RateTerm Benchmark Advance or the date of the continuation of, or Conversion of any Base Rate Advance into, such Eurodollar RateTerm Benchmark Advance and ending on the last day of the period selected by the Borrower pursuant to the provisions below. The duration of each such Interest Period shall be one, two, three or six months, as the Borrower may, upon notice received by the Administrative Agent not later than 11:00 A.M. (New York City time) on the third Business Day prior to the first day of such Interest Period (or in any case at such later time as the Administrative Agent, in its reasonable discretion, may agree to), select; provided, however, that: (a) the Borrower may not select any Interest Period that ends after the latest then-effective Commitment Termination Date; (b) Interest Periods commencing on the same date for Eurodollar RateTerm Benchmark Advances comprising part of the same Borrowing shall be of the same duration (it being understood that the Borrower shall be permitted to make multiple Borrowings consisting of Eurodollar RateTerm Benchmark Advances on the same date, each of which may be of different durations); (c) whenever the last day of any Interest Period would otherwise occur on a day other than a Business Day, the last day of such Interest Period shall be extended to occur on the next succeeding Business Day, provided, however, that, if such extension would cause the last day of such Interest Period to occur in the next succeeding calendar month, the last day of such Interest Period shall occur on the immediately preceding Business Day; and (d) whenever the first day of any Interest Period occurs on a day of an initial calendar month for which there is no numerically corresponding day in the calendar month that succeeds such initial calendar month by the number of months equal to the number of months in such Interest Period, such Interest Period shall end on the last Business Day of such succeeding calendar month.
Internal Revenue Code” means the Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated and the rulings issued thereunder.
IRS” means the United States Internal Revenue Service.
ISDA Definitions” means the 2006 ISDA Definitions published by the International Swaps and Derivatives Association, Inc. or any successor thereto, as amended or supplemented from time to time, or any successor definitional booklet for interest rate derivatives published from time to time by the International Swaps and Derivatives Association, Inc. or such successor thereto.
19



Laws” means, collectively, all international, foreign, federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of Law.
Lender Joinder Agreement” means a joinder agreement in a form reasonably satisfactory to the Administrative Agent delivered in connection with Section 2.05(c).
Lenders” means, collectively, (a) each bank, financial institution and other institutional lender listed on the signature pages hereof (each, an “Initial Lender”) and (b) each Eligible Assignee that shall become a party hereto pursuant to Section 8.07(a), (b) and (c).
Lien” means any lien, security interest or other charge or encumbrance of any kind, or any other type of preferential arrangement, including, without limitation, the lien or retained security title of a conditional vendor and any easement, right of way or other encumbrance on title to real property.
Loan Documents” means this Agreement and any Lender Joinder Agreements, notes, security agreements or other documents entered into in connection herewith, each as amended, restated, supplemented, waived or otherwise modified from time to time.
Material Adverse Effect” means a material adverse effect on (a) the financial condition or results of operations of the Borrower or the Borrower and its Subsidiaries taken as a whole, (b) the rights and remedies of the Administrative Agent or any Lender under this Agreement, taken as a whole, or (c) the ability of the Borrower to perform its obligations under this Agreement.
Moody’s” means Moody’s Investors Service, Inc. (or any successor thereof).
Multiemployer Plan” means a multiemployer plan, as defined in Section 4001(a)(3) of ERISA, to which the Borrower or any ERISA Affiliate is making or accruing an obligation to make contributions, or has within any of the preceding five plan years made or accrued an obligation to make contributions.
Multiple Employer Plan” means a single employer plan, as defined in Section 4001(a)(15) of ERISA, that (a) is maintained for employees of the Borrower or any ERISA Affiliate and at least one Person other than the Borrower and the ERISA Affiliates or (b) was so maintained and in respect of which the Borrower or any ERISA Affiliate could have liability under Section 4064 or 4069 of ERISA in the event such plan has been or were to be terminated.
Non-Defaulting Lender” means, at any time, a Lender that is not a Defaulting Lender.
20



Notice of Borrowing” has the meaning specified in Section 2.02(a).
NPL” means the National Priorities List under the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended from time to time.
OFAC” means the U.S. Treasury Department’s Office of Foreign Assets Control.
Other Connection Taxes” means, with respect to any Lender or the Administrative Agent, Taxes imposed as a result of a present or former connection between such Lender or the Administrative Agent and the jurisdiction imposing such Tax (other than connections arising from such Lender or the Administrative Agent having executed, delivered, become a party to, performed its obligations under, received payments under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Advance or Loan Document).
Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to the first parenthetical clause in Section 8.07(a)).
Overnight Bank Funding Rate” means, for any day, the rate comprised of both overnight federal funds and overnight eurodollar borrowings by U.S.-managed banking offices of depository institutions, as such composite rate shall be determined by the Federal Reserve Bank of New York as set forth on its public website from time to time, and published on the next succeeding Business Day by the Federal Reserve Bank of New York as an overnight bank funding rate.
Participant Register” has the meaning specified in Section 8.07(e).
Patriot Act” means the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L. 107-56, signed into law October 26, 2001.
PBGC” means the Pension Benefit Guaranty Corporation (or any successor thereto).
Person” means an individual, partnership, corporation (including a business trust), joint stock company, trust, unincorporated association, joint venture, limited liability company or other entity, or a government or any political subdivision or agency thereof.
Plan” means a Single Employer Plan or a Multiple Employer Plan.
Plan Asset Regulations” means 29 CFR § 2510.3-101 et seq., as modified by Section 3(42) of ERISA, as amended from time to time.
Platform” has the meaning specified in Section 5.01(i).
21



Principal Domestic Property” means any building, structure or other facility, together with the land upon which it is erected and fixtures comprising a part thereof, used primarily for manufacturing, processing, research, warehousing or distribution and located in the United States (excluding its territories and possessions and Puerto Rico) owned or leased by a member of the Consolidated Group the net book value of which on the date as of which the determination is being made exceeds 2% of Consolidated Net Assets, other than any such building structure or other facility or portion of any thereof (a) which is an air or water pollution control facility financed by obligations issued by a State or local governmental unit or (b) which the Chief Executive Officer, any President, the Chief Financial Officer, the Controller or the Treasurer of the Borrower determines in good faith is not of material importance to the total business conducted, or assets owned, by the Consolidated Group taken as a whole.
Proceeding” has the meaning specified in Section 8.04(b).
PTE” means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.
Public Debt Rating” means, as of any date of determination, the rating as determined by S&P or Moody’s of the Borrower’s long-term unsecured senior debt; provided, that (a) if only one of S&P and Moody’s shall have in effect a Public Debt Rating, the Applicable Percentage and the Applicable Margin, as applicable, shall be determined by reference to the available Public Debt Rating; (b) if neither S&P nor Moody’s shall have in effect a Public Debt Rating, the Applicable Percentage and the Applicable Margin, as applicable, shall be set in accordance with Level VII of the definition of Applicable Percentage or Applicable Margin, as the case may be, until such time as either S&P or Moody’s shall have in effect a Public Debt Rating; (c) if the Public Debt Ratings established by S&P and Moody’s shall fall within different levels, the Applicable Percentage and the Applicable Margin, as applicable, shall be based upon the higher of such Public Debt Ratings, except that in the event that the lower of such Public Debt Ratings is more than one level below the higher of such Public Debt Ratings, the Applicable Percentage and the Applicable Margin, as applicable, shall be based upon the level immediately below the higher of such Public Debt Ratings; (d) if any Public Debt Rating established by S&P or Moody’s shall be changed, such change shall be effective as of the date on which such change is first announced publicly by the rating agency making such change and (e) if S&P or Moody’s shall change the basis on which Public Debt Ratings are established, each reference to the Public Debt Ratings announced by S&P or Moody’s, as the case may be, shall refer to the then equivalent rating by S&P or Moody’s, as the case may be.
Reference Time” with respect to any setting of the then-current Benchmark means (1) if such Benchmark is Eurodollar Rate, 11:00 a.m. (Londonthe Term SOFR Rate, 5:00 a.m. (Chicago time) on the day that is two London banking daysU.S. Government Securities Business Days preceding the date of such setting, and (2) if such Benchmark is not Eurodollar Ratethe Daily Simple SOFR Rate, then four Business Days prior to such setting or (3) if such Benchmark is none of the Term SOFR Rate or the Daily Simple SOFR Rate, the time determined by the Administrative Agent in its reasonable discretion.
22



Register” has the meaning specified in Section 8.07(d).
Related Parties” means, with respect to any Person, such Person’s Affiliates, and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates.
Related Person” means, as to any Person, (a) any controlling Person, controlled Affiliate or Subsidiary of such Person, (b) the respective directors, officers or employees of such Person or any of its Subsidiaries, controlled Affiliates or controlling Persons and (c) the respective agents and advisors of such Person or any of its Subsidiaries, controlled Affiliates or controlling Persons.
Relevant Governmental Body” means the Federal Reserve Board or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board or the Federal Reserve Bank of New York, or any successor thereto.
“Relevant Rate” means (i) with respect to any Term Benchmark Advance, the Adjusted Term SOFR Rate, and (ii) with respect to any RFR Advance, Adjusted Daily Simple SOFR Rate, as applicable.
Removal Effective Date” has the meaning specified in Section 7.06(b).
Required Lenders” means, at any time, Lenders holding more than 50% of the Commitments at such time or, if the Commitments have been terminated at such time pursuant to Section 2.05 or 6.01, Lenders owed more than 50% of the aggregate unpaid principal amount of the Advances owing to Lenders at such time; provided that the Commitment of, and the Advances held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Lenders.
Resignation Effective Date” has the meaning specified in Section 7.06(a).
Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.
Responsible Officer” means the Chief Executive Officer, the Chief Financial Officer, the Treasurer, the Controller, any Assistant Treasurer, the Director, Capital Markets and Global Treasury Operations and the General Counsel of the Borrower (or other executive officer of the Borrower performing similar functions) or any other officer of the Borrower responsible for overseeing or reviewing compliance with this Agreement.
Revised Percentage” has the meaning specified in Section 2.05(c).
“RFR Advance” means an Advance denominated in Dollars that bears interest as provided in Section 2.07(a)(iii).
S&P” means S&P Global Ratings, a division of S&P Global Inc., or any successor to its rating agency business.
23



Sale and Leaseback Transaction” has the meaning specified in Section 5.02(c).
Sanction(s)” means any economic or trade sanction enacted, imposed, administered or enforced by the United States Government (including, without limitation, the U.S. Department of State and OFAC), the United Nations Security Council, the European Union, HerHis Majesty’s Treasury or other relevant sanctions authority in a jurisdiction material to the Borrower and its Subsidiaries taken as a whole.
    Screen Rate” has the meaning set forth in the definition of “Eurodollar Rate”.
Significant Subsidiary” means any Subsidiary of the Borrower that constitutes a “significant subsidiary” under Regulation S-X promulgated by the Securities and Exchange Commission, as in effect from time to time.
Single Employer Plan” means a single employer plan, as defined in Section 4001(a)(15) of ERISA, that (a) is maintained for employees of the Borrower or any ERISA Affiliate and no Person other than the Borrower and the ERISA Affiliates or (b) was so maintained and in respect of which the Borrower or any ERISA Affiliate could have liability under Section 4069 of ERISA in the event such plan has been or were to be terminated.
SOFR” means, with respect to any Business Day, a rate per annum equal to the secured overnight financing rate for such Business Day publishedas administered by the SOFR Administrator on the SOFR Administrator’s Website on the immediately succeeding Business Day.
“SOFR Adjustment” means 0.10%.
SOFR Administrator” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).
SOFR Administrator’s Website” means the Federal Reserve Bank of New York’s Website, currently at http://www.newyorkfed.org, or any successor source for the secured overnight financing rate identified as such by the SOFR Administrator from time to time.
“SOFR Determination Date” has the meaning specified in the definition of “Daily Simple SOFR Rate”.
“SOFR Rate Day” has the meaning specified in the definition of “Daily Simple SOFR Rate”.
Subsidiary” means, with respect to any Person, any corporation, partnership, joint venture, limited liability company, trust or estate of which (or in which) more than 50% of (a) the issued and outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether at the time capital stock of any other class or classes of such corporation shall or might have voting power upon the occurrence of any contingency), (b) the interest in the capital or profits of such limited liability company, partnership or joint venture or (c) the beneficial interest in such trust or estate is at the time directly or indirectly owned or controlled by such Person,
24



by such Person and one or more of its other Subsidiaries or by one or more of such Person’s other Subsidiaries.
Syndication Agents” means Barclays Bank PLC, Bank of America, N.A., and Morgan Stanley Senior Funding, Inc.
Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other like charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.
Term SOFR” means, for the applicable Corresponding Tenor as of the applicable Reference Time, the forward-looking term rate based on SOFR that has been selected or recommended by the Relevant Governmental Body.
“Term Benchmark Advance” means an Advance denominated in Dollars that bears interest as provided in Section 2.07(a)(ii).
Term SOFR Notice” means a notification by the Administrative Agent to the Lenders and the Borrower of the occurrence of a Term SOFR Transition Event. Determination Day” has the meaning assigned to it under the definition of Term SOFR Reference Rate.
Term SOFR Transition Event” means the determination by the Administrative Agent that (a) Term SOFR has been recommended for use by the Relevant Governmental Body, (b) the administration of Term SOFR is administratively feasible for the Administrative Agent and (c) a Benchmark Transition Event or an Early Opt-in Election, as applicable, has previously occurred resulting in a Benchmark Replacement in accordance with Section 2.18 that is not Term SOFR.Rate” means, with respect to any Term Benchmark Advance and for any tenor comparable to the applicable Interest Period, the Term SOFR Reference Rate at approximately 5:00 a.m., Chicago time, two U.S. Government Securities Business Days prior to the commencement of such tenor comparable to the applicable Interest Period, as such rate is published by the CME Term SOFR Administrator.
“Term SOFR Reference Rate” means, for any day and time (such day, the “Term SOFR Determination Day”), with respect to any Term Benchmark Advance and for any tenor comparable to the applicable Interest Period, the rate per annum published by the CME Term SOFR Administrator and identified by the Administrative Agent as the forward-looking term rate based on SOFR. If by 5:00 pm (New York City time) on such Term SOFR Determination Day, the “Term SOFR Reference Rate” for the applicable tenor has not been published by the CME Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Rate has not occurred, then, so long as such day is otherwise a U.S. Government Securities Business Day, the Term SOFR Reference Rate for such Term SOFR Determination Day will be the Term SOFR Reference Rate as published in respect of the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate was published by the CME Term SOFR
25



Administrator, so long as such first preceding U.S. Government Securities Business Day is not more than five (5) U.S. Government Securities Business Days prior to such Term SOFR Determination Day.
Type” has the meaning specified in the definition of “Advance”.
UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.
UK Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.
Unadjusted Benchmark Replacement” means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.
United States” and “U.S.” each means the United States of America.
“U.S. Government Securities Business Day” means any day except for (i) a Saturday, (ii) a Sunday or (iii) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.
U.S. Person” means any Person that is a “United States person” as defined in Section 7701(a)(30) of the Internal Revenue Code.
U.S. Tax Compliance Certificate” has the meaning specified in Section 2.14
Voting Stock” means shares of capital stock issued by a corporation, or equivalent interests in any other Person, the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such Person, even if the right so to vote has been suspended by the happening of such a contingency.
Withdrawal Liability” has the meaning specified in Part I of Subtitle E of Title IV of ERISA.
Write-Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument
26



under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.
SECTION 1.02    Computation of Time Periods. In this Agreement, in the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including”, the word “through” means “through and including” and each of the words “to” and “until” mean “to but excluding”.
SECTION 1.03    Accounting Terms; Interpretative Provisions. Except as otherwise expressly provided herein, all accounting terms not specifically defined herein shall be construed in accordance with, and all financial data (including financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, generally accepted accounting principles as in effect in the United States from time to time (“GAAP”). If at any time any change in GAAP would affect the calculation of any covenant set forth herein and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith to amend such covenant to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders); provided that, until so amended, (a) such covenant shall continue to be calculated in accordance with GAAP prior to such change and (b) the Borrower shall provide to the Administrative Agent and the Lenders, concurrently with the delivery of any financial statements or reports with respect to such covenant, statements setting forth a reconciliation between calculations of such covenant made before and after giving effect to such change in GAAP.
SECTION 1.04    Interest Rates; LIBORBenchmark Notification. The interest rate on Eurodollar Rate Advances is determined by reference to LIBOR, which is derived from the London interbank offered rate. The London interbank offered rate is intended to represent the rate at which contributing banks may obtain short-term borrowings from each other in the London interbank market. In July 2017, the U.K. Financial Conduct Authority announced that, after the end of 2021, it would no longer persuade or compel contributing banks to make rate submissions to the ICE Benchmark Administration (together with any successor to the ICE Benchmark Administrator, the “IBA”) for purposes of the IBA setting the London interbank offered rate. As a result, it is possible that commencing in 2022, the London interbank offered rate may no longer be available or may no longer be deemed an appropriate reference rate upon which to determine the interest rate on Eurodollar Rate Advances. In light of this eventuality, public and private sector industry initiatives are currently underway to identify new or alternative reference rates to be used in place of the London interbank offered ratean Advance denominated in Dollars may be derived from an interest rate benchmark that may be discontinued or is, or may in the future become, the subject of regulatory reform. Upon the occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, Section 2.18(a) and (b) provide the provides a mechanism for determining an alternative rate of interest. The Administrative Agent will promptly notify the Borrower and the Lenders, pursuant to Section 2.18(d), of any change to the reference rate upon which the interest rate on Eurodollar Rate Advances is based. However, the Administrative Agent does not warrant or accept any responsibility for, and shall not have any liability with respect to, the administration, submission, performance or any other matter related
27



to the London interbank offered rate or other rates in the definition of “Eurodollar Rate”any interest rate used in this Agreement, or with respect to any alternative or successor rate thereto, or replacement rate thereof (including, without limitation, (i) any such alternative, successor or replacement rate implemented pursuant to Section 2.18(a) or (b), whether upon the occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, and (ii) the implementation of any Benchmark Replacement Conforming Changes pursuant to Section 2.18(c)),, including without limitation, whether the composition or characteristics of any such alternative, successor or replacement reference rate will be similar to, or produce the same value or economic equivalence of, the Eurodollar Rateexisting interest rate being replaced or have the same volume or liquidity as did the London interbank offeredany existing interest rate prior to its discontinuance or unavailability. The Administrative Agent and its affiliates and/or other related entities may engage in transactions that affect the calculation of any interest rate used in this Agreement or any alternative, successor or alternative rate (including any Benchmark Replacement) and/or any relevant adjustments thereto, in each case, in a manner adverse to the Borrower. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain any interest rate used in this Agreement, any component thereof, or rates referenced in the definition thereof, in each case pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.
SECTION 1.05    Divisions. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s laws), if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person.
ARTICLE II
AMOUNTS AND TERMS OF THE ADVANCES
SECTION 2.01    The Advances. Each Lender severally agrees, on the terms and conditions hereinafter set forth, to make Advances to the Borrower from time to time on any Business Day during the period from the Closing Date until the Commitment Termination Date in an aggregate amount not to exceed at any time outstanding such Lender’s Commitment. Each Borrowing shall be in an aggregate amount equal to the Borrowing Minimum or a Borrowing Multiple in excess thereof and shall consist of Advances of the same Type made on the same day by the Lenders ratably according to their respective Commitments. Within the limits of each Lender’s Commitment, the Borrower may borrow under this Section 2.01, prepay pursuant to Section 2.10 and reborrow under this Section 2.01.
SECTION 2.02    Making the Advances.
(a)    Each Borrowing shall be made on notice, given not later than (x) 11:00 A.M. (New York City time) on the third U.S. Government Securities Business Day prior to the
28



date of the proposed Borrowing (or at such later time as the Administrative Agent, in its reasonable discretion, may agree to) in the case of a Borrowing consisting of Eurodollar RateTerm Benchmark Advances or RFR Advances or (y) 11:00 A.M. (New York City time) on the date of the proposed Borrowing in the case of a Borrowing consisting of Base Rate Advances, by the Borrower to the Administrative Agent, which shall give to each Lender prompt notice thereof by telecopier or other electronic communication. Each notice of a Borrowing shall be by notice in substantially the form of Exhibit A hereto or such other form as may be approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent) (a “Notice of Borrowing”), specifying therein the requested (i) date of such Borrowing (which shall be a Business Day), (ii) Type of Advances comprising such Borrowing, (iii) aggregate amount of such Borrowing, (iv) initial Interest Period for such Advance, if such Borrowing is to consist of Eurodollar RateTerm Benchmark Advances and (v) account or accounts in which the proceeds of the Borrowing should be credited. Each Lender shall, before 1:00 P.M. (New York City time) on the date of such Borrowing make available for the account of its Applicable Lending Office to the Administrative Agent at the applicable Administrative Agent’s Office, in same day funds, such Lender’s ratable portion of such Borrowing. After the Administrative Agent’s receipt of such funds and upon fulfillment of the applicable conditions set forth in Article III, the Administrative Agent will make such funds available to the Borrower in immediately available funds to the account or accounts specified by the Borrower to the Administrative Agent in the Notice of Borrowing relating to the applicable Borrowing.
(b)    Anything in Section 2.02(a) to the contrary notwithstanding, (i) the Borrower may not select Eurodollar RateTerm Benchmark Advances for any Borrowing if the obligation of the Lenders to make Eurodollar RateTerm Benchmark Advances shall then be suspended pursuant to Section 2.08 or 2.12 and, (ii) the Eurodollar RateTerm Benchmark Advances may not be outstanding as part of more than ten separate Borrowings and (iii) the Borrower may not select RFR Advances for any Borrowing except as contemplated by Section 2.08(b), Section 2.12 or Section 2.18.
(c)    Each Notice of Borrowing shall be irrevocable and binding on the Borrower. In the case of any Borrowing that the related Notice of Borrowing specifies is to be comprised of Eurodollar RateTerm Benchmark Advances, the Borrower shall indemnify each Lender against any reasonable loss, cost or expense incurred by such Lender as a result of any failure to fulfill on or before the date specified in such Notice of Borrowing for such Borrowing the applicable conditions set forth in Article III, including, without limitation, any reasonable loss (excluding loss of anticipated profits), cost or expense incurred by reason of the liquidation or reemployment of deposits or other funds acquired by such Lender to fund the Advance to be made by such Lender as part of such Borrowing when such Advance, as a result of such failure, is not made on such date.
(d)    Unless the Administrative Agent shall have received notice from a Lender prior to the time of any Borrowing that such Lender will not make available to the Administrative Agent such Lender’s ratable portion of such Borrowing, the Administrative Agent may assume that such Lender has made such portion available to the Administrative Agent on the date of such Borrowing in accordance with Section 2.02(a) and the Administrative Agent may, in reliance upon such assumption, make available to the Borrower on such date a corresponding amount. If and to the extent that any Lender shall not have so made such ratable portion available to the
29



Administrative Agent, such Lender and the Borrower severally agree to pay or to repay to the Administrative Agent forthwith on demand such corresponding amount and to pay interest thereon, for each day from the date such amount is made available to the Borrower until the date such amount is paid or repaid to the Administrative Agent, at (i) in the case of the Borrower, the higher of (A) the interest rate applicable at the time to Advances comprising such Borrowing and (B) the cost of funds incurred by the Administrative Agent in respect of such amount and (ii) in the case of such Lender, the Federal Funds Rate. If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period. If such Lender shall pay to the Administrative Agent such corresponding amount, such amount so paid shall constitute such Lender’s Advance as part of such Borrowing for all purposes of this Agreement. Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent.
(e)    The failure of any Lender to make the Advance to be made by it as part of any Borrowing shall not relieve any other Lender of its obligation, if any, hereunder to make its Advance on the date of such Borrowing, but no Lender shall be responsible for the failure of any other Lender to make the Advance to be made by such other Lender on the date of any Borrowing.
(f)    If any Lender makes available to the Administrative Agent funds for any Advance to be made by such Lender as provided herein, and such funds are not made available to a Borrower by the Administrative Agent because the conditions to such Borrowing are not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall promptly return such funds (in like funds as received from such Lender) to such Lender, without interest.
SECTION 2.03    [Reserved].
SECTION 2.04    Fees.
(a)    Commitment Fee. The Borrower agrees to pay to the Administrative Agent, for the account of each Lender (other than a Defaulting Lender for such time as such Lender is a Defaulting Lender), a commitment fee on the actual daily amount of such Lender’s unused Commitment at a rate per annum equal to the Applicable Percentage, payable in arrears quarterly on the last Business Day of each March, June, September and December, and on the Commitment Termination Date.
(b)    Additional Fees. The Borrower shall pay to the Administrative Agent for its own account such fees as may from time to time be agreed between the Borrower and the Administrative Agent.
SECTION 2.05    Termination, Reduction or Increase of the Commitments; Extension of the Commitment Termination Date.
(a)    Ratable Reduction or Termination. The Borrower shall have the right, upon at least three Business Days’ notice to the Administrative Agent, to terminate in whole or permanently reduce ratably in part the unused portions of the respective Commitments of the Lenders; provided that each partial reduction shall be in an aggregate amount of $10,000,000 or
30



an integral multiple of $1,000,000 in excess thereof; provided, further, that the aggregate amount of the Commitments shall not be reduced to an amount that is less than the aggregate principal amount of Advances then outstanding; and provided, further, that any such notice may state that such notice is conditioned upon the effectiveness of other credit facilities or the consummation of a specific transaction, in which case such notice may be revoked by the Borrower if such condition is not satisfied.
(b)    Defaulting Lender Commitment Reductions. The Borrower may terminate the unused amount of the Commitments of any Lender that is a Defaulting Lender upon not less than three Business Days’ prior notice to the Administrative Agent (which shall promptly notify the Lenders thereof), it being understood that notwithstanding such Commitment termination, the provisions of Section 2.19(c) will continue to apply to all amounts thereafter paid by the Borrower for the account of such Defaulting Lender under this Agreement (whether on account of principal, interest, fees, indemnity or other amounts); provided that such termination shall not be deemed to be a waiver or release of any claim the Borrower, the Administrative Agent or any Lender may have against such Defaulting Lender.
(c)    Increase. The Borrower may, from time to time, by means of a notice delivered to the Administrative Agent, request that the aggregate amount of the Commitments be increased by (i) increasing the amount of the Commitment of one or more Lenders that have agreed (in their sole and individual discretion) to such increase (each an “Increasing Lender”) and/or (ii) adding one or more Eligible Assignees as parties hereto (each an “Additional Lender”) with Commitments in amounts agreed to by such Additional Lenders; provided that (A) any such increase shall be in an aggregate amount of $50,000,000 or a higher integral multiple of $5,000,000, (B) no Additional Lender shall be added as a party hereto without the written consent of the Administrative Agent to the extent such consent would be required for an assignment to such Additional Lender pursuant to Section 8.07 (which consent shall not be unreasonably withheld, conditioned or delayed), (C) the aggregate Commitments after giving effect to any such increase shall not exceed $7,000,000,000, and (D) as a condition precedent to such increase, the Borrower shall deliver to the Administrative Agent a certificate dated as of the Increase Effective Date (as defined below) signed by a Responsible Officer of the Borrower certifying that before and after giving effect to such increase (1) no Default has occurred and is continuing as of the date of such increase or would result from such increase and (2) each of the representations and warranties set forth in Section 4.01 are true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects) as of the date of such increase, except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty shall have been true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects) on and as of such earlier date; provided, that for purposes of this Section 2.05(c), the representations and warranties contained in Section 4.01(e) shall be deemed to refer to the most recent statements furnished pursuant to Section 5.01(i)(i) and 5.01(i)(ii). Any such increase in Commitments shall be effected pursuant to one or more Lender Joinder Agreements executed and delivered by the Borrower, the Administrative Agent and the Increasing Lenders and/or Additional Lenders, as applicable (the date on which such Lender Joinder Agreement(s) are delivered, the “Increase Effective Date”).
31



The Lender Joinder Agreement(s) may, without the consent of any other Lenders, effect such amendments to this Agreement and the other Loan Documents as may be necessary or appropriate in the opinion of the Administrative Agent, to effect the provisions of this Section 2.05(c). On the Increase Effective Date, (x) each Lender shall advance funds required (if any) to cause all outstanding Advances and unused Commitments to be held on a pro rata basis in accordance with the respective Commitments of each Lender after giving effect to such increase (for each Lender, its “Revised Percentage”) and (y) the Administrative Agent shall use any funds so received to repay the Advances of each Lender to the extent required so that such Lender has its Revised Percentage of all outstanding Advances (it being understood that the Borrower shall be responsible for any break funding payments owing pursuant to Section 8.04(c) resulting from such repayments). The Administrative Agent shall promptly notify the Borrower and the Lenders of any increase in the amount of the Commitments pursuant to this Section 2.05(c) and of the amount of the Commitment of each Lender after giving effect thereto.
(d)    Extension of the Facility. The Borrower may, by written notice to the Administrative Agent (which shall promptly deliver a copy to each Lender) not more than 60 days and not less than 30 days prior to the proposed date of effectiveness of an extension (an “Extension Date”), request that the Lenders extend the Commitment Termination Date for an additional period of one year from the applicable Commitment Termination Date then in effect hereunder (the then “Existing Commitment Termination Date”), provided that in no event shall the Commitment Termination Date be extended beyond (i) the fifth anniversary of the effective date of the Extension Date and (ii) the seventh anniversary of the Closing Date. Each Lender shall, by notice to the Borrower and the Administrative Agent given not more than 15 days (or such other date specified by the Borrower in such written notice or any supplement thereto) after such written notice is delivered to the Administrative Agent, advise the Borrower whether or not it agrees to the requested extension (each Lender agreeing to a requested extension being called a “Consenting Lender” and each Lender declining to agree to a requested extension being called a “Declining Lender”). Any Lender that has not so advised the Borrower and the Administrative Agent by such day shall be deemed to have declined to agree to such extension and shall be a Declining Lender (unless such Lender subsequently agrees to such requested extension and the Borrower elects in its sole discretion to treat such Lender as a Consenting Lender). If Lenders constituting the Required Lenders shall have agreed to a Commitment Termination Date extension request, then the Commitment Termination Date shall, as to the Consenting Lenders and any Lender replacing a Declining Lender, be extended effective as of the Extension Date to the date that is one year after the then Existing Commitment Termination Date. The decision to agree or withhold agreement to any Commitment Termination Date extension request shall be at the sole discretion of each Lender. The Commitment of each Declining Lender shall terminate on the Existing Commitment Termination Date applicable to such Declining Lender. The principal amount of any outstanding Advances made by Declining Lenders, together with any accrued interest thereon and any accrued fees and other amounts payable to or for the account of such Declining Lenders hereunder, shall be due and payable on the Existing Commitment Termination Date applicable to such Declining Lender. Notwithstanding the foregoing provisions of this subsection, the Borrower shall have the right, at any time prior to any Existing Commitment Termination Date applicable to any Declining Lender, to require such Declining Lender to assign and delegate its interests, rights and obligations under this Agreement pursuant to Section 8.07 to a Lender or (solely to the extent such consent would be required for an assignment pursuant to Section 8.07, subject to the consent of the Administrative Agent (such consent not to be unreasonably withheld, conditioned or delayed))
32



other Eligible Assignee, that agrees to a Commitment Termination Date extension with respect to such Existing Commitment Termination Date and executes and delivers to the Administrative Agent an appropriate Assignment and Acceptance. Any such assignee shall for all purposes hereunder constitute a Consenting Lender with respect to the applicable Commitment Termination Date extension request. Notwithstanding the foregoing, no extension of the Commitment Termination Date pursuant to this subsection shall become effective unless the Borrower shall have delivered to the Administrative Agent a certificate dated as of the Extension Date signed by a Responsible Officer of the Borrower certifying that before and after giving effect to such extension (A) no Default has occurred and is continuing as of the Extension Date or would result from such extension and (B) each of the representations and warranties set forth in Section 4.01 are true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects) as of the Extension Date, except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty shall have been true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects) on and as of such earlier date; provided, that for purposes of this Section 2.05(d), the representations and warranties contained in Section 4.01(e) shall be deemed to refer to the most recent statements furnished pursuant to Section 5.01(i)(i) and 5.01(i)(ii). The Borrower may extend the Commitment Termination Date up to two times under this Section 2.05(d).
SECTION 2.06    Repayment of Advances. The Borrower shall repay to the Administrative Agent, for the account of each Lender on the Commitment Termination Date applicable to such Lender, the aggregate principal amount of all Advances owing to such Lender outstanding on such date.
SECTION 2.07    Interest on Advances.
(a)    Scheduled Interest. The Borrower shall pay interest on the unpaid principal amount of each Advance made to it from the date of such Advance until such principal amount shall be paid in full, at the following rates per annum:
(i)    Base Rate Advances. During such periods as such Advance is a Base Rate Advance, a rate per annum equal at all times to the sum of (A) the Base Rate in effect from time to time and (B) the Applicable Margin, payable in arrears quarterly on the last Business Day of each March, June, September and December, during such periods and on the Commitment Termination Date applicable to any Lender.
(ii)    Eurodollar RateTerm Benchmark Advances. During such periods as such Advance is a Eurodollar RateTerm Benchmark Advance, a rate per annum equal at all times during each Interest Period for such Advance to the sum of (A) the EurodollarAdjusted Term SOFR Rate for such Interest Period for such Advance, and (B) the Applicable Margin, payable in arrears on the last day of such Interest Period and, if such Interest Period has a duration of more than three months, on each day that occurs during such Interest Period every three months from the first day of such Interest Period
33



and on the date such Eurodollar RateTerm Benchmark Advance shall be Converted, continued or paid in full.
(iii)    RFR Advances. During such periods as such Advance is a RFR Advance, a rate per annum equal at all times to the sum of (A) the Adjusted Daily Simple SOFR Rate in effect from time to time, and (B) the Applicable Margin, payable in arrears monthly on each date that is on the numerically corresponding day in each calendar month that is one month after the borrowing of such Advance (or, if there is no such numerically corresponding day in such month, then the last day of such month) and on the Commitment Termination Date applicable to any Lender.
(b)    Default Interest. Upon the occurrence and during the continuance of an Event of Default, the Administrative Agent shall, upon the request of the Required Lenders, require the Borrower to pay interest (“Default Interest”), which amount shall accrue as of the date of occurrence of the Event of Default, on (i) the unpaid principal amount of each Advance owing to each Lender, payable in arrears on the datesapplicable date referred to in Section 2.07(a)(i) or 2.07(a)(ii), at a rate per annum equal at all times to 2% per annum above the rate per annum required to be paid on such Advance pursuant to Section 2.07(a)(i) or 2.07(a)(ii) and (ii) to the fullest extent permitted by Law, the amount of any interest, fee or other amount payable hereunder that is not paid when due, from the date such amount shall be due until such amount shall be paid in full, payable in arrears on the date such amount shall be paid in full and on demand, at a rate per annum equal at all times to 2% per annum above the rate per annum required to be paid on Base Rate Advances pursuant to Section 2.07(a)(i), provided, however, that following acceleration of the Advances pursuant to Section 6.01, Default Interest shall accrue and be payable hereunder whether or not previously required by the Administrative Agent.
SECTION 2.08    Interest Rate Determination.
(a)    The Administrative Agent shall give prompt notice to the Borrower and the Lenders of the applicable interest rate determined by the Administrative Agent for purposes of Section 2.07(a)(i) or 2.07(a)(ii).
(b)    If, with respect to any Eurodollar Rate Advances, the the Required Lenders notify the Administrative Agent that (i) they are unable to obtain matching deposits in the London inter-bank market at or about 11:00 A.M. (London time) on the second Business Day before the making of a Borrowing in sufficient amounts to fund their respective Advances as a part of such Borrowing during its Interest Period or (ii) the Eurodollarwith respect to any Term Benchmark Advances, the Adjusted Term SOFR Rate for any Interest Period for such Advances will not adequately and fairly reflect the cost to the Required Lenders of making, funding or maintaining their respective Eurodollar RateTerm Benchmark Advances for such Interest Period or (ii) with respect to any RFR Advances, at any time, the applicable Adjusted Daily Simple SOFR Rate will not adequately and fairly reflect the cost to the Required Lenders of making or maintaining their RFR Advances, the Administrative Agent shall forthwith so notify the Borrower and the Lenders, whereupon (A) the Borrower will, on the last day of the then existing Interest Period therefor, either (1) prepay such Advances or (2) Convert such Advances into Base Rate Advances and (B) the obligation of the Lenders to make, continue Eurodollar Rate Advances as, or to Convert Advances into, Eurodollar Rate Advances shall be suspended until theand, until (x) the
34



Administrative Agent shall notifynotifies the Borrower and the Lenders that the circumstances causinggiving rise to such suspensionnotice no longer exist. with respect to the relevant Benchmark and (y) the Borrower delivers a new Interest Election Request in accordance with the terms of Section 2.09 or a new Notice of Borrowing in accordance with the terms of Section 2.02, an Interest Election Request that requests the conversion of any Borrowing to, or continuation of any Borrowing as, Term Benchmark Advances and any Notice of Borrowing that requests Term Benchmark Advances shall instead be deemed to be an Interest Election Request or a Notice of Borrowing, as applicable, for (1) an RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not also the subject of this Section 2.08(b) or (2) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate also is the subject of this Section 2.08(b). Furthermore, if any Term Benchmark Advance or RFR Advance is outstanding on the date of the Borrower’s receipt of the notice from the Administrative Agent referred to in this Section 2.08(b) with respect to the Relevant Rate applicable to such Term Benchmark Advance or RFR Advance, then until (x) the Administrative Agent notifies the Borrower and the Lenders that the circumstances giving rise to such notice no longer exist with respect to the relevant Benchmark and (y) the Borrower delivers a new Interest Election Request in accordance with the terms of Section 2.09 or a new Notice of Borrowing in accordance with the terms of Section 2.02, (1) any Term Benchmark Advance shall on the last day of the Interest Period applicable to such Advance, be converted by the Administrative Agent to, and shall constitute, (x) an RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not also the subject of this Section 2.08(b) or (y) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate also is the subject of this Section 2.08(b), on such day, and (2) any RFR Advance shall on and from such day be converted by the Administrative Agent to, and shall constitute, a Base Rate Advance.
(c)    On the date on which the aggregate unpaid principal amount of Eurodollar RateTerm Benchmark Advances comprising any Borrowing shall be reduced, by payment or prepayment or otherwise, to less than $5,000,000, such Advances shall automatically Convert into Base Rate Advances.
(d)    Upon the occurrence and during the continuance of any Event of Default, (i) each Eurodollar RateTerm Benchmark Advance will automatically, on the last day of the then existing Interest Period therefor, be Converted into a Base Rate Advance (unless the Required Lenders otherwise consent) and (ii) the obligation of the Lenders to make, continue Eurodollar RateTerm Benchmark Advances as, or to Convert Advances into, Eurodollar RateTerm Benchmark Advances shall be suspended.
SECTION 2.09    Interest Elections.
(a)    Each Borrowing initially shall be of the Type specified in the applicable Notice of Borrowing and, in the case of a Eurodollar RateTerm Benchmark Advance, shall have an initial Interest Period as specified in such Notice of Borrowing. Thereafter, the Borrower may elect to Convert such Borrowing to a different Type or to continue such Borrowing and, in the case of a Eurodollar RateTerm Benchmark Advance, may elect Interest Periods therefor, all as provided in this Section. The Borrower may elect different options with respect to different portions of the affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding the Advances comprising such Borrowing, and the Advances comprising each such portion shall be considered a separate Borrowing.
35



(b)    To make an election pursuant to this Section, the Borrower shall notify the Administrative Agent of such election by delivering to the Administrative Agent an Interest Election Request by the time that a Notice of Borrowing would be required under Section 2.02 if the Borrower were requesting a Borrowing of the Type resulting from such election to be made on the effective date of such election.
(c)    Each Interest Election Request shall specify the following information:
(i)    the Borrowing to which such Interest Election Request applies and, if different options are being elected with respect to different portions thereof, the portions thereof to be allocated to each resulting Borrowing (in which case the information to be specified pursuant to clauses (iii) and (iv) below shall be specified for each resulting Borrowing);
(ii)    the effective date of the election made pursuant to such Interest Election Request, which shall be a Business Day;
(iii)    whether the resulting Borrowing is to consist of Base Rate Advances or Eurodollar RateTerm Benchmark Advances; and
(iv)    if the resulting Borrowing is to consist of Eurodollar RateTerm Benchmark Advances, the Interest Period to be applicable thereto (which Interest Period shall be a period contemplated by the definition of the term “Interest Period”).
(d)    Promptly following receipt of an Interest Election Request, the Administrative Agent shall advise each Lender of the details thereof and of such Lender’s portion of each resulting Borrowing.
If the Borrower requests a Borrowing of Eurodollar RateTerm Benchmark Advances but does not specify an Interest Period or fails to deliver a timely Interest Election Request with respect to a Borrowing consisting of Eurodollar RateTerm Benchmark Advances prior to the end of the Interest Period applicable thereto, then, unless such Borrowing is repaid as provided herein or Section 2.08(d) is applicable thereto, at the end of such Interest Period, such Borrowing shall automatically continue as a Borrowing consisting of Eurodollar RateTerm Benchmark Advances with an Interest Period of one month unless such Borrowing is or was repaid in accordance with Section 2.10.
SECTION 2.10    Optional Prepayments of Advances. The Borrower may, upon notice to the Administrative Agent stating the proposed date and aggregate principal amount of the proposed prepayment, given not later than 11:00 A.M. (New York City time) on the date (which date shall be a Business Day) of such proposed prepayment, in the case of a Borrowing consisting of Base Rate Advances, and not later than 11:00 A.M. (New York City time) at least two U.S. Government Securities Business Days prior to the date of such proposed prepayment, in the case of a Borrowing consisting of Eurodollar RateTerm Benchmark Advances and not later than 11:00 A.M. (New York City time) at least three U.S. Government Securities Business Days prior to the date of such proposed prepayment, in the case of a Borrowing consisting of RFR Advances, and if such notice is given, the Borrower shall, prepay the outstanding principal amount of the Advances comprising part of the same Borrowing in whole or ratably in part, and in the case
36



of any Borrowing consisting of Eurodollar RateTerm Benchmark Advances, together with accrued interest to the date of such prepayment on the principal amount prepaid; provided, however, that (a) each partial prepayment shall be in an aggregate principal amount of the Borrowing Minimum or a Borrowing Multiple in excess thereof and (b) if any prepayment of a Eurodollar RateTerm Benchmark Advance is made on a date other than the last day of an Interest Period for such Eurodollar RateTerm Benchmark Advance, the Borrower shall also pay any amount owing pursuant to Section 8.04(c); and provided, further, that, subject to clause (b) of the immediately preceding proviso, any such notice may state that such notice is conditioned upon the effectiveness of other credit facilities or the consummation of a specific transaction, in which case such notice may be revoked by the Borrower if such condition is not satisfied.
SECTION 2.11    Increased Costs; Reserves on Eurodollar Rate Loans.
(a)    If, due to either (i) the introduction of or any change in or in the interpretation of any Law or regulation or (ii) the compliance with any directive, guideline or request from any central bank or other Governmental Authority including, without limitation, any agency of the European Union or similar monetary or multinational authority (whether or not having the force of Law), in each case after the date hereof (or with respect to any Lender, if later, the date on which such Lender becomes a Lender), there shall be any increase in the cost to any Lender of agreeing to make or making, funding or maintaining Eurodollar RateTerm Benchmark Advances (excluding for purposes of this Section 2.11 any such increased costs resulting from (A) Taxes as to which such Lender is indemnified under Section 2.14, (B) Excluded Taxes and (C) Other Taxes), and such Lender is generally charging, or intends to generally charge, such amounts to its customers that are similarly situated to the Borrower and with similar credit facilities, to the extent such Lender has the right under such similar credit facilities to do so (but such Lender shall not be required to disclose any confidential or proprietary information), then the Borrower shall from time to time, upon demand by such Lender (with a copy of such demand to the Administrative Agent), pay to the Administrative Agent for the account of such Lender additional amounts sufficient to compensate such Lender for such increased cost. A certificate as to such increased cost submitted to the Borrower and the Administrative Agent by such Lender shall be conclusive and binding for all purposes, absent demonstrable error.
(b)    If any Lender determines that compliance with any Law or regulation or any directive, guideline or request from any central bank or other Governmental Authority including, without limitation, any agency of the European Union or similar monetary or multinational authority (whether or not having the force of Law), in each case promulgated or given after the date hereof (or with respect to any Lender, if later, the date on which such Lender becomes a Lender), affects or would affect the amount of capital or liquidity required or expected to be maintained by such Lender or any corporation controlling such Lender and that the amount of such capital or liquidity is increased by or based upon the existence of such Lender’s commitment to lend hereunder and other commitments of this type, and such Lender is generally charging, or intends to generally charge, such amounts to its customers that are similarly situated to the Borrower and with similar credit facilities, to the extent such Lender has the right under such similar credit facilities to do so (but such Lender shall not be required to disclose any confidential or proprietary information), the Borrower shall, from time to time upon demand by such Lender (with a copy of such demand to the Administrative Agent), pay to the Administrative Agent for the account of such Lender, additional amounts sufficient to compensate such Lender or such
37



corporation in the light of such circumstances, to the extent that such Lender reasonably determines such increase in capital or liquidity to be allocable to the existence of such Lender’s commitment to lend hereunder. A certificate as to such amounts submitted to the Borrower and the Administrative Agent by such Lender shall be conclusive and binding for all purposes, absent demonstrable error.
(c)    Notwithstanding anything in this Section 2.11 to the contrary, for purposes of this Section 2.11, (i) the Dodd Frank Wall Street Reform and Consumer Protection Act and the rules and regulations issued thereunder or in connection therewith or in implementation thereof, and (ii) all requests, rules, guidelines and directions promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any similar or successor agency, or the United States or foreign regulatory authorities, in each case, pursuant to Basel III) shall be deemed to have been enacted following the date hereof (or with respect to any Lender, if later, the date on which such Lender becomes a Lender).
(d) The Borrower shall pay to each Lender, as long as such Lender shall be required to maintain reserves with respect to liabilities or assets consisting of or including Eurocurrency funds or deposits (currently known as Eurocurrency Liabilities), additional interest on the unpaid principal amount of each Eurodollar Rate Advance equal to the actual costs of such reserves allocated to such Advance by such Lender (as determined by such Lender in good faith, which determination shall be conclusive and binding absent demonstrable error), which shall be due and payable on each date on which interest is payable on such Advance, provided the Borrower shall have received at least 10 days’ prior notice (with a copy to the Administrative Agent) of such additional interest from such Lender. If a Lender fails to give notice 10 days prior to the relevant interest payment date, but such Lender gives notice within 30 days after such interest payment date, such additional interest shall be due and payable 10 days from receipt of such notice.
SECTION 2.12    Illegality. Notwithstanding any other provision of this Agreement, (a) if any Lender shall notify the Administrative Agent that the introduction of or any change in or in the interpretation of any Law or regulation makes it unlawful, or any central bank or other Governmental Authority, including without limitation, any agency of the European Union or similar monetary or multinational authority, asserts that it is unlawful, for such Lender or its EurodollarApplicable Lending Office to perform its obligations hereunder to make Eurodollar RateTerm Benchmark Advances or to fund or maintain Eurodollar RateTerm Benchmark Advances hereunder, (i) each Eurodollar RateTerm Benchmark Advance of such Lender will automatically, upon such notification, be Converted into (x) a RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not also the subject of this Section 2.12 or (y) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate also is the subject of this Section 2.12, (ii) the obligation of such Lender to make Eurodollar RateTerm Benchmark Advances or to Convert Advances into Eurodollar RateTerm Benchmark Advances shall be suspended and any Interest Election Request that requests the conversion of any Borrowing to, or continuation of any Borrowing as, a Term Benchmark Advance and any Notice of Borrowing that requests a Term Benchmark Advance shall, with respect to such Lender, instead be deemed to be an Interest Election Request or a Notice of Borrowing, as applicable, for (x) an RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not also the subject of this Section 2.12 or (y) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate also is the subject of this Section 2.12, in each case, until the Administrative Agent shall notify the Borrower and such Lender that
38



the circumstances causing such suspension no longer exist and (iii) the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the EurodollarAdjusted Term SOFR Rate component thereof and (b) if Lenders constituting the Required Lenders so notify the Administrative Agent, (i) each Eurodollar RateTerm Benchmark Advance of each Lender will automatically, upon such notification, Convert into (x) a RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not also the subject of this Section 2.12 or (y) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate also is the subject of this Section 2.12, (ii) the obligation of each Lender to make Eurodollar RateTerm Benchmark Advances or to Convert Advances into, or to continue Eurodollar RateTerm Benchmark Advances as, Eurodollar RateTerm Benchmark Advances shall be suspended and any Interest Election Request that requests the conversion of any Borrowing to, or continuation of any Borrowing as, a Term Benchmark Advance and any Notice of Borrowing that requests a Term Benchmark Advance shall instead be deemed to be an Interest Election Request or a Notice of Borrowing, as applicable, for (x) an RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not also the subject of this Section 2.12 or (y) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate also is the subject of this Section 2.12, in each case, until the Administrative Agent shall notify the Borrower and each Lender that the circumstances causing such suspension no longer exist and (iii) the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to each Lender without reference to the EurodollarAdjusted Term SOFR Rate component thereof.
SECTION 2.13    Payments and Computations.
(a)    The Borrower shall make each payment required to be made by it under this Agreement not later than 11:00 A.M. (New York City time) on the day when due in Dollars to the Administrative Agent at the applicable Administrative Agent’s Office in same day funds. The Administrative Agent will promptly thereafter cause to be distributed like funds relating to the payment of principal or interest or commitment fees ratably (other than amounts payable pursuant to Section 2.02(c), 2.11, 2.12(a), 2.14, 2.15 or 8.04(c)) to the Lenders for the account of their respective Applicable Lending Offices, and like funds relating to the payment of any other amount payable to any Lender to such Lender for the account of its Applicable Lending Office, in each case to be applied in accordance with the terms of this Agreement. Upon its acceptance of an Assignment and Acceptance and recording of the information contained therein in the Register pursuant to Section 8.07(c), from and after the effective date specified in such Assignment and Acceptance, the Administrative Agent shall make all payments hereunder in respect of the interest assigned thereby to the assignor for amounts which have accrued to but excluding the effective date of such assignment and to the assignee for amounts which have accrued from and after the effective date of such assignment. All payments to be made by the Borrower shall be made without condition or deduction for any counterclaim, defense, recoupment or setoff.
(b)    The Borrower hereby authorizes each Lender, if and to the extent payment owed to such Lender is not made when due hereunder, to charge from time to time against any or all of the Borrower’s accounts with such Lender any amount so due.
(c)    All computations of interest based on the Base Rate shall be made by the Administrative Agent on the basis of a year of 365 or 366 days, as the case may be, and all computations of interest based on the EurodollarAdjusted Term SOFR Rate, the Adjusted Daily
39



Simple SOFR Rate or the Federal Funds Rate (other than determinations of the Base Rate made at any time by reference to the Federal Funds Rate) and of commitment fees shall be made by the Administrative Agent on the basis of a year of 360 days, in each case for the actual number of days (including the first day but excluding the last day) occurring in the period for which such interest or such fees are payable. Each determination by the Administrative Agent of an interest rate hereunder shall be conclusive and binding for all purposes, absent demonstrable error.
(d)    Whenever any payment hereunder shall be stated to be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day, and such extension of time shall in such case be included in the computation of payment of interest or commitment fee, as the case may be; provided, however, that, if such extension would cause payment of interest on or principal of Eurodollar RateTerm Benchmark Advances to be made in the next following calendar month, such payment shall be made on the immediately preceding Business Day.
(e)    Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Lenders hereunder that the Borrower will not make such payment in full, the Administrative Agent may assume that the Borrower has made such payment in full to the Administrative Agent on such date and the Administrative Agent may, in reliance upon such assumption, cause to be distributed to each Lender on such due date an amount equal to the amount then due such Lender. If and to the extent the Borrower shall not have so made such payment in full to the Administrative Agent, each Lender shall repay to the Administrative Agent, following prompt notice thereof, forthwith on demand such amount distributed to such Lender, together with interest thereon, for each day from the date such amount is distributed to such Lender until the date such Lender repays such amount to the Administrative Agent, at the Federal Funds Rate.
SECTION 2.14    Taxes.
(a)    Obligation to Withhold; Payments on Account of Taxes.
(i)    Any and all payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable Laws. If any applicable Laws require the deduction or withholding of any Tax from any such payment by the Administrative Agent or the Borrower, then the Administrative Agent or the Borrower shall be entitled to make such deduction or withholding, upon the basis of the information and documentation to be delivered pursuant to subsection (e) below.
(ii)    If the Borrower or the Administrative Agent shall be required by any applicable Laws to withhold or deduct any Taxes from any payment, then (A) the Borrower or the Administrative Agent, as required by such Laws, shall withhold or make such deductions as required based upon the information and documentation it has received pursuant to subsection (e) below, (B) the Borrower or the Administrative Agent, to the extent required by such Laws, shall timely pay the full amount withheld or deducted to the relevant Governmental Authority in accordance with such Laws, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable
40



by the Borrower shall be increased as necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this Section 2.14) the Lender (or, as applicable, the Administrative Agent) receives an amount equal to the sum it would have received had no such withholding or deduction been made.
(b)    Payment of Other Taxes. Without limiting the provisions of subsection (a) above, the Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes.
(c)    Tax Indemnifications. (i) The Borrower shall, and does hereby, indemnify each Lender and the Administrative Agent, and shall make payment in respect thereof within 30 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 2.14) payable or paid by such Lender or the Administrative Agent or required to be withheld or deducted from a payment to such Lender and the Administrative Agent, and reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.
(ii)    Each Lender shall, and does hereby, severally indemnify, and shall make payment in respect thereof within 10 days after demand therefor, (x) the Administrative Agent against any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower have not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (y) the Administrative Agent against any Taxes attributable to such Lender’s failure to comply with the provisions of Section 8.07(e) relating to the maintenance of a Participant Register and (z) the Administrative Agent against any Excluded Taxes attributable to such Lender that are payable or paid by the Administrative Agent or the Borrower in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under this Agreement or any other Loan Document against any amount due to the Administrative Agent under this clause (ii).
(d)    Evidence of Payments. Upon request by the Borrower or the Administrative Agent, as the case may be, after any payment of Taxes by the Borrower or by the Administrative Agent to a Governmental Authority as provided in this Section 2.14, the Borrower shall deliver to the Administrative Agent or the Administrative Agent shall deliver to the Borrower, as the case may be, the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of any return required by Laws to report such payment or other evidence of
41



such payment reasonably satisfactory to the Borrower or the Administrative Agent, as the case may be.
(e)    Status of Lenders; Tax Documentation.
(i)    Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Sections 2.14(e)(ii)(A), 2.14(e)(ii)(B) and 2.14(e)(ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.
(ii)    Without limiting the generality of the foregoing,
(A)    any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed originals of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;
(B)    any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:
(I)    in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed originals of IRS Form W-8BEN-E (or W-8BEN, as applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN-E (or W-8BEN, as applicable)
42



establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;
(II)    executed originals of IRS Form W-8ECI;
(III)    in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Internal Revenue Code, (x) a certificate substantially in the form of Exhibit C-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a “10 percent shareholder” of any of the Borrower within the meaning of Section 881(c)(3)(B) of the Internal Revenue Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Internal Revenue Code (a “U.S. Tax Compliance Certificate”) and (y) executed originals of IRS Form W-8BEN-E (or W-8BEN, as applicable); or
(IV)    to the extent a Foreign Lender is not the beneficial owner, executed originals of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN-E (or W-8BEN, as applicable), a U.S. Tax Compliance Certificate substantially in the form of Exhibit C-2 or Exhibit C-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit C-4 on behalf of each such direct and indirect partner;
(C)    any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed originals of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and
(D)    if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Internal Revenue Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably
43



requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.
(iii)    Each Lender agrees that if any form or certification it previously delivered pursuant to this Section 2.14 expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.
(f)    Treatment of Certain Refunds. Unless required by applicable Laws, at no time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender any refund of Taxes withheld or deducted from funds paid for the account of such Lender. If any Lender or the Administrative Agent determines, in its sole discretion, that it has received a refund of any Taxes as to which it has been indemnified by the Borrower or with respect to which the Borrower has paid additional amounts pursuant to this Section 2.14, it shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by the Borrower under this Section 2.14 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) incurred by such Lender or the Administrative Agent, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that the Borrower, upon the request of such Lender or the Administrative Agent, agrees to repay the amount paid over to the Borrower (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to such Lender or the Administrative Agent in the event such Lender or the Administrative Agent is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this subsection, in no event will the applicable Lender or the Administrative Agent be required to pay any amount to the Borrower pursuant to this subsection the payment of which would place such Lender or the Administrative Agent in a less favorable net after-Tax position than it would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This subsection shall not be construed to require any Lender or the Administrative Agent to make available its Tax returns to the Borrower or any other Person.
SECTION 2.15    Sharing of Payments, Etc. Subject to Section 2.19 in the case of a Defaulting Lender, if any Lender shall obtain any payment (whether voluntary, involuntary, through the exercise of any right of setoff, or otherwise) on account of the Advances owing to it (other than pursuant to Section 2.02(c), 2.11, 2.12(a), 2.14 or 8.04(c)) in excess of its ratable share of payments on account of the Advances obtained by all the Lenders, such Lender shall forthwith purchase from the other Lenders such participations in the Advances owing to them as shall be necessary to cause such purchasing Lender to share the excess payment ratably with each of them; provided, however, that if all or any portion of such excess payment is thereafter
44



recovered from such purchasing Lender, such purchase from each Lender shall be rescinded and such Lender shall repay to the purchasing Lender the purchase price to the extent of such recovery together with an amount equal to such Lender’s ratable share (according to the proportion of (a) the amount of such Lender’s required repayment to (b) the total amount so recovered from the purchasing Lender) of any interest or other amount paid or payable by the purchasing Lender in respect of the total amount so recovered. The Borrower agrees that any Lender so purchasing a participation from another Lender pursuant to this Section 2.15 may, to the fullest extent permitted by Law, exercise all its rights of payment (including the right of setoff) with respect to such participation as fully as if such Lender were the direct creditor of the Borrower in the amount of such participation.
SECTION 2.16    Use of Proceeds. The proceeds of the Advances shall be available, and the Borrower agrees that it shall use such proceeds, solely for general corporate purposes of the Borrower and its Subsidiaries.
SECTION 2.17    Evidence of Debt.
(a)    Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the indebtedness of the Borrower to such Lender resulting from each Advance owing to such Lender from time to time, including the amounts of principal and interest payable and paid to such Lender from time to time hereunder in respect of Advances.
(b)    The Register maintained by the Administrative Agent pursuant to Section 8.07(d) shall include a control account, and a subsidiary account for each Lender, in which accounts (taken together) shall be recorded (i) the date and amount of each Borrowing made hereunder, the Type of Advances comprising such Borrowing and, if appropriate, the Interest Period applicable thereto, (ii) the terms of each Assignment and Acceptance delivered to and accepted by it, (iii) the amount of any principal or interest due and payable or to become due and payable from the Borrower to each Lender hereunder and (iv) the amount of any sum received by the Administrative Agent from the Borrower hereunder and each Lender’s share thereof.
(c)    Entries made reasonably and in good faith by the Administrative Agent in the Register pursuant to subsection 2.17(b) above, and by each Lender in its account or accounts pursuant to subsection 2.17(a) above, shall be prima facie evidence of the amount of principal and interest due and payable or to become due and payable from the Borrower to, in the case of the Register, each Lender and, in the case of such account or accounts, such Lender, under this Agreement, absent manifest error; provided, however, that the failure of the Administrative Agent or such Lender to make an entry, or any finding that an entry is incorrect, in the Register or such account or accounts shall not limit, expand or otherwise affect the obligations of the Borrower under this Agreement.
(d)    Upon the request of any Lender made through the Administrative Agent, the Borrower shall prepare, execute and deliver to such Lender a promissory note of the Borrower payable to such Lender, substantially in the form of any promissory note delivered to any Lender on the Closing Date pursuant to Section 3.01(j) (or such other form reasonably approved by the Administrative Agent), which promissory note shall, in addition to the Register, evidence such Lender’s Advances.
45



SECTION 2.18    Alternate Rate of Interest(a)    .
(a)    Notwithstanding anything to the contrary herein or in any other Loan Document, if a Benchmark Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with clause (1) or (2) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any other Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with clause (32) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any other Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders.
(b) Notwithstanding anything to the contrary herein or in any other Loan Document and subject to the proviso below in this paragraph, if a Term SOFR Transition Event and its related Benchmark Replacement Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then the applicable Benchmark Replacement will replace the then-current Benchmark for all purposes hereunder or under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings, without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document; provided that, this clause (b) shall not be effective unless the Administrative Agent has delivered to the Lenders and the Borrower a Term SOFR Notice. For the avoidance of doubt, the Administrative Agent shall not be required to deliver a Term SOFR Notice after a Term SOFR Transition Event and may do so in its sole discretion.
(b)    (c) In connection with the implementation of a Benchmark Replacement, Notwithstanding anything to the contrary herein or in any other Loan Document, the Administrative Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.
(c)    (d) The Administrative Agent will promptly notify the Borrower and the Lenders of (i) any occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date, (ii) the implementation of any Benchmark Replacement, (iii) the effectiveness of any Benchmark Replacement Conforming Changes, (iv) the removal or reinstatement of any tenor of a Benchmark pursuant to clause (ed) below and (v) the commencement or conclusion of any Benchmark Unavailability Period. Any determination, decision or election that may be made by
46



the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 2.18, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 2.18.
(d)    (e) Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR or LIBORRate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is or will be no longer representative, then the Administrative Agent may modify the definition of “Interest Period” for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is or will no longer be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of “Interest Period” for all Benchmark settings at or after such time to reinstate such previously removed tenor.
(e)    (f) Upon the Borrower’s receipt of notice of the commencement of a Benchmark Unavailability Period, the Borrower may revoke any request for a borrowing of, conversion to or continuation of Eurodollar RateTerm Benchmark Advances to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to Base Rate Advances(A) an RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not the subject of a Benchmark Transition Event or (B) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate is the subject of a Benchmark Transition Event. During any Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of Base Rate based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of Base Rate. Furthermore, if any Term Benchmark Advance or RFR Advance is outstanding on the date of the Borrower’s receipt of notice of the commencement of a Benchmark Unavailability Period with respect to a Relevant Rate applicable to such Term Benchmark Advance or RFR Advance, then until such time as a Benchmark Replacement is implemented pursuant to this Section 2.18, (1) any Term Benchmark Advance shall on the last day of the Interest Period applicable to such Advance, be converted by the Administrative Agent to, and shall constitute, (x) an RFR Advance so long as the Adjusted Daily Simple SOFR Rate is not the subject of a Benchmark Transition Event or (y) a Base Rate Advance if the Adjusted Daily Simple SOFR Rate is the subject of a Benchmark Transition Event, on such day and (2) any RFR Advance shall on and from such day be converted by the Administrative Agent to, and shall constitute, a Base Rate Advance.
47



SECTION 2.19    Defaulting Lenders.
(a)    Notwithstanding any provision of this Agreement to the contrary, if any Lender becomes a Defaulting Lender, then the following provisions shall apply for so long as such Lender is a Defaulting Lender (it being understood that the determination of whether a Lender is no longer a Defaulting Lender shall be made as described in Section 2.19(b)):
(i)    such Defaulting Lender will not be entitled to any fees accruing during such period pursuant to Section 2.04(a);
(ii)    to the fullest extent permitted by applicable Law, such Lender will not be entitled to vote in respect of amendments and waivers hereunder, and the Commitment and the outstanding Advances of such Lender hereunder will not be taken into account in determining whether the Required Lenders or all of the Lenders, as required, have approved any such amendment or waiver (and the definition of “Required Lenders” will automatically be deemed modified accordingly for the duration of such period); provided that any such amendment or waiver that would increase or extend the term of the Commitment of such Defaulting Lender, extend the date fixed for the payment of principal or interest owing to such Defaulting Lender hereunder, reduce the principal amount of any obligation owing to such Defaulting Lender, reduce the amount of or the rate or amount of interest on any amount owing to such Defaulting Lender or of any fee payable to such Defaulting Lender hereunder, or alter the terms of this proviso, will require the consent of such Defaulting Lender; and
(iii)    the Borrower may, at its sole expense and effort, require such Defaulting Lender to assign and delegate its interests, rights and obligations under this Agreement pursuant to Section 8.07.
(b)    If the Borrower and the Administrative Agent agree in writing in their sole discretion that a Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein, such Lender will, to the extent applicable, purchase at par such portion of outstanding Advances of the other Lenders and/or make such other adjustments as the Administrative Agent may determine to be necessary to cause the Advances and unused Commitments to be on a pro rata basis in accordance with their respective Commitments, whereupon such Lender will cease to be a Defaulting Lender and will be a Non-Defaulting Lender; provided, that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while such Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Non-Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from such Lender’s having been a Defaulting Lender.
(c)    Any payment of principal, interest, fees or other amounts received by the Administrative Agent hereunder for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 6.01 or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to Section 8.05 shall be applied at such time or times as follows: first, to the payment of any amounts owing by such Defaulting Lender to the
48



Administrative Agent hereunder; second as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Advance in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as reasonably determined by the Administrative Agent; third, as the Borrower may request, to be held in a deposit account and released pro rata in order to satisfy such Defaulting Lender’s potential future funding obligations with respect to Advances under this Agreement; fourth, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; fifth, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and sixth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or otherwise pursuant to this Section 2.19(c) shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto.
SECTION 2.20    Mitigation.
(a)    Each Lender shall promptly notify the Borrower and the Administrative Agent of any event of which it has knowledge that will result in, and will use reasonable commercial efforts available to it (and not, in such Lender’s good faith judgment, otherwise disadvantageous to such Lender) to mitigate or avoid, (i) any obligation by the Borrower to pay any amount pursuant to Sections 2.11 or 2.14 or (ii) the occurrence of any circumstance described in Section 2.12 (and, if any Lender has given notice of any such event described in clause (i) or (ii) above and thereafter such event ceases to exist, such Lender shall promptly so notify the Borrower and the Administrative Agent). In furtherance of the foregoing, each Lender will designate a different Applicable Lending Office if such designation will avoid (or reduce the cost to the Borrower of) any event described in clause (i) or (ii) of the preceding sentence and such designation will not, in such Lender’s good faith judgment, be otherwise disadvantageous to such Lender.
(b)    Failure or delay on the part of any Lender to demand compensation pursuant to Sections 2.11 or 2.14 shall not constitute a waiver of such Lender’s right to demand such compensation; provided that, notwithstanding any other provision of this Agreement, if any Lender fails to notify the Borrower of any event or circumstance which will entitle such Lender to compensation pursuant to Sections 2.11 or 2.14 within 180 days after such Lender obtains knowledge of such event or circumstance, then such Lender shall not be entitled to compensation from the Borrower for any amount arising prior to the date which is 180 days before the date on which such Lender notifies the Borrower of such event or circumstance (except that, if the event or circumstance giving rise to such entitlement for compensation is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive effect thereof).
49



ARTICLE III
CONDITIONS TO EFFECTIVENESS AND LENDING
SECTION 3.01    Conditions Precedent to Closing Date. This Agreement shall become effective on and as of the first date on which the following conditions precedent have been satisfied (or waived in accordance with Section 8.01):
(a)    The Administrative Agent (or its counsel) shall have received from each party hereto either (i) a counterpart of this Agreement and the other Loan Documents signed on behalf of such party or (ii) written evidence reasonably satisfactory to the Administrative Agent (which may include facsimile transmission of a signed signature page of this Agreement) that such party has signed a counterpart of this Agreement.
(b)    Since December 31, 2019, there shall not have occurred any event or condition that has had or would be reasonably expected to have, either individually or in the aggregate, a Material Adverse Effect.
(c)    All fees due to the Administrative Agent, the Arrangers and the Lenders shall have been paid, and all expenses of the Administrative Agent and the Arrangers that are required to be paid or reimbursed by the Borrower and that have been invoiced at least three Business Days prior to the Closing Date shall have been so paid or reimbursed.
(d)    On the Closing Date, the following statements shall be true and the Administrative Agent shall have received a certificate of the Borrower, dated the Closing Date, stating that:
(i)    Each of the representations and warranties set forth in Section 4.01 are true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects), on and as of the Closing Date, except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty shall have been true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects) on and as of such earlier date; and
(ii)    No event has occurred and is continuing, or shall occur as a result of the occurrence of the Closing Date, that constitutes a Default.
(e)    The Administrative Agent shall have received on or before the Closing Date, each dated on or about such date:
(i)    Certified copies of the resolutions or similar authorizing documentation of the governing body of the Borrower, and of all documents
50



evidencing other necessary corporate action and governmental approvals, if any, with respect to this Agreement;
(ii)    A certificate of the Secretary or an Assistant Secretary of the Borrower certifying the names and true signatures of the officers of the Borrower authorized to sign this Agreement and the other documents to be delivered by it hereunder; and
(iii)    A favorable opinion letter from Latham & Watkins LLP, as counsel to the Borrower, in the form agreed on or prior to the Closing Date.
(f)    The 2018 Credit Agreement shall have been terminated in accordance with Section 8.15.
(g)    To the extent requested by a Lender, delivery of executed promissory notes.
(h)    To the extent requested by any Lender through the Administrative Agent in writing at least 10 Business Days prior to the Closing Date, the Borrower shall have provided the documentation and other information to the Administrative Agent that is required by regulatory authorities under applicable “know-your-customer” rules and regulations, including the Patriot Act and the Beneficial Ownership Regulation, at least three Business Days prior to the Closing Date.
The Administrative Agent shall notify the Borrower and the Lenders of the Closing Date in writing promptly upon such conditions precedent being satisfied (or waived in accordance with Section 8.01), and such notice shall be conclusive and binding evidence of the occurrence thereof.
SECTION 3.02    Conditions Precedent to Each Borrowing. The obligation of each Lender to make an Advance on the occasion of each Borrowing (other than a Borrowing consisting only of a Conversion of Advances to the other Type, or a continuation of Eurodollar RateTerm Benchmark Advances) shall be subject to the conditions precedent that the Closing Date shall have occurred and on the date of such Borrowing the following statements shall be true (and each of the giving of the applicable Notice of Borrowing and the acceptance by the Borrower of the proceeds of such Borrowing shall constitute a representation and warranty by the Borrower that on the date of such Borrowing such statements are true):
(a)    Each of the representations and warranties set forth in Section 4.01 (other than the representations and warranties set forth in Section 4.01(f)(i)) are true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects) as of such date, before and after giving effect to such Borrowing and the application of proceeds therefrom, as though made on and as of such date, except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty shall have been true and correct in all material respects (except to the extent such representations and warranties are qualified with “materiality” or “Material Adverse
51



Effect” or similar terms, in which case such representations and warranties shall be true and correct in all respects) on and as of such earlier date, and
(b)    no event has occurred and is continuing, or would result from such Borrowing or from the application of the proceeds therefrom, that constitutes a Default.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES
SECTION 4.01    Representations and Warranties of the Borrower. The Borrower represents and warrants on the Closing Date, on the date of the making of each Advance, on any Increase Effective Date and on any Extension Date as follows (but with respect to the representations and warranties set forth in Section 4.01(f)(i), only on the Closing Date, any Increase Effective Date and any Extension Date):
(a)    The Borrower is a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction of organization.
(b)    The execution, delivery and performance by the Borrower of this Agreement and the other Loan Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, (i) are within the Borrower’s corporate powers, (ii) have been duly authorized by all necessary corporate action, (iii) do not contravene (A) the Borrower’s charter or by-laws or other organizational documents or (B) any Law, regulation or contractual restriction binding on or affecting the Borrower and (iv) will not result in or require the creation or imposition of any Lien upon or with respect to any of the properties of the Consolidated Group (other than Liens created or required to be created pursuant to the terms hereof), except, in the case of clause (iii)(B) and (iv), as would not be reasonably expected to have a Material Adverse Effect.
(c)    No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or regulatory body or, except as would not be reasonably expected to have a Material Adverse Effect, any other third party is required for the due execution, delivery and performance by the Borrower of this Agreement.
(d)    This Agreement has been duly executed and delivered by the Borrower. This Agreement is the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as affected by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors’ rights generally and general principles of equity (whether considered in a proceeding in equity or at Law) and an implied covenant of good faith and fair dealing.
(e)    The Consolidated balance sheet of the Borrower and its Subsidiaries as at December 31, 2019, and the related Consolidated statements of earnings and cash flows of the Borrower and its Subsidiaries for the fiscal year then ended, accompanied by an opinion of Ernst & Young LLP or other independent public accountants of recognized national standing, and the Consolidated balance sheet of the Borrower and its Subsidiaries as at
52



September 30, 2020, and the related Consolidated statements of earnings and cash flows of the Borrower and its Subsidiaries for the nine months then ended, duly certified by the Executive Vice President, Finance and Chief Financial Officer of the Borrower, copies of which have been furnished to each Lender, fairly present, in all material respects, the Consolidated financial condition of the Borrower and its Subsidiaries as at such dates and the Consolidated results of the operations of the Borrower and its Subsidiaries for the periods ended on such dates, all in accordance with GAAP (subject, in the case of the Consolidated balance sheet as at September 30, 2020 and the related statements of earnings and cash flows, to the absence of footnotes and year-end audit adjustments); provided that information referenced in this Section 4.01(e) shall be deemed to have been furnished if such information, or one or more annual or quarterly or other reports or proxy statements containing such information, shall have been posted and be available on the website of the Securities and Exchange Commission at http://www.sec.gov.
(f)    As of the Closing Date (or, in the case that this representation and warranty is made on any Increase Effective Date or any Extension Date, as of such Increase Effective Date or Extension Date, as applicable), there is no action, suit, investigation, litigation or proceeding (including, without limitation, any Environmental Action), affecting the Consolidated Group pending or, to the knowledge of the Borrower, threatened before any court, governmental agency or arbitrator that would reasonably be expected to be adversely determined, and if so determined, (i) would reasonably be expected to have a material adverse effect on the financial condition or results of operations of the Consolidated Group taken as a whole (other than the litigation set forth on Schedule 4.01(f) attached hereto (or, in the case that this representation and warranty is made on any date after the date hereof, as set forth on a schedule delivered to the Administrative Agent on or prior to such date, as applicable)) or (ii) would adversely affect the legality, validity and enforceability of any material provision of this Agreement in any material respect.
(g)    Following application of the proceeds of each Advance, not more than 25 percent of the value of the assets of the Borrower and of the Consolidated Group, on a Consolidated basis, subject to the provisions of Section 5.02(a) will be margin stock (within the meaning of Regulation U issued by the Board of Governors of the Federal Reserve System).
(h)    All written information (other than the projections, any forward-looking statements and information of a general economic or industry nature) concerning the Borrower, its Subsidiaries and the transactions contemplated hereby included in the Information Memorandum or otherwise prepared by the Borrower and its Subsidiaries and furnished to the Agents or the Lenders in connection with the negotiation of, or pursuant to the terms of, this Agreement when taken as a whole, was true and correct in all material respects as of the date when furnished by the Borrower and its subsidiaries to the Agents or the Lenders and did not, taken as a whole, when so furnished contain any untrue statement of a material fact as of any such date or omit to state a material fact necessary in order to make the statements contained therein, taken as a whole, not misleading in light of the circumstances under which such statements were made.
53



(i)    No ERISA Event has occurred or is reasonably expected to occur with respect to any Plan which would reasonably be expected to have a Material Adverse Effect.
(j)    As of the last annual actuarial valuation date prior to the Closing Date, the Abbott Laboratories Annuity Retirement Plan was not in at-risk status (as defined in Section 430(i)(4) of the Internal Revenue Code) and no other Plan subject to ERISA was in at-risk status (as defined in Section 430(i)(4) of the Internal Revenue Code), and since such annual actuarial valuation date there has been no material adverse change in the funding status of any Plan subject to ERISA that would reasonably be expected to cause such Plan to be in at-risk status (as defined in Section 430(i)(4) of the Internal Revenue Code).
(k)    Neither the Borrower nor any ERISA Affiliate (i) is reasonably expected to incur any Withdrawal Liability to any Multiemployer Plan or has incurred any such Withdrawal Liability that has not been satisfied in full or (ii) has been notified by the sponsor of a Multiemployer Plan that such Multiemployer Plan is in reorganization (within the meaning of Section 4241 of ERISA), insolvent (within the meaning of Section 4245 of ERISA) or has been determined to be in “endangered” or “critical” status (within the meaning of Section 432 of the Internal Revenue Code or Section 305 of ERISA), and no such Multiemployer Plan is reasonably expected to be in reorganization, insolvent or in “endangered” or “critical” status.
(l)    (i) The operations and properties of the Consolidated Group comply in all respects with all applicable Environmental Laws and Environmental Permits except to the extent that the failure to so comply, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect; (ii) all past non-compliance with such Environmental Laws and Environmental Permits has been resolved without any ongoing obligations or costs except to the extent that such non-compliance, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect; and (iii) no circumstances exist that would be reasonably expected to (A) form the basis of an Environmental Action against a member of the Consolidated Group or any of its properties that, either individually or in the aggregate, would have a Material Adverse Effect or (B) cause any such property to be subject to any restrictions on ownership, occupancy, use or transferability under any Environmental Law that, either individually or in the aggregate, would have a Material Adverse Effect.
(m)    (i) None of the properties currently or formerly owned or operated by a member of the Consolidated Group is listed or proposed for listing on the NPL or on the CERCLIS or any analogous foreign, state or local list or, to the best knowledge of the Borrower, is adjacent to any such property other than such properties of a member of the Consolidated Group that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect; (ii) there are no, and never have been any, underground or aboveground storage tanks or any surface impoundments, septic tanks, pits, sumps or lagoons in which Hazardous Materials are being or have been treated, stored or disposed of on any property currently owned or operated by any member of the Consolidated Group or, to the best knowledge of the Borrower, on any property formerly owned or operated by a member of the Consolidated Group that, either individually or in
54



the aggregate, would reasonably be expected to have a Material Adverse Effect; (iii) there is no asbestos or asbestos-containing material on any property currently owned or operated by a member of the Consolidated Group that, either individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; and (iv) Hazardous Materials have not been released, discharged or disposed of on any property currently or formerly owned or operated by a member of the Consolidated Group or, to the best knowledge of the Borrower, on any adjoining property that, either individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.
(n)    No member of the Consolidated Group is undertaking, and no member of the Consolidated Group has completed, either individually or together with other potentially responsible parties, any investigation or assessment or remedial or response action relating to any actual or threatened release, discharge or disposal of Hazardous Materials at any site, location or operation, either voluntarily or pursuant to the order of any governmental or regulatory authority or the requirements of any Environmental Law that, either individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; and all Hazardous Materials generated, used, treated, handled or stored at, or transported to or from, any property currently or formerly owned or operated by a member of the Consolidated Group have been disposed of in a manner that, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
(o)    No member of the Consolidated Group is an “investment company”, or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment company” (each as defined in the Investment Company Act of 1940, as amended). Neither the making of any Advances nor the application of the proceeds or repayment thereof by the Borrower, nor the consummation of the other transactions contemplated hereby, will violate any provision of such Act or any rule, regulation or order of the Securities and Exchange Commission thereunder.
(p)    The Advances and all related obligations of the Borrower under this Agreement rank pari passu with all other unsecured obligations of the Borrower that are not, by their terms, expressly subordinate to the obligations of the Borrower hereunder.
(q)    The proceeds of the Advances will be used in accordance with Section 2.16.
(r)    Neither the Borrower nor any of its Subsidiaries or, to the knowledge of senior management of the Borrower, any director, officer, employee or agent of the Borrower or any of its Subsidiaries is an individual or entity currently the subject of any Sanctions, and neither the Borrower nor any of its Subsidiaries is located, organized or resident in a Designated Jurisdiction in violation of any Sanctions; provided that if the Borrower or any Subsidiary is located, organized or resident in a jurisdiction that becomes a Designated Jurisdiction after the Closing Date, such Person shall not be included in this representation so long as (i) the Borrower is taking reasonable steps to either obtain appropriate licenses for transacting business in such country or territory or to cause such Person to no longer be located, be organized or be resident in such country or territory and (ii) such Person’s being located, organized or resident in such country or territory (A) will
55



not result in any violation of Sanctions by any Lender, any Arranger or the Administrative Agent and (B) would not be reasonably expected to have Material Adverse Effect.
(s)    The Borrower and its Subsidiaries (i) have conducted their businesses in compliance with applicable anti-corruption Laws, except to the extent that failure to so comply would not be reasonably expected to have Material Adverse Effect; and (ii) have instituted and maintained policies and procedures reasonably designed to promote and achieve compliance with such Laws.
(t)    As of the Closing Date, the information included in any Beneficial Ownership Certification (to the extent required to be provided) is true and correct in all respects.
ARTICLE V
COVENANTS OF THE BORROWER
SECTION 5.01    Affirmative Covenants. So long as any Advance shall remain unpaid or any Lender shall have any Commitment hereunder, the Borrower will:
(a)    Compliance with Laws, Etc. Comply, and cause each of its Subsidiaries to comply, with all applicable Laws, rules, regulations and orders (such compliance to include, without limitation, compliance with ERISA and Environmental Laws), except to the extent that the failure to so comply, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
(b)    Payment of Taxes, Etc. Pay and discharge, or cause to be paid and discharged, before the same shall become delinquent, all Taxes imposed upon any member of the Consolidated Group except to the extent that (i) the amount, applicability or validity thereof is being contested in good faith and by proper proceedings or (ii) the failure to pay such Taxes, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
(c)    Maintenance of Insurance. Maintain, and cause each of its Subsidiaries to maintain, insurance with responsible and reputable insurance companies or associations (or pursuant to self-insurance arrangements) in such amounts and covering such risks as is usually carried by companies engaged in similar businesses and owning similar properties in the same general areas in which any member of the Consolidated Group operates.
(d)    Preservation of Existence, Etc. Do, or cause to be done, all things necessary to preserve and keep in full force and effect its (i) existence and (ii) rights (charter and statutory) and franchises; provided, however, that the Borrower may consummate any merger or consolidation permitted under Section 5.02(b); and provided, further, that the Borrower shall not be required to preserve any such right or franchise if the management of the Borrower shall determine that the preservation thereof is no longer desirable in the conduct of the business of the Borrower and that the loss thereof is not disadvantageous in any material respect to the Lenders.
56



(e)    Visitation Rights. At any reasonable time and from time to time during normal business hours, upon reasonable notice to the Borrower, permit the Administrative Agent or any of the Lenders, or any agents or representatives thereof, to examine and make copies of and abstracts from the records and books of account, and visit the properties, of the Borrower, and to discuss the affairs, finances and accounts of the Borrower and/or any of its Subsidiaries with any of the members of the senior treasury staff of the Borrower.
(f)    Keeping of Books. Keep, and cause each of its Subsidiaries to keep, proper books of record and account, in which full and correct entries shall be made of all financial transactions and the assets and business of the Borrower and each such Subsidiary sufficient to permit the preparation of financial statements in accordance with GAAP.
(g)    Maintenance of Properties, Etc. Cause all of its properties that are used or useful in the conduct of its business or the business of any of its Subsidiaries to be maintained and kept in good condition, repair and working order and supplied with all necessary equipment, and cause to be made all necessary repairs, renewals, replacements, betterments and improvements thereof, all as in the judgment of the Borrower may be necessary so that the business carried on in connection therewith may be properly and advantageously conducted at all times, except, in each case, where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.
(h)    Transactions with Affiliates. Conduct, and cause each of its Subsidiaries to conduct, all material transactions otherwise permitted under this Agreement with any of their Affiliates (excluding the members of the Consolidated Group) on terms that are fair and reasonable and no less favorable to the Borrower or such Subsidiary than it would obtain in a comparable arm’s-length transaction with a Person not an Affiliate; provided that the provisions of this Section 5.01(h) shall not apply to the following:
(i)    the payment of dividends or other distributions (whether in cash, securities or other property) with respect to any equity interests in a member of the Consolidated Group, or any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such equity interests in such Person or any option, warrant or other right to acquire any such equity interests in such Person;
(ii)    payment of, or other consideration in respect of, compensation to, the making of loans to and payment of fees and expenses of and indemnities to officers, directors, employees or consultants of a member of the Consolidated Group and payment, or other consideration in respect of, directors’ and officers’ indemnities;
(iii)    transactions pursuant to any agreement to which a member of the Consolidated Group is a party on the date hereof; or
57



(iv)    transactions with joint ventures for the purchase or sale of property or other assets and services entered into in the ordinary course of business and in a manner consistent with past practices.
(i)    Reporting Requirements. Furnish to the Administrative Agent for further distribution to the Lenders:
(i)    as soon as available and in any event within 50 days after the end of each of the first three quarters of each fiscal year of the Borrower, a Consolidated balance sheet of the Consolidated Group as of the end of such quarter and Consolidated statements of earnings and cash flows of the Consolidated Group for the period commencing at the end of the previous fiscal year and ending with the end of such quarter, duly certified by the Chief Financial Officer, the Controller or the Treasurer of the Borrower as having been prepared in accordance with GAAP (subject to the absence of footnotes and year end audit adjustments);
(ii)    as soon as available and in any event within 100 days after the end of each fiscal year of the Borrower, a copy of the annual audit report for such year for the Consolidated Group, containing a Consolidated balance sheet of the Consolidated Group as of the end of such fiscal year and Consolidated statements of earnings and cash flows of the Consolidated Group for such fiscal year, in each case accompanied by an unqualified opinion or an opinion reasonably acceptable to the Required Lenders by Ernst & Young LLP or other independent public accountants of recognized national standing;
(iii)    simultaneously with each delivery of the financial statements referred to in subclauses (i)(i) and (i)(ii) of this Section 5.01, a certificate of the Chief Financial Officer, the Controller or the Treasurer of the Borrower as to compliance with the terms of this Agreement and setting forth in reasonable detail the calculations necessary to demonstrate compliance with Section 5.03;
(iv)    as soon as possible and in any event within five days after any Responsible Officer shall have obtained knowledge of the occurrence of each Default continuing on the date of such statement, a statement of the Chief Financial Officer, the Controller or the Treasurer of the Borrower setting forth details of such Default and the action that the Borrower has taken and proposes to take with respect thereto;
(v)    promptly after the sending or filing thereof, copies of all reports that the Borrower sends to any of its securityholders, and copies of all reports and registration statements that members of the Consolidated Group file with the Securities and Exchange Commission or any national securities exchange;
(vi)    promptly after a Responsible Officer obtains knowledge of the commencement thereof, notice of all actions, suits, investigations, litigations and proceedings before any court, governmental agency or arbitrator affecting the Consolidated Group of the type described in Section 4.01(f)(ii); and
58



(vii)    such other information respecting the Consolidated Group as any Lender through the Administrative Agent may from time to time reasonably request.
Information required to be delivered pursuant to subsections (i), (ii) and (v) of this Section 5.01(i) shall be deemed to have been delivered if such information, or one or more annual or quarterly or other reports or proxy statements containing such information, shall have been posted and be available on the website of the Securities and Exchange Commission at http://www.sec.gov (and a confirming electronic correspondence is delivered or caused to be delivered by the Borrower to the Administrative Agent providing notice of such availability). The Borrower hereby acknowledges that the Administrative Agent and/or the Arrangers will make available to the Lenders materials and/or information provided by or on behalf of the Borrower hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on IntraLinks or another similar secure electronic system (the “Platform”).
(j)    Anti-Corruption Laws. Maintain policies and procedures with respect to itself and its Subsidiaries reasonably designed to promote and achieve compliance with applicable anti-corruption Laws.
SECTION 5.02    Negative Covenants. So long as any Advance shall remain unpaid or any Lender shall have any Commitment hereunder, the Borrower will not:
(a)    Liens, Etc. Incur, issue, assume or guarantee, or permit any Domestic Subsidiary to incur, issue, assume or guaranty, at any time, any Borrowed Debt secured by a Lien on any Principal Domestic Property of the Borrower or any Domestic Subsidiary, or any shares of stock or Borrowed Debt of any Domestic Subsidiary, without effectively providing that the Advances outstanding at such time (together with, if the Borrower shall so determine, any other Borrowed Debt of the Borrower or such Domestic Subsidiary existing at such time or thereafter created that is not subordinate to the Advances) shall be secured equally and ratably with (or prior to) such secured Borrowed Debt, so long as such secured Borrowed Debt shall be so secured, unless, after giving effect thereto, the aggregate amount of all such secured Borrowed Debt plus the aggregate amount of all Attributable Debt of the Borrower and the Domestic Subsidiaries in respect of Sale and Leaseback Transactions would not exceed 15% of Consolidated Net Assets; provided, however, that this Section 5.02(a) shall not apply to, and there shall be excluded from secured Borrowed Debt in any computation under this Section 5.02(a), Borrowed Debt secured by:
(i)    Liens on property of, or on any shares of stock or Borrowed Debt of, any Person existing at the time such Person becomes a Domestic Subsidiary;
(ii)    Liens in favor of the Borrower or any Domestic Subsidiary;
(iii)    Liens on property of the Borrower or a Domestic Subsidiary in favor of the United States or any State thereof, or any department, agency or
59



instrumentality or political subdivision of the United States or any State thereof, or in favor of any other country, or any political subdivision thereof, to secure partial, progress, advance or other payments pursuant to any contract or statute;
(iv)    Liens on property, shares of stock or Borrowed Debt existing at the time of acquisition thereof (including acquisition through merger or consolidation) or to secure the payment of all or any part of the purchase price or construction or improvement cost thereof or to secure any Debt incurred prior to, at the time of, or within 120 days after, the acquisition of such property or shares or Borrowed Debt or the completion of any such construction or improvement for the purpose of financing all or any part of the purchase price or construction or improvement cost thereof;
(v)    Liens existing on the Closing Date;
(vi)    Liens incurred in connection with pollution control, industrial revenue or similar financing; and
(vii)    Any extension, renewal or replacement (or successive extensions, renewals or replacements), as a whole or in part, of any Borrowed Debt secured by any Lien referred to in subclauses (i) through (vi) of this Section 5.02(a); provided, that (A) such extension renewal or replacement Lien shall be limited to all or a part of the same property, shares of stock or Debt that secured the Lien extended, renewed or replaced (plus improvements on such property) and (B) the Borrowed Debt secured by such Lien at such time is not increased.
(b)    Mergers, Etc. Merge or consolidate with or into, or convey, transfer, lease or otherwise dispose (including by means of a Division) of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to, any Person, or permit any of its Subsidiaries to do so, except that:
(i)    any Subsidiary of the Borrower may merge or consolidate with or into, or dispose (including by means of a Division) of assets to, any other Subsidiary of the Borrower or the Borrower;
(ii)    the Borrower may merge or consolidate with or into any other Person so long as (A) the Borrower is the surviving Person or (B) if the Borrower is not the surviving Person, (1) the surviving Person shall assume, by agreement reasonably satisfactory in form and substance to the Required Lenders, all of the rights and obligations of the Borrower under this Agreement and the other Loan Documents, (2) such surviving Person shall have delivered to the Administrative Agent (x) an officer’s certificate stating that such surviving Person’s obligations under this Agreement are enforceable and (y) if requested by the Administrative Agent, an opinion of counsel to the effect that such merger or consolidation does not violate this Agreement or any other Loan Document and that such surviving Person’s obligations under this Agreement are enforceable and (3) the Administrative Agent shall have received the information and documentation
60



reasonably requested by the Administrative Agent or any Lender, in each case with respect to such surviving Person, for purposes of compliance with applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the Patriot Act and the Beneficial Ownership Regulation (it being understood that, if the foregoing are satisfied, such surviving Person will succeed to, and be substituted for, the Borrower under this Agreement);
(iii)    any Subsidiary of the Borrower may merge or consolidate with or into another Person, or convey, transfer, lease or otherwise dispose (including by means of a Division) of all or any portion of its assets so long as (A) the consideration received in respect of such merger, consolidation, conveyance, transfer, lease or other disposition is at least equal to the fair market value of such assets and (B) no Material Adverse Effect would reasonably be expected to result from such merger, consolidation, conveyance, transfer, lease or other disposition;
provided, in the cases of clause (ii) hereof, that no Default shall have occurred and be continuing at the time of such proposed transaction or would result therefrom.
(c)    Sales and Leaseback. Enter into, or permit any Domestic Subsidiary to enter into, any arrangement with any bank, insurance company or other lender or investor (not including any member of the Consolidated Group) or to which any such lender or investor is a party, providing for the leasing by the Borrower or any Domestic Subsidiary for a period, including renewals, in excess of three years of any Principal Domestic Property which has been or is to be sold or transferred, more than 120 days after the acquisition thereof or the completion of construction and commencement of full operation thereof, by the Borrower or any Domestic Subsidiary to such lender or investor or to any Person to whom funds have been or are to be advanced by such lender or investor on the security of such Principal Domestic Property (any such arrangement being referred to herein as a “Sale and Leaseback Transaction”) unless either:
(i)    the Borrower or such Domestic Subsidiary could create Borrowed Debt secured by a Lien pursuant to Section 5.02(a) on the Principal Domestic Property to be leased back in an amount equal to the Attributable Debt with respect to such Sale and Leaseback Transaction without equally and ratably securing Advances outstanding at the time the Borrower or such Domestic Subsidiary enters into such Sale and Leaseback Transaction, or
(ii)    the Borrower, within 120 days after the sale or transfer shall have been made by the Borrower or by such Domestic Subsidiary, applies an amount equal to the greater of (A) the net proceeds of the sale of the Principal Domestic Property sold and leased back pursuant to such Sale and Leaseback Transaction or (B) the fair market value of the Principal Domestic Property so sold and leased back at the time of entering into such Sale and Leaseback Transaction (as determined by any two of the following: the Chief Executive Officer, any President, the Chief Financial Officer, the Controller or the Treasurer of the Borrower) to the retirement of Funded Debt; provided that the amount to be applied to the retirement of Funded Debt shall be reduced by (1) the principal amount of any Advances paid or prepaid
61



within 120 days after such sale or transfer and (2) the principal amount of such Funded Debt voluntarily retired by the Borrower within 120 days after such sale or transfer. Notwithstanding the foregoing, no retirement referred to in this Section 5.02(c)(ii) may be effected by payment at maturity or pursuant to any mandatory sinking fund payment or any mandatory prepayment provision.
(d)    Accounting Changes. Change its fiscal year-end from December 31 of each calendar year.
(e)    Change in Nature of Business. Make any material change in the nature of the business of the Consolidated Group, taken as a whole, from that carried out at the Closing Date; it being understood that this Section 5.02(e) shall not prohibit members of the Consolidated Group from conducting any business or business activities incidental or related to the business of the Borrower and its Subsidiaries as carried on as of the Closing Date or any business or activity that is reasonably similar or complementary thereto or a reasonable extension, development or expansion thereof or ancillary thereto.
(f)    Use of Proceeds. Directly or, to the knowledge of the Borrower, indirectly (i) use the proceeds of any Borrowing for any purpose that would breach the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act of 2010, or other similar applicable legislation in other jurisdictions or (ii) use the proceeds of any Borrowing, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other individual or entity, to fund any activities of or business with any individual or entity that, at the time of such funding, is (A) the subject of Sanctions or (B) in any Designated Jurisdiction, in each case in violation of Sanctions.
SECTION 5.03    Financial Covenant. So long as any Advance shall remain unpaid or any Lender shall have any Commitment hereunder, as of the last day of each fiscal quarter of the Borrower, commencing with the first fiscal quarter-end date occurring after the Closing Date, the Borrower shall not permit Consolidated Net Worth to be less than $10,000,000,000; provided that, notwithstanding the foregoing, if the Borrower has Public Debt Ratings of (a) A2 or higher from Moody’s and (b) A or higher from S&P, in each case as of the last day of any fiscal quarter, this Section 5.03 shall cease to apply to the Borrower for such fiscal quarter and thereafter, until (x) the Public Debt Rating from Moody’s shall be lower than A2, (y) the Public Debt Rating from S&P shall be lower than A or (z) either Moody’s or S&P shall not have in effect a Public Debt Rating, in each case as of the last day of any fiscal quarter, in which
62



case this Section 5.03 shall once again apply to the Borrower as of such fiscal quarter and thereafter.
ARTICLE VI
EVENTS OF DEFAULT
SECTION 6.01    Events of Default. If any of the following events (“Events of Default”) shall occur and be continuing:
(a)    The Borrower shall fail (i) to pay any principal of any Advance when the same becomes due and payable or (ii) to pay any interest on any Advance or make any payment of fees or other amounts payable under this Agreement within five Business Days after the same becomes due and payable; or
(b)    Any representation or warranty made by the Borrower herein or by the Borrower (or any of its officers) in connection with this Agreement shall prove to have been incorrect in any material respect when made; or
(c)    (i) The Borrower shall fail to perform or observe any term, covenant or agreement contained in Section 5.01(d)(i), 5.01(i)(iv), 5.02(a), 5.02(b), 5.02(c), 5.02(e), 5.02(f)(ii) (to the extent the use of proceeds would result in a violation of Sanctions by a Lender, an Arranger or the Administrative Agent) or 5.03 or (ii) the Borrower shall fail to perform or observe any term, covenant or agreement contained in Section 5.01(e) or clauses (i)-(iii) or (v)-(vii) of Section 5.01(i) if such failure shall remain unremedied for 10 Business Days after written notice thereof shall have been given to the Borrower by the Administrative Agent or any Lender, or (iii) the Borrower shall fail to perform or observe any other term, covenant or agreement contained in this Agreement on its part to be performed or observed if such failure shall remain unremedied for 30 days after written notice thereof shall have been given to the Borrower by the Administrative Agent or any Lender; or
(d)    The Borrower or a Significant Subsidiary shall fail to pay any principal of or premium or interest on any Debt that is outstanding in a principal amount, or, in the case of any Hedge Agreement, having a maximum Agreement Value, of at least $250,000,000 in the aggregate (but excluding Debt outstanding hereunder) of the Borrower or such Significant Subsidiary, when the same becomes due and payable (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise), and such failure shall continue after the applicable grace period, if any, specified in the agreement or instrument relating to such Debt; or the Borrower or a Significant Subsidiary shall default in its obligations under any agreement or instrument relating to any such Debt, which default shall continue after the applicable grace period, if any, specified in such agreement or instrument if the effect of such default is to accelerate the maturity of such Debt; or any such Debt shall be declared to be due and payable, or required to be prepaid or redeemed, purchased or defeased, or an offer to prepay, redeem, purchase or defease such Debt shall be required to be made, in each case prior to the stated maturity thereof (other than due to any (i) regularly scheduled required prepayment or redemption or (ii) prepayment of Debt
63



which is mandatory under the terms of the documentation governing such Debt by reason of the receipt of net cash proceeds of other Debt or dispositions (including, without limitation, as the result of casualty events and governmental takings); or
(e)    The Borrower or any Significant Subsidiary shall generally not pay its debts as such debts become due, or shall admit in writing its inability to pay its debts generally, or shall make a general assignment for the benefit of creditors; or any proceeding shall be instituted by or against the Borrower or any Significant Subsidiary seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, or composition of it or its debts under any Law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking the entry of an order for relief or the appointment of a receiver, trustee, custodian or other similar official for it or for any substantial part of its property and, in the case of any such proceeding instituted against it (but not instituted by it), such proceeding shall remain undismissed or unstayed for a period of 60 days; or the Borrower or any Significant Subsidiary shall take any corporate action to authorize any of the actions set forth above in this Section 6.01(e); or
(f)    Any one or more judgments or orders for the payment of money in excess of $250,000,000 shall be rendered against the Borrower or a Significant Subsidiary and either (i) enforcement proceedings shall have been commenced by any creditor upon such judgment or order or (ii) there shall be any period of 60 consecutive days during which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect; provided, however, that, for purposes of determining whether an Event of Default has occurred under this Section 6.01(f), the amount of any such judgment or order shall be reduced to the extent that (A) such judgment or order is covered by a valid and binding policy of insurance between the defendant and the insurer covering payment thereof and (B) such insurer, which shall be rated at least “A” by A.M. Best Company, has been notified of, and has not disputed the claim made for payment of, such judgment or order; or
(g)    (i) Any Person or two or more Persons acting in concert shall have acquired beneficial ownership (within the meaning of Rule 13d-3 of the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended), directly or indirectly, of Voting Stock of the Borrower (or other securities convertible into or exchangeable for such Voting Stock) representing more than 50% of the combined voting power of all Voting Stock of the Borrower (on a fully diluted basis) or (ii) during any period of up to 24 consecutive months, commencing before or after the date of this Agreement, a majority of the members of the board of directors of the Borrower shall not be Continuing Directors; or
(h)    The Borrower or any of its ERISA Affiliates shall incur, or shall be reasonably likely to incur, liability in excess of $250,000,000 in the aggregate as a result of one or more of the following: (i) the occurrence of any ERISA Event; (ii) the partial or complete withdrawal of the Borrower or any ERISA Affiliate from a Multiemployer Plan; or (iii) the reorganization or termination of a Multiemployer Plan;
64



then, and in any such event, (i) the Administrative Agent shall at the request, or may with the consent, of the Required Lenders, by notice to the Borrower, declare the Commitments of each Lender to be terminated, whereupon the same shall forthwith terminate, and (ii) shall at the request, or may with the consent, of the Required Lenders, by notice to the Borrower, declare the Advances, all interest thereon and all other amounts payable under this Agreement to be forthwith due and payable, whereupon the Advances, all such interest and all such amounts shall become and be forthwith due and payable, without presentment, demand, protest or further notice of any kind, all of which are hereby expressly waived by the Borrower; provided, however, that in the event of an actual or deemed entry of an order for relief with respect to the Borrower under the Federal Bankruptcy Code, (A) the Commitment of each Lender shall automatically be terminated and (B) the Advances, all such interest and all such amounts shall automatically become and be due and payable, without presentment, demand, protest or any notice of any kind, all of which are hereby expressly waived by the Borrower.

ARTICLE VII
THE AGENTS
SECTION 7.01    Authorization and Action. Each Lender hereby irrevocably appoints JPMorgan to act on its behalf as the Administrative Agent hereunder and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Article VII (other than the third sentence of Section 7.04 and Section 7.06) are solely for the benefit of the Administrative Agent and the Lenders, and the Borrower shall not have rights as a third-party beneficiary of any of such provisions (other than the third sentence of Section 7.04 and Section 7.06). It is understood and agreed that the use of the term “agent” herein (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.
SECTION 7.02    Administrative Agent Individually. The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity as a Lender. Such Person and its Affiliates may accept deposits from, own securities of, lend money to, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with any member of the Consolidated Group or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.
65



SECTION 7.03    Duties of Administrative Agent; Exculpatory Provisions.
(a)    The Administrative Agent’s duties hereunder and under the other Loan Documents are solely ministerial and administrative in nature, and the Administrative Agent shall not have any duties or obligations except those expressly set forth herein or in any other Loan Document. Without limiting the generality of the foregoing, the Administrative Agent (i) shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing, (ii) shall not have any duty to take any discretionary action or exercise any discretionary powers but shall be required to act or refrain from acting (and shall be fully protected in so acting or refraining from acting) upon the written direction of the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in any other Loan Document); provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent or any of its Affiliates to liability or that is contrary to any Loan Document or applicable Law, including for the avoidance of doubt, any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law and (iii) shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.
(b)    The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Section 8.01 or 6.01) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default or Event of Default unless and until the Borrower or any Lender shall have given notice to the Administrative Agent describing such Default or Event of Default.
(c)    Neither the Administrative Agent nor any other Agent shall be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty, representation or other information made or supplied in or in connection with this Agreement, any other Loan Document or the Information Memorandum, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith or the adequacy, accuracy and/or completeness of the information contained therein, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Article III or elsewhere herein, other than (but subject to the foregoing clause (ii)) to confirm receipt of items expressly required to be delivered to the Administrative Agent.
(d)    Nothing in this Agreement or any other Loan Document shall require the Administrative Agent or any of its Related Parties to carry out any “know your customer” or
66



other checks in relation to any Person on behalf of any Lender, and each Lender confirms to the Administrative Agent that it is solely responsible for any such checks it is required to carry out and that it may not rely on any statement in relation to such checks made by the Administrative Agent or any of its Related Parties.
SECTION 7.04    Reliance by Administrative Agent. The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the Closing Date or the making of any Advance that by its terms must be fulfilled to the satisfaction of a Lender, each Lender shall be deemed to have consented to, approved or accepted such condition unless (a) an officer of the Administrative Agent responsible for the transactions contemplated hereby shall have received notice to the contrary from such Lender prior to the Closing Date or the making of such Advance, as applicable, and (b) in the case of a condition to the making of an Advance, such Lender shall not have made available to the Administrative Agent such Lender’s ratable portion of such Borrowing. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.
SECTION 7.05    Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. Each such sub-agent and the Related Parties of the Administrative Agent and each such sub-agent shall be entitled to the benefits of all provisions of this Article VII and Section 8.04 (as though such sub-agents were the “Administrative Agent” under this Agreement) as if set forth in full herein with respect thereto. The Administrative Agent shall not be responsible to any Lender for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.
SECTION 7.06    Resignation of Administrative Agent.
(a)    The Administrative Agent may at any time give notice of its resignation to the Lenders and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the “Resignation Effective Date”), then the retiring Administrative Agent may (but shall not be
67



obligated to), on behalf of the Lenders and in consultation with the Borrower, appoint a successor Administrative Agent meeting the qualifications set forth above. Whether or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date.
(b)    If the Person serving as Administrative Agent is a Defaulting Lender pursuant to clause (d) of the definition thereof, such Person shall automatically and without the taking of any action by any Person, be removed as Administrative Agent on the date that is 30 days following the date such Person became a Defaulting Lender (or such earlier day as shall be agreed by the Required Lenders) (the “Removal Effective Date”). In connection therewith, the Required Lenders, in consultation with the Borrower, shall appoint a successor. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment on or prior to the Removal Effective Date, then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date.
(c)    With effect from the Resignation Effective Date or the Removal Effective Date (as applicable) (i) the retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (ii) except for any indemnity payments owed to the retiring or removed Administrative Agent, all payments, communications and determinations to be made by, to or through the Administrative Agent shall instead be made by or to each Lender directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed Administrative Agent (other than any rights to indemnity payments or other amounts owed to the retiring or removed Administrative Agent), and the retiring or removed Administrative Agent shall be discharged from all of its duties and obligations hereunder and under the other Loan Documents (if not already discharged therefrom as provided above in this Section 7.06). The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring or removed Administrative Agent’s resignation or removal hereunder and under the other Loan Documents, the provisions of this Article VII and Section 8.04 shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring or removed Administrative Agent was acting as Administrative Agent.
SECTION 7.07    Non-Reliance on Administrative Agent and OtherAcknowledgments of Lenders. (a) Each Lender acknowledges thatrepresents and warrants that (i) the Loan Documents set forth the terms of a commercial lending facility, (ii) it is engaged in making, acquiring or holding commercial loans and in providing other facilities set forth herein as may be applicable to such Lender in the ordinary course of business, and not for the purpose of purchasing, acquiring or holding any other type of financial instrument (and each Lender agrees not to assert a claim in contravention of the foregoing), (iii) it has, independently and without reliance upon the Administrative Agent or any other Lender, or any of theirthe Related Parties of any of the foregoing, and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement as a Lender, and to make, acquire or hold Advances hereunder and (iv) it is sophisticated with respect to decisions to make,
68



acquire and/or hold commercial loans set forth herein, as may be applicable to such Lender, and either it, or the Person exercising discretion in making its decision to make, acquire and/or hold such commercial loans, is experienced in making, acquiring or holding such commercial loans. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender, or any of theirthe Related Parties of any of the foregoing, and based on such documents and information (which may contain material, non-public information within the meaning of the United States securities laws concerning the Borrower and its Affiliates) as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.
(b)    Each Lender, by delivering its signature page to this Agreement on the Closing Date, or delivering its signature page to an Assignment and Acceptance or any other Loan Document pursuant to which it shall become a Lender hereunder, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be delivered to, or be approved by or satisfactory to, the Administrative Agent or the Lenders on the Closing Date.
(c)    (i) Each Lender hereby agrees that (x) if the Administrative Agent notifies such Lender that the Administrative Agent has determined in its sole discretion that any funds received by such Lender from the Administrative Agent or any of its Affiliates (whether as a payment, prepayment or repayment of principal, interest, fees or otherwise; individually and collectively, a “Payment”) were erroneously transmitted to such Lender (whether or not known to such Lender) (any such Payment or any Payment identified as an Erroneous Payment in the immediately following paragraph, an “Erroneous Payment”), and demands the return of such Erroneous Payment (or a portion thereof), such Lender shall promptly, but in no event later than one Business Day thereafter, return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made in same day funds, together with interest thereon in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Lender to the date such amount is repaid to the Administrative Agent at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect, and (y) to the extent permitted by applicable law, such Lender shall not assert, and hereby waives any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payments received, including without limitation any defense based on “discharge for value” or any similar doctrine. A notice of the Administrative Agent to any Lender under this Section 7.07(c) shall be conclusive, absent manifest error.
(ii)    Each Lender hereby further agrees that if it receives a Payment from the Administrative Agent or any of its Affiliates (x) that is in a different amount than, or on a different date from, that specified in a notice of payment sent by the Administrative Agent (or any of its Affiliates) with respect to such Payment (a “Payment Notice”) or (y) that was not preceded or accompanied by a Payment Notice, it shall be on notice, in each such case, that an error has been made with respect to such Payment and that such Payment is, accordingly, an Erroneous Payment. Each Lender agrees that, in each such case, or if it otherwise becomes aware a Payment (or portion thereof) may have been sent in error (and, accordingly, that such Payment (or portion thereof) is
69



an Erroneous Payment), such Lender shall promptly notify the Administrative Agent of such occurrence and, upon demand from the Administrative Agent, it shall promptly, but in no event later than one Business Day thereafter, return to the Administrative Agent the amount of any such Payment (or portion thereof) as to which such a demand was made in same day funds, together with interest thereon in respect of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid to the Administrative Agent at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect.
(iii)    The Borrower hereby agrees that (x) in the event an Erroneous Payment (or portion thereof) is not recovered from any Lender that has received such Erroneous Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the rights of such Lender with respect to such amount and (y) an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any obligations owed by the Borrower hereunder or under any other Loan Document; provided, that for the avoidance of doubt, the immediately preceding clauses (x) and (y) shall not apply to the extent any such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrower for the purpose of making any payment hereunder that became subject to such Erroneous Payment.
(iv)    Each party’s obligations under this Section 7.07(c) shall survive the resignation or replacement of the Administrative Agent or any transfer of rights or obligations by, or the replacement of, a Lender, the termination of the Commitments or the repayment, satisfaction or discharge of all obligations of the Borrower under any Loan Document.
SECTION 7.08    Indemnification. The Lenders agree to indemnify the Administrative Agent (to the extent not reimbursed by the Borrower), ratably according to the respective principal amounts of the Advances made by each of them (or, if no Advances are at the time outstanding, ratably according to the respective amounts of their Commitments), from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses and disbursements of any kind or nature whatsoever that may be imposed on, incurred by, or asserted against the Administrative Agent in any way relating to or arising out of this Agreement or any action taken or omitted by the Administrative Agent under this Agreement, in each case, acting in the capacity of Administrative Agent; provided that no Lender shall be liable for any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements resulting from the Administrative Agent’s gross negligence or willful misconduct. Without limitation of the foregoing, each Lender agrees to reimburse the Administrative Agent promptly upon demand for its ratable share of any out-of-pocket expenses (including reasonable counsel fees) incurred by the Administrative Agent in connection with the preparation, execution, delivery, administration, modification, amendment or enforcement (whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this Agreement, to the extent that the Administrative Agent is not promptly reimbursed for such expenses by the Borrower.
SECTION 7.09    Other Agents. None of the Lenders identified on the facing page or signature pages of this Agreement as a “joint lead arranger”, “joint bookrunner”, or “syndication agent” shall have any right, power, obligation, liability, responsibility or duty under
70



this Agreement other than those applicable to all Lenders as such. Without limiting the foregoing, none of the Lenders so identified shall have or be deemed to have any fiduciary relationship with any Lender. Each Lender acknowledges that it has not relied, and will not rely, on any of the Lenders so identified in deciding to enter into this Agreement or in taking or not taking action hereunder.
SECTION 7.10    ERISA.
(a)    Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Agents and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower, that at least one of the following is and will be true:
(i)    such Lender is not using “plan assets” (within the meaning of the Plan Asset Regulations) of one or more Benefit Plans in connection with the Advances or the Commitments,
(ii)    the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender’s entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement, and the conditions for exemptive relief thereunder are and will continue to be satisfied in connection therewith,
(iii)    (A) such Lender is an investment fund managed by a “Qualified Professional Asset Manager” (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Advances, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender’s entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement, or such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.
(b)    In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or (2) such Lender has not provided another
71



representation, warranty and covenant as provided in sub-clause (iii) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, each Agent and its respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower, that none of the Agents or any of their respective Affiliates is a fiduciary with respect to the assets of such Lender involved in such Lender’s entrance into, participation in, administration of and performance of the Advances, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any Loan Document or any documents related to hereto or thereto).
(c)    The Agents and the Arrangers hereby inform the Lenders that each such Person is not undertaking to provide impartial investment advice, or to give advice in a fiduciary capacity, in connection with the transactions contemplated hereby, and that such Person has a financial interest in the transactions contemplated hereby in that such Person or an Affiliate thereof (i) may receive interest or other payments with respect to the Advances, the Commitments and this Agreement, (ii) may recognize a gain if it extended the Advances or the Commitments for an amount less than the amount being paid for an interest in the Advances or the Commitments by such Lender or (iii) may receive fees or other payments in connection with the transactions contemplated hereby, the Loan Documents or otherwise, including structuring fees, commitment fees, arrangement fees, facility fees, upfront fees, underwriting fees, ticking fees, agency fees, administrative agent or collateral agent fees, utilization fees, minimum usage fees, letter of credit fees, fronting fees, deal-away or alternate transaction fees, amendment fees, processing fees, term out premiums, banker’s acceptance fees, breakage or other early termination fees or fees similar to the foregoing.
ARTICLE VIII
MISCELLANEOUS
SECTION 8.01    Amendments, Etc. Subject to Section 2.05(c) and 2.18, no amendment or waiver of any provision of this Agreement, nor consent to any departure by the Borrower therefrom, shall in any event be effective unless the same shall be in writing and signed by the Required Lenders and the Borrower and acknowledged by the Administrative Agent, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no amendment, waiver or consent shall, unless in writing, do any of the following:
(a)    waive any of the conditions specified in Section 3.01, unless signed by each Lender directly and adversely affected thereby:
(b)    increase or extend the Commitments of a Lender or subject a Lender to any additional obligations, unless signed by such Lender;
(c)    reduce the principal of, or stated rate of interest on, the Advances, the stated rate at which any fees hereunder are calculated or any other amounts payable hereunder, unless signed by each Lender directly and adversely affected thereby;
72



(d)    postpone any date fixed for any payment of principal of, or interest on, the Advances or any fees or other amounts payable hereunder, unless signed by each Lender directly and adversely affected thereby;
(e)    change the percentage of the Commitments or of the aggregate unpaid principal amount of the Advances, or the number of Lenders, that shall be required for the Lenders or any of them to take any action hereunder (including the definition of “Required Lenders”), unless signed by all Lenders;
(f)    amend this Section 8.01, unless signed by all Lenders; and
(g)    amend or waive any of the provisions of Section 2.15 or 2.19(c), unless signed by each Lender directly and adversely affected thereby.
and provided, further, that (i) no amendment, waiver or consent shall, unless in writing and signed by the Administrative Agent in addition to the Lenders required above to take such action, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document; (ii) the Fee Letter may be amended, or rights or privileges thereunder waived, in a writing executed only by the parties thereto; and (iii) any amendment or waiver with respect to Section 8.16 shall require the consent of any Lender that is an Affected Financial Institution. Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except (x) to the extent set forth in Section 2.19(a)(ii) and (y) that any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender.
SECTION 8.02    Notices, Etc.
(a)    Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in Section 8.02(b) below), all notices and other communications provided for hereunder shall be in writing (including telecopier) and mailed, telecopied or delivered, if to the Borrower or the Administrative Agent, to the address, telecopier number, electronic mail address or telephone number specified for such Person on Schedule II; or, as to the Borrower or the Administrative Agent, at such other address as shall be designated by such party in a written notice to the other parties and, as to each other party, at such other address as shall be designated by such party in a written notice to the Borrower and the Administrative Agent. Notices and other communications sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices and other communications sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient). Notices and other communications delivered through electronic communications to the extent provided in Section 8.02(b) below, shall be effective as provided in such Section 8.02(b).
73



(b)    Electronic Communications. Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including e-mail, FpML messaging and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall not apply to notices to any Lender pursuant to Article II if such Lender has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices or communications.
Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement), provided that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient, and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor.
(c)    THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD-PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the Borrower, any Lender or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of the Borrower’s or the Administrative Agent’s transmission of Borrower Materials or notices through the platform, any other electronic platform or electronic messaging service, or through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party; provided, however, that in no event shall any Agent Party have any liability to the Borrower, any Lender or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages).
(d)    Each of the Borrower and the Administrative Agent may change its address, facsimile or telephone number for notices and other communications hereunder by notice to the other parties hereto. Each Lender may change its address, facsimile or telephone number for notices and other communications hereunder by notice to the Borrower and the Administrative Agent. In addition, each Lender agrees to notify the Administrative Agent from time to time to
74



ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, facsimile number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender.
(e)    The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices (including telephonic notices and Notices of Borrowing) reasonably believed to have been given by or on behalf of the Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower shall indemnify the Administrative Agent, each Lender and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reasonable reliance by such Person on each notice reasonably believed to have been given by or on behalf of the Borrower. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording. With respect to notices and other communications hereunder from the Borrower to any Lender, the Borrower shall provide such notices and other communications to the Administrative Agent, and the Administrative Agent shall promptly deliver such notices and other communications to any such Lender in accordance with Section 8.02(b) above or otherwise.
SECTION 8.03    No Waiver; Remedies. No failure on the part of any Lender or the Administrative Agent to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by applicable Law.
SECTION 8.04    Expenses; Indemnity.
(a)    Costs and Expenses. The Borrower shall pay upon demand (i) all reasonable and documented or invoiced out-of-pocket fees and expenses incurred by the Administrative Agent and its respective Affiliates (including, but not limited to, the reasonable and documented or invoiced fees, charges and disbursements of counsel which shall be limited to the reasonable and documented or invoiced out-of-pocket fees and other charges of one counsel to the Administrative Agent and its respective Affiliates (which as of the date hereof is Shearman & Sterling LLP), and, if necessary, of one local counsel to the Administrative Agent and its respective Affiliates in each relevant jurisdiction, and due diligence expenses), in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated) and (ii) all out of pocket expenses incurred by the Administrative Agent or any Lender (including, but not limited to, the reasonable and documented or invoiced fees, charges and disbursements of counsel which shall be limited to the reasonable and documented or invoiced out-of-pocket fees and other charges of one counsel to the Lenders and the Administrative Agent, and, if necessary, of one local counsel to the Lenders, retained by the Administrative Agent in each relevant jurisdiction (and, solely in the case of an actual or potential conflict of interest, of one additional counsel (and, if reasonably necessary, one additional local counsel in any relevant jurisdiction) for all such affected Lenders), and due
75



diligence expenses), in connection with the enforcement or protection of its rights (A) in connection with this Agreement and the other Loan Documents, including its rights under this Section 8.04, or (B) in connection with the Advances made hereunder, including all such out of pocket expenses incurred during any workout, restructuring or negotiations in respect of such Advances.
(b)    Indemnification by the Borrower. The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof) and each Lender, and each Related Party of any of the foregoing Persons and any successors or assigns (each such Person being called an “Indemnified Party”) against, and hold each Indemnified Party harmless from, all losses, claims, damages, liabilities and related expenses to which any Indemnified Party may become subject resulting from or in connection with this Agreement, the other Loan Documents, the use of the proceeds under this Agreement or any related transaction, any actual or alleged presence of Hazardous Materials on any property of the Consolidated Group or any Environmental Liability related in any way to the Borrower or any of its Subsidiaries or any claim, litigation, investigation or proceeding relating to any of the foregoing, regardless of whether any Indemnified Party is a party thereto and regardless of whether brought by a third party or by the Borrower or any of its Affiliates (any of the foregoing, a “Proceeding”), and shall reimburse each Indemnified Party upon demand for any legal or other expenses incurred in connection with investigating, defending, preparing to defend or participating in any such Proceeding, provided that (i) the foregoing indemnity will not, as to any Indemnified Party, apply to losses, claims, damages, liabilities or related expenses (A) to the extent they are found by a final, non-appealable judgment of a court of competent jurisdiction to result from the bad faith, willful misconduct or gross negligence of such Indemnified Party or any of its Related Persons, (B) to the extent resulting from any Proceeding that does not involve an act or omission of the Borrower or any of its Affiliates and that is brought by an Indemnified Party solely against another Indemnified Party, other than claims against any the Administrative Agent or the Arrangers in its capacity in fulfilling its role as an administrative agent or lead arranger under this Agreement or (C) to the extent resulting from a material breach by such Indemnified Party or any Related Person thereof of its obligations hereunder as found by a final, non-appealable judgment by a court of competent jurisdiction and (ii) the Borrower’s obligation to reimburse legal expenses pursuant to this Section 8.04(b) shall be limited to the fees, charges and disbursements of one counsel to all Indemnified Parties (and, if reasonably necessary, one local counsel in any relevant jurisdiction) and, solely in the case of an actual or potential conflict of interest, of one additional counsel (and, if reasonably necessary, one additional local counsel in any relevant jurisdiction). This Section 8.04(b) shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.
(c)    Compensation for Losses. If any payment of principal of, or Conversion of, any Eurodollar RateTerm Benchmark Advance is made by the Borrower to or for the account of a Lender other than on the last day of the Interest Period for such Advance, as a result of (i) a payment or Conversion pursuant to Section 2.06, 2.08(c), 2.08(d), 2.10 or 2.12, (ii) acceleration of the maturity of the Advances pursuant to Section 6.01, (iii) a payment by an Eligible Assignee to any Lender other than on the last day of the Interest Period for such Advance upon an assignment of the rights and obligations of such Lender under this Agreement pursuant to Section 8.07 as a result of a demand by the Borrower pursuant to Section 8.07(a) or (iv) for any other reason (other than, subject to the foregoing clause (iii), a payment by an Eligible Assignee to any Lender), the Borrower shall, upon demand by such Lender (with a copy of such demand to the Administrative
76



Agent), pay to the Administrative Agent for the account of such Lender any amounts required to compensate such Lender for any additional reasonable losses, costs or expenses that it may reasonably incur as a result of such payment or Conversion or as a result of any inability to Convert or exchange in the case of Section 2.08 or 2.12, including, without limitation, any reasonable loss (excluding loss of anticipated profits), cost or expense incurred by reason of the liquidation or reemployment of deposits or other funds acquired by any Lender to fund or maintain such Advance.
(d)    Reimbursement by Lenders. Without duplication with respect to Section 7.08, to the extent that the Borrower for any reason fails to indefeasibly pay any amount required under subsection (a) or (b) of this Section 8.04 to be paid by it to the Administrative Agent (or any sub-agent thereof) or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender), such payment to be made severally among them based on such Lenders’ pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender’s pro rata share at such time), provided, further that, the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent) in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) in connection with such capacity.
(e)    Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable law, the Borrower shall not assert, and hereby waives, and acknowledges that no other Person shall have, any claim against the Administrative Agent (and any sub-agent thereof) and each Lender, and each Related Party of any of the foregoing Persons and any successors or assigns (each such Person being called a “Lender-Related Person”), on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Advance or the use of the proceeds thereof. No Lender-Related Person shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed to such unintended recipients by such Lender-Related Person through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby other than for direct or actual damages resulting from the gross negligence, bad faith or willful misconduct of such Lender-Related Person as determined by a final and nonappealable judgment of a court of competent jurisdiction. Nothing in this Section 8.04(e) shall relieve the Borrower of any obligation it may have to indemnify an Indemnified Party against special, indirect, consequential or punitive damages to the extent required under Section 8.04(b).
(f)    Survival. Without prejudice to the survival of any other agreement of the Borrower hereunder, the agreements and obligations of the Borrower contained in Section 2.11, Section 2.14 and this Section 8.04 shall survive the payment in full of principal, interest and all other amounts payable hereunder.
77



SECTION 8.05    Right of Setoff. Upon (a) the occurrence and during the continuance of any Event of Default and (b) the making of the request or the granting of the consent specified by Section 6.01 to authorize the Administrative Agent to declare the Advances due and payable pursuant to the provisions of Section 6.01, each Lender and each of its Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable Law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by such Lender or such Affiliate to or for the credit or the account of the Borrower against any and all of the obligations of the Borrower now or hereafter existing under this Agreement, whether or not such Lender shall have made any demand under this Agreement and although such obligations may be unmatured. Each Lender agrees promptly to notify the Administrative Agent and the Borrower after any such setoff and application is made by such Lender; provided that the failure to give such notice shall not affect the validity of such setoff and application. The rights of each Lender and its Affiliates under this Section 8.05 are in addition to other rights and remedies (including, without limitation, other rights of setoff) that such Lender and its Affiliates may have.
SECTION 8.06    Binding Effect. This Agreement shall become effective (other than Section 2.01, which shall only become effective upon satisfaction of the applicable conditions precedent set forth in Section 3.01) when it shall have been executed by the Borrower and the Administrative Agent and when the Administrative Agent shall have been notified by each Initial Lender that such Initial Lender has executed it and, thereafter, shall be binding upon and inure to the benefit of, and be enforceable by, the Borrower, the Administrative Agent and each Lender and their respective successors and permitted assigns, except that, subject to Section 8.07, the Borrower shall have no right to assign their rights hereunder or any interest herein without the prior written consent of each of the Lenders, and any purported assignment without such consent shall be null and void.
SECTION 8.07    Assignments and Participations.
(a)    Each Lender may, with the consent of the Borrower and the Administrative Agent, which consents shall not be unreasonably withheld, conditioned or delayed and, in the case of the Borrower, (i) shall not be required while an Event of Default has occurred and is continuing and (ii) shall be deemed given if the Borrower shall not have objected within 10 Business Days following its receipt of notice of such assignment (and, within five days after demand by the Borrower (with a copy of such demand to the Administrative Agent) to (A) any Defaulting Lender, (B) any Lender that has made a demand for payment pursuant to Section 2.11 or 2.14, (C) any Lender that has asserted pursuant to Section 2.08(b) or 2.12 that it is impracticable or unlawful for such Lender to make Eurodollar RateTerm Benchmark Advances or (D) any Lender that fails to consent to an amendment or waiver hereunder for which consent of all Lenders (or all affected Lenders) is required and as to which the Required Lenders have given their consent, such Lender will), assign to one or more Persons all or a portion of its rights and obligations under this Agreement (including, without limitation, all or a portion of its Commitment and the Advances owing to it); provided, however, that:
(1)    such consent shall not be required in the case of an assignment to any other Lender or an Affiliate of any Lender, provided that notice thereof shall have been given to the Borrower and the Administrative Agent;
78



(2)    each such assignment shall be of a constant, and not a varying, percentage of all rights and obligations under this Agreement;
(3)    except in the case of an assignment to a Person that, immediately prior to such assignment, was a Lender or an assignment of all of a Lender’s rights and obligations under this Agreement, the amount of the Commitment of the assigning Lender being assigned pursuant to each such assignment (determined as of the date of the Assignment and Acceptance with respect to such assignment) shall in no event be less than $10,000,000 or an integral multiple of $1,000,000 in excess thereof;
(4)    each such assignment shall be to an Eligible Assignee;
(5)    each such assignment made as a result of a demand by the Borrower pursuant to this Section 8.07(a) shall be arranged by the Borrower with the approval of the Administrative Agent (which approval shall not be unreasonably withheld, conditioned or delayed) and shall be either an assignment of all of the rights and obligations of the assigning Lender under this Agreement or an assignment of a portion of such rights and obligations made concurrently with another such assignment or other such assignments that, in the aggregate, cover all of the rights and obligations of the assigning Lender under this Agreement;
(6)    no Lender shall be obligated to make any such assignment as a result of a demand by the Borrower pursuant to this Section 8.07(a), (I) (except in the case of an assignment of the type described in clause (D) of the first parenthetical clause in this Section 8.07(a) to the extent such Default would no longer be continuing after giving effect to the relevant amendment or waiver) so long as a Default shall have occurred and be continuing and (II) unless and until such Lender shall have received one or more payments from one or more Eligible Assignees in an aggregate amount at least equal to the aggregate outstanding principal amount of the Advances owing to such Lender, together with accrued interest thereon to the date of payment of such principal amount, and from the Borrower or one or more Eligible Assignees in an aggregate amount equal to all other amounts accrued to such Lender under this Agreement (including, without limitation, any amounts owing under Sections 2.11, 2.14 or 8.04(c)) and (III) if any such Eligible Assignee is not an existing Lender, unless and until the Borrower shall have paid (or caused to be paid) to the Administrative Agent a processing and recordation fee of $3,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire; and
(7)    the parties to each such assignment (other than, except in the case of a demand by the Borrower pursuant to this Section 8.07(a), the Borrower) shall execute and deliver to the Administrative Agent, for its acceptance and recording in the Register, an Assignment and Acceptance and, if such assignment does not occur as a result of a demand by the Borrower pursuant to this Section 8.07(a) (in
79



which case the Borrower shall pay the fee required by subclause (6)(III) of this Section 8.07(a)), a processing and recordation fee of $3,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment; provided, further, that in the event that, in connection with a demand by the Borrower pursuant to this Section 8.07(a), the assignor shall not execute and deliver the relevant Assignment and Acceptance within one Business Day of the Borrower’s request, such assignor shall be deemed to have executed and delivered such Assignment and Acceptance. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire.
Upon such execution, delivery, acceptance and recording, from and after the effective date specified in each Assignment and Acceptance, (x) the assignee thereunder shall be a party hereto and, to the extent that rights and obligations hereunder have been assigned to it pursuant to such Assignment and Acceptance, have the rights and obligations of a Lender hereunder and (y) the Lender assignor thereunder shall, to the extent that rights and obligations hereunder have been assigned by it pursuant to such Assignment and Acceptance, relinquish its rights and be released from its obligations under this Agreement, except that such assigning Lender shall continue to be entitled to the benefit of Section 8.04(a) and (b) with respect to matters arising out of the prior involvement of such assigning Lender as a Lender hereunder (and, in the case of an Assignment and Acceptance covering all or the remaining portion of an assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto).
(b)    By executing and delivering an Assignment and Acceptance, the Lender assignor thereunder and the assignee thereunder confirm to and agree with each other and the other parties hereto as follows:
(i)    other than as provided in such Assignment and Acceptance, such assigning Lender makes no representation or warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with this Agreement or the execution, legality, validity, enforceability, genuineness, sufficiency or value of this Agreement or any other instrument or document furnished pursuant hereto;
(ii)    such assigning Lender makes no representation or warranty and assumes no responsibility with respect to the financial condition of the Borrower or the performance or observance by the Borrower of any of its obligations under this Agreement or any other instrument or document furnished pursuant hereto;
(iii)    such assignee confirms that it has received a copy of this Agreement, together with copies of the financial statements referred to in Section 4.01(e) and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into such Assignment and Acceptance;
(iv)    such assignee will, independently and without reliance upon any Agent, such assigning Lender or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under this Agreement;
80



(v)    such assignee confirms that it is an Eligible Assignee;
(vi)    such assignee appoints and authorizes the Administrative Agent to take such action as agent on its behalf and to exercise such powers and discretion under this Agreement as are delegated to the Administrative Agent by the terms hereof, together with such powers and discretion as are reasonably incidental thereto; and
(vii)    such assignee agrees that it will perform in accordance with their terms all of the obligations that by the terms of this Agreement are required to be performed by it as a Lender.
(c)    Upon its receipt of an Assignment and Acceptance executed by an assigning Lender and an assignee representing that it is an Eligible Assignee, the Administrative Agent shall, if such Assignment and Acceptance has been completed and is in substantially the form of Exhibit B hereto, (i) accept such Assignment and Acceptance, (ii) record the information contained therein in the Register and (iii) give prompt notice thereof to the Borrower.
(d)    The Administrative Agent, acting solely for this purpose as the agent of the Borrower, shall maintain at its address referred to in Section 8.02(a) a copy of each Assignment and Acceptance delivered to and accepted by it and a register for the recordation of the names and addresses of the Lenders and the Commitment of, and principal amount (and stated interest) of the Advances owing to, each Lender from time to time (the “Register”). The entries in the Register shall be conclusive and binding for all purposes, absent demonstrable error, and the Borrower, the Agents and the Lenders may treat each Person whose name is recorded in the Register as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower or any Lender at any reasonable time and from time to time upon reasonable prior notice.
(e)    Each Lender may sell participations to one or more banks or other entities (other than a natural person, the Borrower or any of its Affiliates) in or to all or a portion of its rights and obligations under this Agreement (including, without limitation, all or a portion of its Commitment and the Advances owing to it) without the prior consent of, or notice to, the Administrative Agent or the Borrower; provided, however, that:
(i)    such Lender’s obligations under this Agreement (including, without limitation, its Commitment) shall remain unchanged;
(ii)    such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations;
(iii)    such Lender shall remain the Lender of any such Advance for all purposes of this Agreement;
(iv)    the Borrower, the Agents and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement; and
81



(v)    no participant under any such participation shall have any right to approve any amendment or waiver of any provision of this Agreement, or any consent to any departure by the Borrower herefrom or therefrom, except to the extent that such amendment, waiver or consent would reduce the principal of, or stated rate of interest on, the Advances or the stated rate at which any fees or any other amounts payable hereunder are calculated, in each case to the extent subject to such participation, or postpone any date fixed for any payment of principal of, or interest on, the Advances or any fees or any other amounts payable hereunder, in each case to the extent subject to such participation.
Subject to the immediately succeeding paragraph, the Borrower agrees that such participant shall be entitled to the benefits of Sections 2.11 and 2.14 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (a) of this Section 8.07 (it being understood that the documentation required under Section 2.14(e) shall be delivered to the Lender who sells the participation); provided that such participant (A) agrees to be subject to the provisions of Sections 2.15, 2.20 and 8.05 as if it were an assignee under subsection (a) of this Section 8.07 and (B) shall not be entitled to receive any greater payment under Sections 2.11 or 2.14, with respect to any participation, than the Lender from whom it acquired the applicable participation would have been entitled to receive, unless the sale of such participation is made with the prior written consent of the Borrower and the Borrower expressly waives the benefit of this provision at the time of such participation. Each Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Sections 2.15, 2.20 and 8.05 with respect to any participant.
A participant shall not be entitled to the benefits of Section 2.14 unless the Borrower is notified of the participation sold to such participant and such participant agrees, for the benefit of the Borrower, to comply with Sections 2.14(e) as though it were a Lender (it being understood that the documentation required under Section 2.14(e) shall be delivered by each participant to the participating Lender).

Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant’s interest in the Advances or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant’s interest in any Commitments, Advances or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such Commitment, Advance or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent demonstrable error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.
(f)    Any Lender may, in connection with any assignment or participation or proposed assignment or participation pursuant to this Section 8.07, disclose to the assignee or participant or proposed assignee or participant, any information relating to the Borrower furnished
82



to such Lender by or on behalf of the Borrower; provided that, prior to any such disclosure, the assignee or participant or proposed assignee or participant shall agree to preserve the confidentiality of any Information relating to the Borrower received by it from such Lender as more fully set forth in Section 8.08.
(g)    Notwithstanding any other provision set forth in this Agreement, any Lender may at any time create a security interest in all or any portion of its rights under this Agreement (including, without limitation and the Advances owing to it) to secure obligations of such Lender, including, without limitation, any pledge or assignment to secure obligations in favor of any Federal Reserve Bank in accordance with Regulation A of the Board of Governors of the Federal Reserve System or any central bank having jurisdiction over such Lender.
SECTION 8.08    Confidentiality. Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates’ respective managers, administrators, trustees, partners, directors, officers, employees, agents, advisors and other representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it or its Affiliates (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable Laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or any action or proceeding relating to this Agreement or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section 8.08, to (i) any assignee of or participant in, or any prospective assignee of or participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective party (or its managers, administrators, trustees, partners, directors, officers, employees, agents, advisors and other representatives) to any swap or derivative or similar transaction under which payments are to be made by reference to the Borrower and its obligations, this Agreement or payments hereunder, (iii) any rating agency, or (iv) the CUSIP Service Bureau or any similar organization, (g) with the consent of the Borrower or (h) to the extent such Information (i) becomes publicly available other than as a result of a breach of this Section or (ii) becomes available to the Administrative Agent, any Lender or any of their respective Affiliates on a non-confidential basis from a source other than the Borrower, which it has no reason, after due inquiry, to believe has any confidentiality or fiduciary obligation to the Borrower with respect to such Information.
For purposes of this Section 8.08, “Information” means all information received from the Borrower or any of its Subsidiaries relating to the Borrower or any of its Subsidiaries or any of their respective businesses, other than any such information that is available to the Administrative Agent or any Lender on a non-confidential basis prior to disclosure by the Borrower or any of its Subsidiaries, provided that, in the case of information received from the Borrower or any of its Subsidiaries after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section 8.08 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the
83



confidentiality of such Information as such Person would accord to its own confidential information.
SECTION 8.09    Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.
SECTION 8.10    Execution in Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
SECTION 8.11    Electronic Execution of Assignments and Certain Other Documents. The words “execute,” “execution,” “signed,” “signature,” and words of like import in or related to this Agreement, any other document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation Assignment and Acceptances, Notices of Borrowing, amendments or other modifications, waivers and consents) shall be deemed to include Electronic Signatures (as defined below), deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state Laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary the Administrative Agent is under no obligation to agree to accept Electronic Signatures in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it. “Electronic Signatures” means any electronic symbol or process attached to, or associated with, any contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record.
SECTION 8.12    Jurisdiction, Etc.
(a)    The Borrower and the other parties hereto irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in Law or equity, whether in contract or in tort or otherwise, against any party hereto or any Related Party of the foregoing in any way relating to this Agreement or any other Loan Document or the transactions relating hereto or thereto, in any forum other than the federal courts located in the County of New York County (or if such courts lack subject matter jurisdiction, the Supreme Court of the State of New York sitting in the Borough of Manhattan), and each of the Borrower and the other parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such federal court (or if such courts lack subject matter jurisdiction, the Supreme Court of the State of New York sitting in the Borough of Manhattan) to the fullest extent permitted by applicable Law. The Borrower and the other parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.
84



(b)    The Borrower and the other parties hereto irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any federal court located in the County of New York County (or if such courts lack subject matter jurisdiction, the Supreme Court of the State of New York sitting in the Borough of Manhattan). The Borrower and the other parties hereto hereby irrevocably waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.
(c)    The Borrower and the other parties hereto irrevocably consents to service of process in the manner provided for notices in Section 8.02(a). Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by applicable Law.
SECTION 8.13    Patriot Act Notice; Beneficial Ownership Regulation. Each Lender and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the Patriot Act and the Beneficial Ownership Regulation, it is required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower in accordance with the Patriot Act and the Beneficial Ownership Regulation. The Borrower shall provide, to the extent commercially reasonable, such information and take such actions as are reasonably requested by the Administrative Agent or any Lenders in order to assist the Administrative Agent and the Lenders in maintaining compliance with the Patriot Act and the Beneficial Ownership Regulation.
SECTION 8.14    No Advisory or Fiduciary Responsibility. In its capacity as an Agent or a Lender, (a) no Agent or Lender has any responsibility except as set forth herein and (b) no Agent or Lender shall be subject to any fiduciary duties or other implied duties (to the extent permitted by Law to be waived). The Borrower agrees that it will not take any position or bring any claim against any Agent or any Lender that is contrary to the preceding sentence.
In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof), the Borrower acknowledges and agrees that: (i) the arranging and other services regarding this Agreement provided by the Agents and the Lenders are arm’s-length commercial transactions between the Borrower and its Affiliates, on the one hand, and the Agents and the Lenders, on the other hand; (ii) each Agent and each Lender is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor or agent for the Borrower or any of its Affiliates, or any other Person; and (iii) the Agents, the Lenders and each of their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower and its Affiliates, and no Agent or Lender has any obligation to disclose any of such interests to the Borrower or its Affiliates.
SECTION 8.15    Termination of Credit Documents. The Borrower and each applicable Lender agree that concurrently with the effectiveness of this Agreement, the commitment amounts under the 2018 Credit Agreement shall automatically reduce to zero and
85



the 2018 Credit Agreement shall terminate, without any notice or other action of any kind and notwithstanding any notice or other requirement contained therein; provided that (a) the Borrower shall have paid all amounts then payable under the 2018 Credit Agreement; and (b) any provision of the 2018 Credit Agreement that by its terms survives termination thereof shall continue in full force and effect. Each Lender that is a party to the 2018 Credit Agreement hereby waives any requirement of prior notice thereunder in respect of any prepayment or termination of the commitments under such agreement.
SECTION 8.16    Acknowledgment and Consent to Bail-In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:
(a)    the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
(b)    the effects of any Bail-In Action on any such liability, including, if applicable: (i) a reduction in full or in part or cancellation of any such liability; (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent entity, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or (iii) the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.
SECTION 8.17    Integration. This Agreement, together with the other Loan Documents, comprises the complete and integrated agreement of the parties on the subject matter hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter. In the event of any conflict between the provisions of this Agreement and those of any other Loan Document, the provisions of this Agreement shall control; provided that the inclusion of supplemental rights or remedies in favor of the Administrative Agent or the Lenders in any other Loan Document shall not be deemed a conflict with this Agreement. Each Loan Document was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor in favor of any party, but rather in accordance with the fair meaning thereof.

SECTION 8.18    Waiver of Jury Trial. Each of the Borrower, the Administrative Agent and the Lenders hereby irrevocably waives all right to trial by jury in any action, proceeding or counterclaim (whether based on contract, tort or otherwise) arising out of or relating to this Agreement or the actions of the Administrative Agent or any Lender in the negotiation, administration, performance or enforcement thereof.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
86



IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first above written.
ABBOTT LABORATORIES

By: ________________________________
Name: Karen M. Peterson
Title: Vice President, Treasurer

[Abbott – Signature Page to 2020 Revolver]


JPMORGAN CHASE BANK, N.A., as Administrative Agent and as a Lender

By: ________________________________
Name:
Title:

[Abbott – Signature Page to 2020 Revolver]


[LENDER], as a Lender

By: ________________________________
Name:
Title:
[Abbott – Signature Page to 2020 Revolver]




EX-31.1 3 q2202310qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: August 3, 2023/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer

EX-31.2 4 q2202310qex312.htm EX-31.2 Document

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert E. Funck, Jr., certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: August 3, 2023/s/ ROBERT E. FUNCK, JR.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer

EX-32.1 5 q2202310qex321.htm EX-32.1 Document

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer
August 3, 2023
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 q2202310qex322.htm EX-32.2 Document

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ ROBERT E. FUNCK, JR.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer
August 3, 2023
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 7 abt-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Business Acquisition link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Incentive Stock Programs link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Debt and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - New Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Incentive Stock Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Supplemental Financial Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Supplemental Financial Information - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Business Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Restructuring Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Restructuring Plans - Restructuring Activity and Related Accruals (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Incentive Stock Programs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Incentive Stock Programs - Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Debt and Lines of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954728 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 9954729 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 9954730 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954731 - Disclosure - Post-Employment Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954732 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954733 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 abt-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 abt-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 abt-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Expected timing of satisfaction period (in months) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Prepaid expenses and other receivables Prepaid Expense and Other Receivables [Member] The Other Prepaid Expenses and Receivables line item in the statement of financial position in which the amounts are included. Debt and Lines of Credit Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Neuromodulation Neuromodulation [Member] It represents the neuromodulation, segment of the entity. Acquisitions of businesses and technologies, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets. Net actuarial (losses) and prior service (costs) and credits Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Exercisable options, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Pediatric Nutritionals Pediatric Nutritionals [Member] It represents the pediatric nutritionals, segment of the entity. Restatement Determination Date: Restatement Determination Date [Axis] Commitments and Contingencies Commitments and Contingencies Impairment of indefinite-lived intangible assets Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Insider Trading Policies and Procedures [Line Items] Exercisable options, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Curtailment gain Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations. Geographical [Axis] Geographical [Axis] Taxes on Earnings Income Tax Disclosure [Text Block] Current Liabilities: Liabilities, Current [Abstract] Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Securities in mutual funds held in a rabbi trust Common Stock, Shares Held in Employee Trust Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Inventories: Inventory, Net [Abstract] Dividends paid Payments of Ordinary Dividends, Common Stock Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted Earnings Per Common Share (in dollars per share) Earnings Per Share, Diluted Yen-denominated term loan Fair Value - Liabilities (Payable) position Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Trade receivables, less allowances of $485 in 2023 and $500 in 2022 Accounts Receivable, after Allowance for Credit Loss, Current Deferred income taxes and other assets Deferred Income Taxes and Other Assets, Noncurrent [Member] The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included. Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $4 and $(54) in 2023 and $61 and $46 in 2022 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Acquisition share price (in dollars per share) Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs Fair Value, Inputs, Level 3 [Member] Common shares held in treasury (in shares) Beginning balance, treasury stock, common (in shares) Ending balance, treasury stock, common (in shares) Treasury Stock, Common, Shares Condensed Cash Flow Statement [Table] Condensed Cash Flow Statement [Table] Molecular Molecular [Member] It represents the molecular, segment of the entity. Stock options outstanding, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Net Periodic Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Trading Symbol Trading Symbol Five Year Term Loan due 2024 Five Year Term Loan due 2024 [Member] Five Year Term Loan due 2024 Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net Earnings Net Earnings Net earnings Net Income (Loss) Total Current Liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Liabilities and Shareholders’ Investment Liabilities and Equity [Abstract] 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses [Member] The entity's 2022 and 2023 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. Sales (purchases) of other investment securities, net Payments for (Proceeds from) Investments Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Cost of products sold Cost of Goods and Services Sold [Member] Cost of Goods and Services Sold Beginning balance Ending balance Contract with Customer, Liability Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Cost of products sold, excluding amortization of intangible assets Cost of Goods and Services Sold Service cost - benefits earned during the period Defined Benefit Plan, Service Cost Inventory recall expense Inventory Recall Expense Executive Category: Executive Category [Axis] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Quoted Prices in Active Markets Fair Value, Inputs, Level 1 [Member] Debt Debt [Member] Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(3) and $(3) in 2023 and $12 and $25 in 2022 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Name Forgone Recovery, Individual Name Carrying Value Reported Value Measurement [Member] Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Incentive stock program, shares reserved for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Investment Type [Axis] Investment Type [Axis] Measurement Basis [Axis] Measurement Basis [Axis] Stock options granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Estimated annual amortization expense, intangible assets, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Investments [Domain] Investments [Domain] Changes In Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Trade receivables Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Tax expense from prior year tax positions Tax Adjustments, Settlements, and Unusual Provisions Derivative, notional amount Derivative, Notional Amount Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Cash dividends declared on common shares (in dollars per share) Common Stock, Dividends, Per Share, Declared Measurement Frequency [Axis] Measurement Frequency [Axis] Prepaid expenses and other receivables, current Prepaid Expenses and Other Receivables, Current [Member] Prepaid Expenses and Other Receivables, Current Retirement Plan Type [Domain] Retirement Plan Type [Domain] Diabetes Care Diabetes Care [Member] It represents the Diabetes Care, segment of the entity. Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt instrument, term Debt Instrument, Term Effect of common and treasury share transactions Effect of Common and Treasury Share Transactions This element represents the effect on retained earning due to common and treasury stock transactions. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] St. Jude Medical St Jude Medical [Member] Represents information relating to acquisition of St. Jude Medical, Inc. Income Statement Location [Axis] Income Statement Location [Axis] Andrea F. Wainer [Member] Andrea F. Wainer Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Foreign Exchange Forward Foreign Exchange Forward [Member] Structural Heart Structural Heart [Member] It represents the structural heart, segment of the entity. Heart Failure Heart Failure [Member] It represents the Heart Failure, segment of the entity. Income taxes payable Accrued Income Taxes, Current Schedule of Carrying Values and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Rhythm Management Rhythm Management [Member] It represents the rhythm management, segment of the entity. Other Performance Measure, Amount Other Performance Measure, Amount Increase in in-process R&D due to acquisition Indefinite-Lived Intangible Assets, Period Increase (Decrease) Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Research and Development Research and Development Expense [Member] Cash Flow From (Used in) Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Accrued balance at beginning of the period Accrued balance at end of the period Restructuring Reserve Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Outstanding Common Stock Options Having No Dilutive Effect (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted stock awards granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Property and equipment, at cost Property, Plant and Equipment, Gross Stock options outstanding, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Key Emerging Markets Key Emerging Markets [Member] It represents the key emerging markets, segment of the entity. Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Estimated annual amortization expense, intangible assets, 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Issued under incentive stock programs Stock Issued During Period, Value, Incentive Stock Programs Stock Issued During Period, Value, Incentive Stock Programs Trading Arrangement: Trading Arrangement [Axis] Pension contributions Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Investments Long-term Investment Securities: Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and Cash Equivalents, Beginning of Year Cash and Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization of intangible assets Finite-Lived Intangible Assets, Accumulated Amortization Prepaid expenses and other receivables Prepaid Expense and Other Receivables Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer. Interest (income) Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common shares, issued (in shares) Common Stock, Shares, Issued Acquisition purchase price Business Combination, Consideration Transferred Restructuring charges Restructuring charges in 2023 Severance Costs Common shares held in treasury, at cost — Shares: 2023: 251,823,511; 2022: 248,724,257 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Total Assets Assets, Fair Value Disclosure Total Long-term Debt Long-Term Debt Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive income (loss) Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Stock Options Employee Stock Option [Member] Cumulative Foreign Currency Translation (Loss) Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Interest rate swap derivative financial instruments Interest Rate Derivative Liabilities, at Fair Value Total unrecognized compensation cost, recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating cost and expenses Costs and Expenses Maximum Maximum [Member] Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Purchased Treasury Stock, Value, Acquired, Cost Method Increase in amortizable intangible assets due to acquisition Finite-Lived Intangible Assets, Period Increase (Decrease) Incentive Stock Programs Share-Based Payment Arrangement [Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Trade receivables, allowances Accounts Receivable, Allowance for Credit Loss, Current Derivative [Table] Derivative [Table] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Income Statement [Abstract] Income Statement [Abstract] Materials Inventory, Raw Materials, Net of Reserves Issued under incentive stock programs (in shares) Stock Issued During Period, Shares, Incentive Stock Programs Stock Issued During Period, Shares, Incentive Stock Programs Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Point of Care Point of Care [Member] It represents the point of care, segment of the entity. Restructuring Activity and Related Accruals Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Business Acquisition Business Combination Disclosure [Text Block] Indefinite-lived intangible assets related to in-process R&D acquired in a business combination Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Share-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Dividends payable Dividends Payable, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Increase in goodwill due to foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Equity method investments carrying value Equity Method Investments Total inventories Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Other Other Investments [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Total Shareholder Return Amount Total Shareholder Return Amount Purchases of common shares Payments for Repurchase of Common Stock Corporate functions and benefit plan costs Corporate and Benefit Plan Costs The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Restricted Stock Awards Restricted stock awards [Member] Restricted stock awards. Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Consolidation Items [Domain] Consolidation Items [Domain] Earnings employed in the business Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Payment of cash taxes Payments for Other Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current Assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash Flow From (Used in) Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Diagnostics Diagnostic Products Diagnostic Products [Member] The diagnostics products segment of the entity. Estimated annual amortization expense, intangible assets, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Interest cost on projected benefit obligations Defined Benefit Plan, Interest Cost PEO PEO [Member] Estimation of possible loss Loss Contingency, Estimate of Possible Loss Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Fair Value - Assets Receivable position Derivative Asset, Subject to Master Netting Arrangement, before Offset Foreign currency translation gain (loss) adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net Cash From (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Equity securities Equity Securities, FV-NI, Current Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Net earnings allocated to common shares Net Income (Loss) Available to Common Stockholders, Basic Interest Rate Swap Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Increase in goodwill due to acquisition Goodwill, Period Increase (Decrease) Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Repayments of debt Repayments of Debt Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Andrea F. Wainer Trading Arrangement, Common Stock [Member] Andrea F. Wainer Trading Arrangement, Common Stock Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold Minimum Length Of Time Hedged In Cash Flow Hedge Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Net Actuarial (Losses) and Prior Service (Costs) and Credits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] CHICAGO STOCK EXCHANGE, INC NYSE CHICAGO, INC. [Member] Number of reportable segments Number of Reportable Segments Decrease reasonably possible in gross unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,181,491; 2022: 1,986,519,278 Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total Current Assets Assets, Current Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Medical Devices Medical Devices [Member] The medical devices segment of the entity. Net cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Contingent consideration related to business combinations Business Combination, Contingent Consideration, Liability Equity securities Equity Securities [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Other, net Other Cost and Expense, Operating and Nonoperating The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses. Subsegments [Domain] Subsegments [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Trade accounts payable Accounts Payable, Trade, Current PEO Name PEO Name Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred shares, authorized (in shares) Preferred Stock, Shares Authorized Medical and Dental Plans Other Postretirement Benefits Plan [Member] Net Cash From Operating Activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Excess tax benefits associated with share-based compensation Excess Tax Benefit from Share-based Compensation Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other accrued liabilities Other Accrued Liabilities, Current Prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Other Corporate, Non-Segment [Member] Deferred income taxes and other assets Deferred Income Taxes and Other Assets, Noncurrent Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Unearned revenue from cash received during the period Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized Amount of revenue recognized arising from contract liability from change in cash received to be satisfied. Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Net deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Postemployment Benefits [Abstract] Postemployment Benefits [Abstract] Business Combination and Asset Acquisition [Abstract] Total Abbott Shareholders’ Investment Beginning of the period End of the period Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Amount of reductions of goodwill relating to impairments Goodwill, Impairment Loss Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue recognized related to contract liability balance Contract with Customer, Liability, Revenue Recognized Subsegments [Axis] Subsegments [Axis] Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Earnings before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Equity investment without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Fixed asset impairment charges Tangible Asset Impairment Charges Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Preferred shares, issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Accounting Standards Update and Change in Accounting Principle [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Significant Other Observable Inputs Fair Value, Inputs, Level 2 [Member] Other Other Security Investments [Member] Net Investment Hedging Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Intangible assets, net of amortization Intangible Assets, Net (Excluding Goodwill) Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Shareholders' Investment Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Developed technology intangible asset Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Restricted stock units granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Title Trading Arrangement, Individual Title Stock options outstanding, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Common Shares Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total Shareholders’ Investment Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Net property and equipment Property, Plant and Equipment, Net Summary of Options Outstanding and Exercisable Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Gain (loss) from foreign currency forward exchange contracts not designated as hedges Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash dividends declared on common shares Dividends, Common Stock, Cash Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Total Liabilities Liabilities, Fair Value Disclosure Summary of Amounts and Location of Derivative Financial Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Net foreign exchange (gain) loss Gain (Loss), Foreign Currency Transaction, before Tax Net Cash From (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Other Payments for (Proceeds from) Other Investing Activities Earnings Employed in the Business Retained Earnings [Member] Current portion of long-term debt Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total Liabilities and Shareholders' Investment Liabilities and Equity Other net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic Earnings Per Common Share (in dollars per share) Earnings Per Share, Basic Core Laboratory Core Laboratory [Member] It represents the core laboratory, segment of the entity. Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Percentage of remaining performance obligation expected to be recognized in period Revenue Remaining Performance Obligation Expected Timing Percentage Represents the percentage of revenue recognized for remaining performance obligations. Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Arrangement Duration Trading Arrangement Duration Schedule of Long-term Investments Schedule of Long Term Investments [Table Text Block] Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle). Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Established Pharmaceutical Products Established Pharmaceutical Products [Member] Represents Established Pharmaceutical Products, segment of the entity. Schedule of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Disclosure Text Block Supplement [Abstract] Disclosure Text Block Supplement [Abstract] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Termination Date Trading Arrangement Termination Date Proceeds from business dispositions Proceeds from Sales of Business, Affiliate and Productive Assets Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Common shares, authorized (in shares) Common Stock, Shares Authorized 2.55% Long-term Notes Due 2022 2.55% Long-term Notes Due 2022 [Member] 2.55% Long-term Notes Due 2022 Fair value of hedged long-term debt Hedged Liability, Fair Value Hedge Document Information [Table] Document Information [Table] Summary of Investment Holdings [Line Items] Summary of Investment Holdings [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net earnings to net cash from operating activities — Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Nutritionals Nutritional Products Nutritional Products [Member] The nutritional products segment of the entity. All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Award Timing Disclosures [Line Items] Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Compensation Amount Outstanding Recovery Compensation Amount Rapid Diagnostics Rapid Diagnostics [Member] It represents the rapid diagnostics, segment of the entity. Provisions/charges to income Accounts Receivable, Credit Loss Expense (Reversal) Document and Entity Information Document Information [Line Items] Restructuring Plan [Axis] Restructuring Plan [Axis] Proceeds from stock options exercised Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Increase in intangible assets due to foreign currency translation adjustments Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Estimated annual amortization expense, intangible assets, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] Changes in accumulated other comprehensive income (loss), net of income taxes AOCI Attributable to Parent, Net of Tax [Roll Forward] Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Vascular Vascular [Member] It represents the vascular products, segment of the entity. Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Registrant Name Entity Registrant Name Contract Liabilities: Contract Liabilities [Roll Forward] Contract Liabilities Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Dilutive Common Stock Options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Estimated annual amortization expense, intangible assets, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Condensed Cash Flow Statements, Captions [Line Items] Condensed Cash Flow Statements, Captions [Line Items] Electrophysiology Electrophysiology [Member] It represents the electrophysiology, segment of the entity. Adjustment to Compensation, Amount Adjustment to Compensation Amount Exchange [Domain] Exchange [Domain] Noncontrolling Interests in Subsidiaries Equity, Attributable to Noncontrolling Interest Net borrowings (repayments) of short-term debt and other Proceeds from (Repayments of) Short-Term Debt Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Issuance of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable options, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Net amortization of: Defined Benefit Plan Net Amortization Costs [Abstract] No definition available. Repayments of long-term debt Repayments of Long-Term Debt Summary of Allowance for Doubtful Accounts Activity Accounts Receivable, Allowance for Credit Loss [Table Text Block] Common Shares Held in Treasury Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Recorded accrual balance for legal proceedings and exposures Loss Contingency Accrual Liabilities, at Fair Value Liabilities, Fair Value Disclosure [Abstract] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Annual share-based awards recognized in first quarter (as a percent) Annual Share Based Awards Recognized in First Quarter Percent Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter. Share-based compensation Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Gross amount of amortizable intangible assets Finite-Lived Intangible Assets, Gross Taxes on earnings Income Tax Expense (Benefit) International Non-US [Member] Finished products Inventory, Finished Goods, Net of Reserves Designated as Hedging Instrument Designated as Hedging Instrument [Member] Amounts charged off and other deductions Accounts Receivable, Allowance for Credit Loss, Writeoff Salaries, wages and commissions Employee-related Liabilities, Current Maximum expected cleanup exposure in aggregate Loss Contingency Range of Possible Loss, Maximum Aggregate Sites The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico. Name Trading Arrangement, Individual Name Other accrued liabilities Other Accrued Liabilities, Current [Member] Other Accrued Liabilities, Current Amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Summary of Revenue by Sales Category Disaggregation of Revenue [Table Text Block] Net sales Net Sales to External Customers Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] CSI Cardiovascular Systems, Inc. [Member] Cardiovascular Systems, Inc. Amendment Flag Amendment Flag In-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Fair Value Hedging Fair Value Hedging [Member] Actuarial loss, net Defined Benefit Plan, Amortization of Gain (Loss) Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net interest expense Interest Income (Expense), Net Allowance for Doubtful Accounts: SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Legal proceedings and environmental exposures Legal proceedings and environmental exposures [Member] Loss contingencies related to legal proceedings and environmental exposures. Assets, at Fair Value Assets, Fair Value Disclosure [Abstract] Purchased (in shares) Treasury Stock, Shares, Acquired Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt Long-Term Debt, Excluding Current Maturities Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Post-employment obligations, deferred income taxes and other long-term liabilities Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities [Member] Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Schedule of Changes in Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Revenue Revenue from Contract with Customer [Text Block] Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss Contingencies [Line Items] Loss Contingencies [Line Items] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Adult Nutritionals Adult Nutritionals [Member] It represents the adult nutritionals, segment of the entity. Cover [Abstract] Cover [Abstract] Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax United States UNITED STATES Maximum expected cleanup exposure for individual site Loss Contingency Range of Possible Loss, Maximum Individual Site The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico. Outstanding Balances Fair Value, Recurring [Member] Segment Reconciling Items Segment Reconciling Items [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Non-NEOs Non-NEOs [Member] Long-term debt Long-Term Debt, Excluding Current Maturities [Member] Long-Term Debt, Excluding Current Maturities Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Short-term investments Short-Term Investments Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Asset at Fair Value Cash Flow Hedging Cash Flow Hedging [Member] Defined Benefit Plans Pension Plan [Member] Segment Information Segment Reporting Disclosure [Text Block] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets Net Increase (Decrease) in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flow From (Used in) Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Post-employment obligations, deferred income taxes and other long-term liabilities Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer. Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Andrea F. Wainer Trading Arrangement, Stock Options [Member] Andrea F. Wainer Trading Arrangement, Stock Options Other Other Emerging Markets [Member] Other Emerging Markets Debt Instrument [Line Items] Debt Instrument [Line Items] Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating earnings Operating Earnings Operating Income (Loss) Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement Statement [Line Items] Fair Value Estimate of Fair Value Measurement [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Summary of Investment Holdings [Table] Summary of Investment Holdings [Table] Shareholders’ Investment: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Noncontrolling Interests in Subsidiaries Noncontrolling Interest [Member] EX-101.PRE 11 abt-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
6 Months Ended
Jun. 30, 2023
shares
Document and Entity Information  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Jun. 30, 2023
Document Transition Report false
Entity File Number 1-2189
Entity Registrant Name ABBOTT LABORATORIES
Entity Incorporation, State or Country Code IL
Entity Tax Identification Number 36-0698440
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 1,735,357,980
Entity Central Index Key 0000001800
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2023
Document Fiscal Period Focus Q2
Amendment Flag false
NEW YORK STOCK EXCHANGE, INC.  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
CHICAGO STOCK EXCHANGE, INC  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Net sales $ 9,978 $ 11,257 $ 19,725 $ 23,152
Cost of products sold, excluding amortization of intangible assets 4,483 4,933 8,814 9,920
Amortization of intangible assets 498 507 989 1,019
Research and development 715 684 1,369 1,381
Selling, general and administrative 2,740 2,757 5,502 5,544
Total operating cost and expenses 8,436 8,881 16,674 17,864
Operating earnings 1,542 2,376 3,051 5,288
Interest expense 159 132 312 263
Interest (income) (98) (26) (199) (40)
Net foreign exchange (gain) loss 21 0 27 (3)
Other (income) expense, net (176) (82) (287) (160)
Earnings before taxes 1,636 2,352 3,198 5,228
Taxes on earnings 261 334 505 763
Net Earnings $ 1,375 $ 2,018 $ 2,693 $ 4,465
Basic Earnings Per Common Share (in dollars per share) $ 0.79 $ 1.15 $ 1.54 $ 2.53
Diluted Earnings Per Common Share (in dollars per share) $ 0.78 $ 1.14 $ 1.53 $ 2.51
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) 1,740,359 1,753,865 1,741,051 1,757,858
Dilutive Common Stock Options (in shares) 9,889 11,598 9,933 12,115
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) 1,750,248 1,765,463 1,750,984 1,769,973
Outstanding Common Stock Options Having No Dilutive Effect (in shares) 5,474 5,419 5,474 2,655
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statement of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]          
Net Earnings $ 1,375 $ 2,018 $ 2,693 $ 4,465  
Foreign currency translation gain (loss) adjustments (52) (315) 87 (421)  
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(3) and $(3) in 2023 and $12 and $25 in 2022 (6) 54 (4) 116  
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $4 and $(54) in 2023 and $61 and $46 in 2022 26 29 (103) (27)  
Other comprehensive income (loss) (32) (232) (20) (332)  
Comprehensive Income 1,343 $ 1,786 2,673 $ 4,133  
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:          
Cumulative foreign currency translation (loss) adjustments (6,646)   (6,646)   $ (6,733)
Net actuarial (losses) and prior service (costs) and credits (1,497)   (1,497)   (1,493)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other 72   72   175
Accumulated other comprehensive income (loss) $ (8,071)   $ (8,071)   $ (8,051)
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit) $ (3) $ 12 $ (3) $ 25
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit) $ 4 $ 61 $ (54) $ 46
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current Assets:    
Cash and cash equivalents $ 7,835 $ 9,882
Short-term investments 320 288
Trade receivables, less allowances of $485 in 2023 and $500 in 2022 6,172 6,218
Inventories:    
Finished products 4,004 3,805
Work in process 845 680
Materials 2,022 1,688
Total inventories 6,871 6,173
Prepaid expenses and other receivables 2,307 2,663
Total Current Assets 23,505 25,224
Investments 799 766
Property and equipment, at cost 20,926 20,212
Less: accumulated depreciation and amortization 11,477 11,050
Net property and equipment 9,449 9,162
Intangible assets, net of amortization 9,834 10,454
Goodwill 23,258 22,799
Deferred income taxes and other assets 6,509 6,033
Total Assets 73,354 74,438
Current Liabilities:    
Trade accounts payable 4,211 4,607
Salaries, wages and commissions 1,362 1,556
Other accrued liabilities 5,334 5,845
Dividends payable 886 887
Income taxes payable 273 343
Current portion of long-term debt 2,284 2,251
Total Current Liabilities 14,350 15,489
Long-term debt 14,562 14,522
Post-employment obligations, deferred income taxes and other long-term liabilities 7,038 7,522
Commitments and Contingencies
Shareholders’ Investment:    
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 0 0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,181,491; 2022: 1,986,519,278 24,612 24,709
Common shares held in treasury, at cost — Shares: 2023: 251,823,511; 2022: 248,724,257 (15,722) (15,229)
Earnings employed in the business 36,355 35,257
Accumulated other comprehensive income (loss) (8,071) (8,051)
Total Abbott Shareholders’ Investment 37,174 36,686
Noncontrolling Interests in Subsidiaries 230 219
Total Shareholders’ Investment 37,404 36,905
Total Liabilities and Shareholders' Investment $ 73,354 $ 74,438
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Trade receivables, allowances $ 485 $ 500
Preferred shares, par value (in dollars per share) $ 1 $ 1
Preferred shares, authorized (in shares) 1,000,000 1,000,000
Preferred shares, issued (in shares) 0 0
Common shares, authorized (in shares) 2,400,000,000 2,400,000,000
Common shares, issued (in shares) 1,987,181,491 1,986,519,278
Common shares held in treasury (in shares) 251,823,511 248,724,257
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Increase (Decrease) in Shareholders' Investment        
Beginning balance     $ 36,905  
Net earnings $ 1,375 $ 2,018 2,693 $ 4,465
Other comprehensive income (loss) (32) (232) (20) (332)
Ending balance 37,404   37,404  
Common Shares        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 24,488 24,304 24,709 24,470
Issued under incentive stock programs 14 10 30 24
Share-based compensation 119 125 415 449
Issuance of restricted stock awards (9) (10) (542) (514)
Ending balance 24,612 24,429 24,612 24,429
Common Shares Held in Treasury        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (15,307) (13,726) (15,229) (11,822)
Issued under incentive stock programs 10 7 252 230
Purchased (425) (1) (745) (2,128)
Ending balance (15,722) (13,720) (15,722) (13,720)
Earnings Employed in the Business        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 35,868 33,295 35,257 31,528
Net earnings 1,375 2,018 2,693 4,465
Cash dividends declared on common shares (889) (827) (1,779) (1,653)
Effect of common and treasury share transactions 1 1 184 147
Ending balance 36,355 34,487 36,355 34,487
Accumulated Other Comprehensive Income (Loss)        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (8,039) (8,474) (8,051) (8,374)
Other comprehensive income (loss) (32) (232) (20) (332)
Ending balance (8,071) (8,706) (8,071) (8,706)
Noncontrolling Interests in Subsidiaries        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 222 230 219 222
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases 8 (4) 11 4
Ending balance $ 230 $ 226 $ 230 $ 226
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Increase (Decrease) in Shareholders' Investment        
Beginning balance, treasury stock, common (in shares)     248,724,257  
Ending balance, treasury stock, common (in shares) 251,823,511   251,823,511  
Common Shares        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (in shares) 1,986,904,170 1,985,525,053 1,986,519,278 1,985,273,421
Issued under incentive stock programs (in shares) 277,321 151,682 662,213 403,314
Ending balance (in shares) 1,987,181,491 1,985,676,735 1,987,181,491 1,985,676,735
Common Shares Held in Treasury        
Increase (Decrease) in Shareholders' Investment        
Beginning balance, treasury stock, common (in shares) 247,957,371 234,582,764 248,724,257 221,191,228
Issued under incentive stock programs (in shares) 157,305 135,663 4,090,470 4,280,139
Purchased (in shares) 4,023,445 9,891 7,189,724 17,545,903
Ending balance, treasury stock, common (in shares) 251,823,511 234,456,992 251,823,511 234,456,992
Earnings Employed in the Business        
Increase (Decrease) in Shareholders' Investment        
Cash dividends declared on common shares (in dollars per share) $ 0.51 $ 0.47 $ 1.02 $ 0.94
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flow From (Used in) Operating Activities:    
Net earnings $ 2,693 $ 4,465
Adjustments to reconcile net earnings to net cash from operating activities —    
Depreciation 617 626
Amortization of intangible assets 989 1,019
Share-based compensation 413 447
Trade receivables 37 (939)
Inventories (667) (1,030)
Other, net (1,736) (113)
Net Cash From Operating Activities 2,346 4,475
Cash Flow From (Used in) Investing Activities:    
Acquisitions of property and equipment (887) (700)
Acquisitions of businesses and technologies, net of cash acquired (826) 0
Proceeds from business dispositions 40 48
Sales (purchases) of other investment securities, net (7) 18
Other 5 10
Net Cash From (Used in) Investing Activities (1,675) (624)
Cash Flow From (Used in) Financing Activities:    
Net borrowings (repayments) of short-term debt and other (29) 13
Proceeds from issuance of long-term debt 1 6
Repayments of long-term debt (2) (752)
Purchases of common shares (966) (2,312)
Proceeds from stock options exercised 77 69
Dividends paid (1,780) (1,660)
Net Cash From (Used in) Financing Activities (2,699) (4,636)
Effect of exchange rate changes on cash and cash equivalents (19) (77)
Net Increase (Decrease) in Cash and Cash Equivalents (2,047) (862)
Cash and Cash Equivalents, Beginning of Year 9,882 9,799
Cash and Cash Equivalents, End of Period $ 7,835 $ 8,937
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.2
New Accounting Standards
6 Months Ended
Jun. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards
Note 2 — New Accounting Standards

Recently Adopted Accounting Standards
In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue
6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended June 30, 2023Three Months Ended June 30, 2022
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $990 $990 $— $946 $946 
Other— 297 297  277 277 
Total— 1,287 1,287 — 1,223 1,223 
Nutritionals —    
Pediatric Nutritionals507 517 1,024 413 512 925 
Adult Nutritionals374 678 1,052 348 680 1,028 
Total881 1,195 2,076 761 1,192 1,953 
Diagnostics —     
Core Laboratory311 982 1,293 287 934 1,221 
Molecular43 98 141 71 141 212 
Point of Care99 43 142 101 38 139 
Rapid Diagnostics508 233 741 1,982 740 2,722 
Total961 1,356 2,317 2,441 1,853 4,294 
Medical Devices —    
Rhythm Management269 314 583 264 284 548 
Electrophysiology245 308 553 226 260 486 
Heart Failure226 69 295 207 62 269 
Vascular264 451 715 228 425 653 
Structural Heart219 279 498 207 233 440 
Neuromodulation185 42 227 157 40 197 
Diabetes Care 505 919 1,424 399 793 1,192 
Total1,913 2,382 4,295 1,688 2,097 3,785 
Other— — 
Total$3,758 $6,220 $9,978 $4,892 $6,365 $11,257 
Six Months Ended June 30, 2023Six Months Ended June 30, 2022
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $1,902 $1,902 $— $1,852 $1,852 
Other— 574 574 — 518 518 
Total— 2,476 2,476 — 2,370 2,370 
Nutritionals —    
Pediatric Nutritionals966 982 1,948 751 1,021 1,772 
Adult Nutritionals727 1,368 2,095 687 1,388 2,075 
Total1,693 2,350 4,043 1,438 2,409 3,847 
Diagnostics —
Core Laboratory600 1,875 2,475 555 1,850 2,405 
Molecular90 198 288 243 389 632 
Point of Care192 84 276 192 75 267 
Rapid Diagnostics1,414 552 1,966 4,163 2,084 6,247 
Total2,296 2,709 5,005 5,153 4,398 9,551 
Medical Devices —
Rhythm Management529 581 1,110 512 560 1,072 
Electrophysiology483 575 1,058 442 529 971 
Heart Failure444 132 576 403 116 519 
Vascular482 850 1,332 437 835 1,272 
Structural Heart429 530 959 397 454 851 
Neuromodulation340 83 423 300 76 376 
Diabetes Care984 1,753 2,737 742 1,576 2,318 
Total3,691 4,504 8,195 3,233 4,146 7,379 
Other— — 
Total$7,686 $12,039 $19,725 $9,829 $13,323 $23,152 

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $28 million of sales in the second quarter of 2022 and $57 million in the first six months of 2022 were moved from Rapid Diagnostics to Heart Failure.

Remaining Performance Obligations

As of June 30, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.2 billion in the Diagnostics segment and approximately $475 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2022$500 
Unearned revenue from cash received during the period243 
Revenue recognized related to contract liability balance(192)
Balance at June 30, 2023$551 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental Financial Information
6 Months Ended
Jun. 30, 2023
Disclosure Text Block Supplement [Abstract]  
Supplemental Financial Information
Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended June 30, 2023 and 2022 were $1.370 billion and $2.009 billion, respectively, and for the six months ended June 30, 2023 and 2022 were $2.682 billion and $4.447 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2023 includes $290 million of pension contributions and the payment of cash taxes of approximately $837 million. The first six months of 2022 includes $348 million of pension contributions and the payment of cash taxes of approximately $657 million.

The following summarizes the activity for the first six months of 2023 related to the allowance for doubtful accounts as of June 30, 2023:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022$262 
Provisions/charges to income16 
Amounts charged off and other deductions(12)
Balance at June 30, 2023$266 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments as of June 30, 2023 and December 31, 2022 are as follows:

(in millions)June 30,
2023
December 31,
2022
Long-term Investments:
Equity securities$574 $558 
Other225 208 
Total$799 $766 

The increase in Abbott’s long-term investments as of June 30, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.

Abbott’s equity securities as of June 30, 2023 include $305 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of June 30, 2023 with a carrying value of $164 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $95 million that do not have a readily determinable fair value.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Changes In Accumulated Other Comprehensive Income (Loss)
6 Months Ended
Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Changes In Accumulated Other Comprehensive Income (Loss)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202320222023202220232022
Balance at March 31$(6,594)$(5,945)$(1,491)$(2,608)$46 $79 
Other comprehensive income (loss) before reclassifications(52)(315)13 80 45 
Amounts reclassified from accumulated other comprehensive income— — (7)41 (54)(16)
Net current period comprehensive income (loss)(52)(315)(6)54 26 29 
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 
Six Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20232022202320222023 2022
Balance at January 1$(6,733)$(5,839)$(1,493)$(2,670)$175 $135 
Other comprehensive income (loss) before reclassifications87 (421)30 38 11 
Amounts reclassified from accumulated other comprehensive income — — (7)86 (141)(38)
Net current period comprehensive income (loss)87 (421)(4)116 (103)(27)
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisition
6 Months Ended
Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Acquisition
Note 6 — Business Acquisition

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complimentary technologies to Abbott's portfolio of vascular device offerings.
The preliminary allocation of the purchase price of the acquisition resulted in the recording of a non-deductible developed technology intangible asset of $290 million; non-deductible in-process research and development of $60 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $340 million; net deferred tax assets of approximately $18 million and other net assets of approximately $143 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $23.3 billion at June 30, 2023 and $22.8 billion at December 31, 2022. The acquisition of CSI increased goodwill by approximately $340 million and foreign currency translation adjustments increased goodwill by approximately $120 million in the first six months of 2023. The amount of goodwill related to reportable segments at June 30, 2023 was $2.7 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.7 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first six months of 2023.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.7 billion and $27.2 billion as of June 30, 2023 and December 31, 2022, respectively. The gross amount of amortizable intangible assets increased by $290 million due to the CSI acquisition. Accumulated amortization was $18.7 billion and $17.6 billion as of June 30, 2023 and December 31, 2022, respectively. Foreign currency translation adjustments increased intangible assets by $47 million in the first six months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026 and $1.3 billion in 2027.

Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were approximately $822 million as of June 30, 2023 and $807 million as of December 31, 2022. In the second quarter of 2023, the acquisition of CSI increased IPR&D by $60 million. This increase was partially offset by $45 million of charges recorded on the Research and development line of the Condensed Consolidated Statement of Earnings for the impairment of certain indefinite-lived intangible assets related to the Medical Devices reportable segment.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring Plans
6 Months Ended
Jun. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Plans
Note 8 — Restructuring Plans

In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the six months ended June 30, 2023, Abbott recorded employee related severance and other charges of approximately $49 million, of which approximately $17 million was recorded in Cost of products sold, approximately $5 million was recorded in Research and development, and approximately $27 million was recorded in Selling, general and administrative expenses. In addition, Abbott recognized fixed asset impairment charges of approximately $17 million related to these restructuring plans.

The following summarizes the activity related to these restructuring actions and the status of the related accruals as of June 30, 2023:

(in millions)Total
Accrued balance at December 31, 2022$228 
Restructuring charges in 202349 
Payments and other adjustments(120)
Accrued balance at June 30, 2023$157 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Incentive Stock Programs
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Incentive Stock Programs
Note 9 — Incentive Stock Programs

In the first six months of 2023, Abbott granted 1,973,371 stock options, 460,447 restricted stock awards and 4,854,027 restricted stock units under its incentive stock program. At June 30, 2023, approximately 74 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at June 30, 2023 is as follows:

OutstandingExercisable
Number of shares 29,508,026 24,819,977 
Weighted average remaining life (years)
5.24.5
Weighted average exercise price $73.66 $66.04 
Aggregate intrinsic value (in millions)
$1,107 $1,101 

The total unrecognized share-based compensation cost at June 30, 2023 amounted to approximately $660 million which is expected to be recognized over the next three years.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Lines of Credit
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Debt and Lines of Credit
Note 10 — Debt and Lines of Credit

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments, Derivatives and Fair Value Measures
6 Months Ended
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments, Derivatives and Fair Value Measures
Note 11 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.1 billion at June 30, 2023 and $7.7 billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At June 30, 2023 and December 31, 2022, Abbott held the gross notional amounts of $12.3 billion and $12.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $446 million as of June 30, 2023 and December 31, 2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.9 billion at June 30, 2023 and December 31, 2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2023 and December 31, 2022:

Fair Value - AssetsFair Value - Liabilities
(in millions)June 30,
2023
December 31, 2022Balance Sheet CaptionJune 30,
2023
December 31, 2022Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current$— $— Deferred income taxes and other assets$142 $136 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables11 20 Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments147 304 Prepaid expenses and other receivables129 96 Other accrued liabilities
Others not designated as hedges78 108 Prepaid expenses and other receivables62 130 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a413 446 Long-term debt
$225 $412 $757 $828 
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2023 and 2022.

Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023202220232022Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$90 $141 $27 $92 $63 $43 $189 $70 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary38 54 33 84 — — — — n/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(6)(47)(168)Interest expense

Gains of $39 million and $303 million were recognized in the three months ended June 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. A loss of $64 million and a gain of $252 million were recognized in the first six months ended June 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of June 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

June 30, 2023December 31, 2022
(in millions)Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
Long-term Investment Securities:
Equity securities$574 $574 $558 $558 
Other225 225 208 208 
Total Long-term Debt(16,846)(16,555)(16,773)(16,313)
Foreign Currency Forward Exchange Contracts:   
Receivable position225 225 412 412 
(Payable) position(191)(191)(226)(226)
Interest Rate Hedge Contracts:    
Receivable position— — — — 
(Payable) position(153)(153)(156)(156)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances
Quoted
Prices in
Active
Markets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
June 30, 2023:
Equity securities$315 $315 $— $— 
Foreign currency forward exchange contracts225 — 225 — 
Total Assets$540 $315 $225 $— 
Fair value of hedged long-term debt$2,697 $— $2,697 $— 
Interest rate swap derivative financial instruments153 — 153 — 
Foreign currency forward exchange contracts191 — 191 — 
Contingent consideration related to business combinations84 — — 84 
Total Liabilities$3,125 $— $3,041 $84 
December 31, 2022:
Equity securities$307 $307 $— $— 
Foreign currency forward exchange contracts412 — 412 — 
Total Assets$719 $307 $412 $— 
Fair value of hedged long-term debt$2,691 $— $2,691 $— 
Interest rate swap derivative financial instruments156 156 
Foreign currency forward exchange contracts226 — 226 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,203 $— $3,073 $130 
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The change in fair value from December 31, 2022 reflects changes in the projected timelines for events that will trigger payment of contingent consideration.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Litigation and Environmental Matters
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Litigation and Environmental Matters
Note 12 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $25 million to $35 million. The recorded accrual balance at June 30, 2023 for these proceedings and exposures was approximately $30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Post-Employment Benefits
6 Months Ended
Jun. 30, 2023
Postemployment Benefits [Abstract]  
Post-Employment Benefits
Note 13 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023202220232022
Service cost - benefits earned during the period$58 $94 $118 $190 $10 $12 $19 $25 
Interest cost on projected benefit obligations114 75 228 151 16 30 18 
Expected return on plan assets(243)(234)(485)(470)(6)(8)(12)(15)
Curtailment gain(14)— (14)— — — — — 
Net amortization of:
Actuarial loss, net57 116 (1)(1)
Prior service cost (credit)— — (4)(6)(7)(12)
Net cost (credit)$(82)$(7)$(147)$(12)$15 $$29 $22 

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first six months of 2023 and 2022, $290 million and $348 million, respectively, were contributed to defined benefit plans. In the first six months of 2023 and 2022, $28 million was contributed, in each year, to the post-employment medical and dental plans.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Taxes on Earnings
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Taxes on Earnings
Note 14 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2023 and 2022, taxes on earnings include approximately $9 million and $32 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of 2023 and 2022, taxes on earnings also include approximately $62 million and $27 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segment Information
Note 15 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023 2022 2023 2022
Established Pharmaceutical Products$1,287 $1,223 $2,476 $2,370 $307 $258 $607 $500 
Nutritional Products2,076 1,953 4,043 3,847 308 230 688 481 
Diagnostic Products2,317 4,294 5,005 9,551 437 1,705 1,088 4,269 
Medical Devices4,295 3,785 8,195 7,379 1,385 1,160 2,463 2,243 
Total Reportable Segments9,975 11,255 19,719 23,147 2,437 3,353 4,846 7,493 
Other
Net sales$9,978 $11,257 $19,725 $23,152 
Corporate functions and benefit plan costs(71)(123)(148)(237)
Net interest expense (61)(106)(113)(223)
Share-based compensation (a) (132)(142)(413)(447)
Amortization of intangible assets(498)(507)(989)(1,019)
Other, net (b)(39)(123)15 (339)
Earnings before taxes$1,636 $2,352 $3,198 $5,228 
______________________________________
Notes:Three and six months ended June 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three and six months ended June 30, 2023 includes costs associated with the acquisition of CSI, charges related to restructurings, and income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and six months ended June 30, 2022 includes $42 million and $162 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment as well as integration costs related to the acquisition of Alere Inc.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure        
Net earnings $ 1,375 $ 2,018 $ 2,693 $ 4,465
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
3 Months Ended 6 Months Ended
Jun. 30, 2023
shares
Jun. 30, 2023
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Andrea F. Wainer [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   On May 1, 2023, Andrea F. Wainer, Executive Vice President, Rapid and Molecular Diagnostics, adopted a plan for the sale of securities of Abbott that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Ms. Wainer's Rule 10b5-1 plan provides for the sale of 5,400 shares and the exercise of up to 111,606 stock options until June 30, 2024.
Name Andrea F. Wainer  
Title Executive Vice President, Rapid and Molecular Diagnostics  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date May 1, 2023  
Arrangement Duration 426 days  
Andrea F. Wainer Trading Arrangement, Common Stock [Member] | Andrea F. Wainer [Member]    
Trading Arrangements, by Individual    
Aggregate Available 5,400 5,400
Andrea F. Wainer Trading Arrangement, Stock Options [Member] | Andrea F. Wainer [Member]    
Trading Arrangements, by Individual    
Aggregate Available 111,606 111,606
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.2
New Accounting Standards (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
Recently Adopted Accounting Standards Recently Adopted Accounting StandardsIn September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Sales Category
The following tables provide detail by sales category:

Three Months Ended June 30, 2023Three Months Ended June 30, 2022
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $990 $990 $— $946 $946 
Other— 297 297  277 277 
Total— 1,287 1,287 — 1,223 1,223 
Nutritionals —    
Pediatric Nutritionals507 517 1,024 413 512 925 
Adult Nutritionals374 678 1,052 348 680 1,028 
Total881 1,195 2,076 761 1,192 1,953 
Diagnostics —     
Core Laboratory311 982 1,293 287 934 1,221 
Molecular43 98 141 71 141 212 
Point of Care99 43 142 101 38 139 
Rapid Diagnostics508 233 741 1,982 740 2,722 
Total961 1,356 2,317 2,441 1,853 4,294 
Medical Devices —    
Rhythm Management269 314 583 264 284 548 
Electrophysiology245 308 553 226 260 486 
Heart Failure226 69 295 207 62 269 
Vascular264 451 715 228 425 653 
Structural Heart219 279 498 207 233 440 
Neuromodulation185 42 227 157 40 197 
Diabetes Care 505 919 1,424 399 793 1,192 
Total1,913 2,382 4,295 1,688 2,097 3,785 
Other— — 
Total$3,758 $6,220 $9,978 $4,892 $6,365 $11,257 
Six Months Ended June 30, 2023Six Months Ended June 30, 2022
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $1,902 $1,902 $— $1,852 $1,852 
Other— 574 574 — 518 518 
Total— 2,476 2,476 — 2,370 2,370 
Nutritionals —    
Pediatric Nutritionals966 982 1,948 751 1,021 1,772 
Adult Nutritionals727 1,368 2,095 687 1,388 2,075 
Total1,693 2,350 4,043 1,438 2,409 3,847 
Diagnostics —
Core Laboratory600 1,875 2,475 555 1,850 2,405 
Molecular90 198 288 243 389 632 
Point of Care192 84 276 192 75 267 
Rapid Diagnostics1,414 552 1,966 4,163 2,084 6,247 
Total2,296 2,709 5,005 5,153 4,398 9,551 
Medical Devices —
Rhythm Management529 581 1,110 512 560 1,072 
Electrophysiology483 575 1,058 442 529 971 
Heart Failure444 132 576 403 116 519 
Vascular482 850 1,332 437 835 1,272 
Structural Heart429 530 959 397 454 851 
Neuromodulation340 83 423 300 76 376 
Diabetes Care984 1,753 2,737 742 1,576 2,318 
Total3,691 4,504 8,195 3,233 4,146 7,379 
Other— — 
Total$7,686 $12,039 $19,725 $9,829 $13,323 $23,152 

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $28 million of sales in the second quarter of 2022 and $57 million in the first six months of 2022 were moved from Rapid Diagnostics to Heart Failure.
Schedule of Changes in Contract Liabilities
Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2022$500 
Unearned revenue from cash received during the period243 
Revenue recognized related to contract liability balance(192)
Balance at June 30, 2023$551 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental Financial Information (Tables)
6 Months Ended
Jun. 30, 2023
Disclosure Text Block Supplement [Abstract]  
Summary of Allowance for Doubtful Accounts Activity
The following summarizes the activity for the first six months of 2023 related to the allowance for doubtful accounts as of June 30, 2023:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022$262 
Provisions/charges to income16 
Amounts charged off and other deductions(12)
Balance at June 30, 2023$266 
Schedule of Long-term Investments
The components of long-term investments as of June 30, 2023 and December 31, 2022 are as follows:

(in millions)June 30,
2023
December 31,
2022
Long-term Investments:
Equity securities$574 $558 
Other225 208 
Total$799 $766 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Changes In Accumulated Other Comprehensive Income (Loss) (Tables)
6 Months Ended
Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202320222023202220232022
Balance at March 31$(6,594)$(5,945)$(1,491)$(2,608)$46 $79 
Other comprehensive income (loss) before reclassifications(52)(315)13 80 45 
Amounts reclassified from accumulated other comprehensive income— — (7)41 (54)(16)
Net current period comprehensive income (loss)(52)(315)(6)54 26 29 
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 
Six Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20232022202320222023 2022
Balance at January 1$(6,733)$(5,839)$(1,493)$(2,670)$175 $135 
Other comprehensive income (loss) before reclassifications87 (421)30 38 11 
Amounts reclassified from accumulated other comprehensive income — — (7)86 (141)(38)
Net current period comprehensive income (loss)87 (421)(4)116 (103)(27)
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring Plans (Tables)
6 Months Ended
Jun. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Activity and Related Accruals
The following summarizes the activity related to these restructuring actions and the status of the related accruals as of June 30, 2023:

(in millions)Total
Accrued balance at December 31, 2022$228 
Restructuring charges in 202349 
Payments and other adjustments(120)
Accrued balance at June 30, 2023$157 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Incentive Stock Programs (Tables)
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Options Outstanding and Exercisable Information regarding the number of options outstanding and exercisable at June 30, 2023 is as follows:
OutstandingExercisable
Number of shares 29,508,026 24,819,977 
Weighted average remaining life (years)
5.24.5
Weighted average exercise price $73.66 $66.04 
Aggregate intrinsic value (in millions)
$1,107 $1,101 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments, Derivatives and Fair Value Measures (Tables)
6 Months Ended
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Amounts and Location of Derivative Financial Instruments
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2023 and December 31, 2022:

Fair Value - AssetsFair Value - Liabilities
(in millions)June 30,
2023
December 31, 2022Balance Sheet CaptionJune 30,
2023
December 31, 2022Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current$— $— Deferred income taxes and other assets$142 $136 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables11 20 Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments147 304 Prepaid expenses and other receivables129 96 Other accrued liabilities
Others not designated as hedges78 108 Prepaid expenses and other receivables62 130 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a413 446 Long-term debt
$225 $412 $757 $828 
Schedule of Derivatives Gain (Loss) in OCI and Income (Expense)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2023 and 2022.

Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023202220232022Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$90 $141 $27 $92 $63 $43 $189 $70 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary38 54 33 84 — — — — n/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(6)(47)(168)Interest expense
Schedule of Carrying Values and Fair Values of Financial Instruments
The carrying values and fair values of certain financial instruments as of June 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

June 30, 2023December 31, 2022
(in millions)Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
Long-term Investment Securities:
Equity securities$574 $574 $558 $558 
Other225 225 208 208 
Total Long-term Debt(16,846)(16,555)(16,773)(16,313)
Foreign Currency Forward Exchange Contracts:   
Receivable position225 225 412 412 
(Payable) position(191)(191)(226)(226)
Interest Rate Hedge Contracts:    
Receivable position— — — — 
(Payable) position(153)(153)(156)(156)
Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances
Quoted
Prices in
Active
Markets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
June 30, 2023:
Equity securities$315 $315 $— $— 
Foreign currency forward exchange contracts225 — 225 — 
Total Assets$540 $315 $225 $— 
Fair value of hedged long-term debt$2,697 $— $2,697 $— 
Interest rate swap derivative financial instruments153 — 153 — 
Foreign currency forward exchange contracts191 — 191 — 
Contingent consideration related to business combinations84 — — 84 
Total Liabilities$3,125 $— $3,041 $84 
December 31, 2022:
Equity securities$307 $307 $— $— 
Foreign currency forward exchange contracts412 — 412 — 
Total Assets$719 $307 $412 $— 
Fair value of hedged long-term debt$2,691 $— $2,691 $— 
Interest rate swap derivative financial instruments156 156 
Foreign currency forward exchange contracts226 — 226 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,203 $— $3,073 $130 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Post-Employment Benefits (Tables)
6 Months Ended
Jun. 30, 2023
Postemployment Benefits [Abstract]  
Schedule of Net Periodic Benefit Costs Net cost recognized for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
Defined Benefit PlansMedical and Dental Plans
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023202220232022
Service cost - benefits earned during the period$58 $94 $118 $190 $10 $12 $19 $25 
Interest cost on projected benefit obligations114 75 228 151 16 30 18 
Expected return on plan assets(243)(234)(485)(470)(6)(8)(12)(15)
Curtailment gain(14)— (14)— — — — — 
Net amortization of:
Actuarial loss, net57 116 (1)(1)
Prior service cost (credit)— — (4)(6)(7)(12)
Net cost (credit)$(82)$(7)$(147)$(12)$15 $$29 $22 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Information
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended June 30
Six Months
Ended June 30
Three Months
Ended June 30
Six Months
Ended June 30
(in millions)20232022202320222023 2022 2023 2022
Established Pharmaceutical Products$1,287 $1,223 $2,476 $2,370 $307 $258 $607 $500 
Nutritional Products2,076 1,953 4,043 3,847 308 230 688 481 
Diagnostic Products2,317 4,294 5,005 9,551 437 1,705 1,088 4,269 
Medical Devices4,295 3,785 8,195 7,379 1,385 1,160 2,463 2,243 
Total Reportable Segments9,975 11,255 19,719 23,147 2,437 3,353 4,846 7,493 
Other
Net sales$9,978 $11,257 $19,725 $23,152 
Corporate functions and benefit plan costs(71)(123)(148)(237)
Net interest expense (61)(106)(113)(223)
Share-based compensation (a) (132)(142)(413)(447)
Amortization of intangible assets(498)(507)(989)(1,019)
Other, net (b)(39)(123)15 (339)
Earnings before taxes$1,636 $2,352 $3,198 $5,228 
______________________________________
Notes:Three and six months ended June 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three and six months ended June 30, 2023 includes costs associated with the acquisition of CSI, charges related to restructurings, and income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and six months ended June 30, 2022 includes $42 million and $162 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment as well as integration costs related to the acquisition of Alere Inc.
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Narrative (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
segment
Jun. 30, 2022
segment
Jun. 30, 2023
USD ($)
segment
Jun. 30, 2022
segment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Number of reportable segments | segment 4 4 4 4
Diagnostics        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 4,200   $ 4,200  
Medical Devices        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 475   $ 475  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     59.00%  
Expected timing of satisfaction period (in months) 24 months   24 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-07-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     17.00%  
Expected timing of satisfaction period (in months) 12 months   12 months  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Summary of Revenue by Sales Category (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting Information [Line Items]        
Net sales $ 9,978 $ 11,257 $ 19,725 $ 23,152
Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 9,975 11,255 19,719 23,147
Other        
Segment Reporting Information [Line Items]        
Net sales 3 2 6 5
United States        
Segment Reporting Information [Line Items]        
Net sales 3,758 4,892 7,686 9,829
United States | Other        
Segment Reporting Information [Line Items]        
Net sales 3 2 6 5
International        
Segment Reporting Information [Line Items]        
Net sales 6,220 6,365 12,039 13,323
International | Other        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,287 1,223 2,476 2,370
Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,287 1,223 2,476 2,370
Nutritionals | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 2,076 1,953 4,043 3,847
Nutritionals | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 881 761 1,693 1,438
Nutritionals | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,195 1,192 2,350 2,409
Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 2,317 4,294 5,005 9,551
Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 961 2,441 2,296 5,153
Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,356 1,853 2,709 4,398
Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 4,295 3,785 8,195 7,379
Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,913 1,688 3,691 3,233
Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 2,382 2,097 4,504 4,146
Key Emerging Markets | Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 990 946 1,902 1,852
Key Emerging Markets | Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Key Emerging Markets | Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 990 946 1,902 1,852
Other | Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 297 277 574 518
Other | Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Other | Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 297 277 574 518
Pediatric Nutritionals | Nutritionals | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,024 925 1,948 1,772
Pediatric Nutritionals | Nutritionals | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 507 413 966 751
Pediatric Nutritionals | Nutritionals | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 517 512 982 1,021
Adult Nutritionals | Nutritionals | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,052 1,028 2,095 2,075
Adult Nutritionals | Nutritionals | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 374 348 727 687
Adult Nutritionals | Nutritionals | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 678 680 1,368 1,388
Core Laboratory | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,293 1,221 2,475 2,405
Core Laboratory | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 311 287 600 555
Core Laboratory | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 982 934 1,875 1,850
Molecular | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 141 212 288 632
Molecular | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 43 71 90 243
Molecular | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 98 141 198 389
Point of Care | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 142 139 276 267
Point of Care | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 99 101 192 192
Point of Care | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 43 38 84 75
Rapid Diagnostics | Diagnostics | Revision of Prior Period, Reclassification, Adjustment        
Segment Reporting Information [Line Items]        
Net sales   (28)   (57)
Rapid Diagnostics | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 741 2,722 1,966 6,247
Rapid Diagnostics | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 508 1,982 1,414 4,163
Rapid Diagnostics | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 233 740 552 2,084
Rhythm Management | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 583 548 1,110 1,072
Rhythm Management | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 269 264 529 512
Rhythm Management | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 314 284 581 560
Electrophysiology | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 553 486 1,058 971
Electrophysiology | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 245 226 483 442
Electrophysiology | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 308 260 575 529
Heart Failure | Medical Devices | Revision of Prior Period, Reclassification, Adjustment        
Segment Reporting Information [Line Items]        
Net sales   28   57
Heart Failure | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 295 269 576 519
Heart Failure | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 226 207 444 403
Heart Failure | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 69 62 132 116
Vascular | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 715 653 1,332 1,272
Vascular | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 264 228 482 437
Vascular | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 451 425 850 835
Structural Heart | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 498 440 959 851
Structural Heart | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 219 207 429 397
Structural Heart | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 279 233 530 454
Neuromodulation | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 227 197 423 376
Neuromodulation | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 185 157 340 300
Neuromodulation | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 42 40 83 76
Diabetes Care | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,424 1,192 2,737 2,318
Diabetes Care | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 505 399 984 742
Diabetes Care | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales $ 919 $ 793 $ 1,753 $ 1,576
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Schedule of Changes in Contract Liabilities (Details)
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
Contract Liabilities:  
Beginning balance $ 500
Unearned revenue from cash received during the period 243
Revenue recognized related to contract liability balance (192)
Ending balance $ 551
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental Financial Information - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Condensed Cash Flow Statements, Captions [Line Items]        
Net earnings allocated to common shares $ 1,370 $ 2,009 $ 2,682 $ 4,447
Payment of cash taxes     837 657
Equity method investments carrying value 164   164  
Equity investment without readily determinable fair value 95   95  
St. Jude Medical | Equity securities        
Condensed Cash Flow Statements, Captions [Line Items]        
Securities in mutual funds held in a rabbi trust $ 305   305  
Defined Benefit Plans        
Condensed Cash Flow Statements, Captions [Line Items]        
Pension contributions     $ 290 $ 348
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental Financial Information - Allowance for Doubtful Accounts (Details)
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
Allowance for Doubtful Accounts:  
Beginning balance $ 262
Provisions/charges to income 16
Amounts charged off and other deductions (12)
Ending balance $ 266
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental Financial Information - Investments (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Summary of Investment Holdings [Line Items]    
Investments $ 799 $ 766
Equity securities    
Summary of Investment Holdings [Line Items]    
Investments 574 558
Other    
Summary of Investment Holdings [Line Items]    
Investments $ 225 $ 208
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Changes In Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period     $ 36,686  
Other comprehensive income (loss) $ (32) $ (232) (20) $ (332)
End of the period 37,174   37,174  
Cumulative Foreign Currency Translation (Loss) Adjustments        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period (6,594) (5,945) (6,733) (5,839)
Other comprehensive income (loss) before reclassifications (52) (315) 87 (421)
Amounts reclassified from accumulated other comprehensive income 0 0 0 0
Other comprehensive income (loss) (52) (315) 87 (421)
End of the period (6,646) (6,260) (6,646) (6,260)
Net Actuarial (Losses) and Prior Service (Costs) and Credits        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period (1,491) (2,608) (1,493) (2,670)
Other comprehensive income (loss) before reclassifications 1 13 3 30
Amounts reclassified from accumulated other comprehensive income (7) 41 (7) 86
Other comprehensive income (loss) (6) 54 (4) 116
End of the period (1,497) (2,554) (1,497) (2,554)
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period 46 79 175 135
Other comprehensive income (loss) before reclassifications 80 45 38 11
Amounts reclassified from accumulated other comprehensive income (54) (16) (141) (38)
Other comprehensive income (loss) 26 29 (103) (27)
End of the period $ 72 $ 108 $ 72 $ 108
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisition (Details) - USD ($)
$ / shares in Units, $ in Millions
Apr. 27, 2023
Jun. 30, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Goodwill   $ 23,258 $ 22,799
CSI      
Business Acquisition [Line Items]      
Acquisition share price (in dollars per share) $ 20    
Acquisition purchase price $ 851    
Developed technology intangible asset 290    
In-process research and development 60    
Goodwill 340    
Net deferred tax assets 18    
Other net assets $ 143    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Apr. 27, 2023
Dec. 31, 2022
Goodwill and Intangible Assets [Line Items]        
Goodwill $ 23,258 $ 23,258   $ 22,799
Increase in goodwill due to foreign currency translation adjustments   120    
Amount of reductions of goodwill relating to impairments   0    
Gross amount of amortizable intangible assets 27,700 27,700   27,200
Accumulated amortization of intangible assets 18,700 18,700   17,600
Increase in intangible assets due to foreign currency translation adjustments   47    
Estimated annual amortization expense, intangible assets, 2023 2,000 2,000    
Estimated annual amortization expense, intangible assets, 2024 1,900 1,900    
Estimated annual amortization expense, intangible assets, 2025 1,700 1,700    
Estimated annual amortization expense, intangible assets, 2026 1,600 1,600    
Estimated annual amortization expense, intangible assets, 2027 1,300 1,300    
Indefinite-lived intangible assets related to in-process R&D acquired in a business combination 822 822   $ 807
CSI        
Goodwill and Intangible Assets [Line Items]        
Goodwill     $ 340  
Increase in goodwill due to acquisition   340    
Increase in amortizable intangible assets due to acquisition   290    
Increase in in-process R&D due to acquisition 60      
Established Pharmaceutical Products        
Goodwill and Intangible Assets [Line Items]        
Goodwill 2,700 2,700    
Nutritionals        
Goodwill and Intangible Assets [Line Items]        
Goodwill 286 286    
Diagnostics        
Goodwill and Intangible Assets [Line Items]        
Goodwill 3,500 3,500    
Medical Devices        
Goodwill and Intangible Assets [Line Items]        
Goodwill 16,700 $ 16,700    
Impairment of indefinite-lived intangible assets $ 45      
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring Plans - Narrative (Details) - 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
Restructuring Cost and Reserve [Line Items]  
Restructuring charges $ 49
Fixed asset impairment charges 17
Cost of products sold  
Restructuring Cost and Reserve [Line Items]  
Restructuring charges 17
Research and Development  
Restructuring Cost and Reserve [Line Items]  
Restructuring charges 5
Selling, General and Administrative Expenses  
Restructuring Cost and Reserve [Line Items]  
Restructuring charges $ 27
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring Plans - Restructuring Activity and Related Accruals (Details) - 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
Restructuring Reserve [Roll Forward]  
Accrued balance at beginning of the period $ 228
Restructuring charges in 2023 49
Payments and other adjustments (120)
Accrued balance at end of the period $ 157
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Incentive Stock Programs - Narrative (Details)
$ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Incentive stock program, shares reserved for future grants (in shares) 74,000,000
Total unrecognized compensation cost | $ $ 660
Total unrecognized compensation cost, recognition period 3 years
Stock Options  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock options granted during the period (in shares) 1,973,371
Restricted Stock Awards  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock awards granted during the period (in shares) 460,447
Restricted Stock Units (RSUs)  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock units granted during period (in shares) 4,854,027
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Incentive Stock Programs - Options (Details) - Stock Options
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock options outstanding, number of shares | shares 29,508,026
Exercisable options, number of shares | shares 24,819,977
Stock options outstanding, weighted-average remaining life 5 years 2 months 12 days
Exercisable options, weighted-average remaining life 4 years 6 months
Stock options outstanding, weighted-average exercise price (in dollars per share) | $ / shares $ 73.66
Exercisable options, weighted-average exercise price (in dollars per share) | $ / shares $ 66.04
Aggregate intrinsic value of options outstanding | $ $ 1,107
Aggregate intrinsic value of options exercisable | $ $ 1,101
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Lines of Credit (Details) - 2.55% Long-term Notes Due 2022
$ in Millions
Mar. 15, 2022
USD ($)
Debt Instrument [Line Items]  
Repayments of debt $ 750
Interest rate percentage 2.55%
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Derivative [Line Items]          
Yen-denominated term loan $ 757   $ 757   $ 828
Net Investment Hedging | Designated as Hedging Instrument | Five Year Term Loan due 2024          
Derivative [Line Items]          
Debt instrument, term     5 years   5 years
Yen-denominated term loan 413   $ 413   $ 446
Foreign Exchange Forward          
Derivative [Line Items]          
Gain (loss) from foreign currency forward exchange contracts not designated as hedges 39 $ 303 (64) $ 252  
Foreign Exchange Forward | Not Designated as Hedging Instrument          
Derivative [Line Items]          
Derivative, notional amount 12,300   12,300   12,000
Foreign Exchange Forward | Cash Flow Hedging | Designated as Hedging Instrument          
Derivative [Line Items]          
Derivative, notional amount 7,100   $ 7,100   7,700
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold     12 months    
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold     18 months    
Interest Rate Swap | Fair Value Hedging | Designated as Hedging Instrument          
Derivative [Line Items]          
Derivative, notional amount $ 2,900   $ 2,900   $ 2,900
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Derivatives, Fair Value [Line Items]    
Fair Value - Assets $ 225 $ 412
Fair Value - Liabilities 757 828
Designated as Hedging Instrument | Interest Rate Swap | Deferred income taxes and other assets | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 0 0
Designated as Hedging Instrument | Interest Rate Swap | Prepaid expenses and other receivables, current | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 0 0
Designated as Hedging Instrument | Interest Rate Swap | Post-employment obligations, deferred income taxes and other long-term liabilities | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 142 136
Designated as Hedging Instrument | Interest Rate Swap | Other accrued liabilities | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 11 20
Designated as Hedging Instrument | Foreign Exchange Forward | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 147 304
Designated as Hedging Instrument | Foreign Exchange Forward | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 129 96
Designated as Hedging Instrument | Debt | Long-term debt | Net Investment Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 413 446
Not Designated as Hedging Instrument | Foreign Exchange Forward | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 78 108
Not Designated as Hedging Instrument | Foreign Exchange Forward | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities $ 62 $ 130
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Foreign Exchange Forward | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges $ 90 $ 141 $ 27 $ 92
Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges 63 43 189 70
Debt        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary 38 54 33 84
Interest Rate Swap | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges $ (6) $ (47) $ 3 $ (168)
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Derivative [Line Items]    
Long-term Investment Securities: $ 799 $ 766
Receivable position 225 412
(Payable) position (757) (828)
Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 574 558
Carrying Value    
Derivative [Line Items]    
Total Long-term Debt (16,846) (16,773)
Carrying Value | Foreign Exchange Forward    
Derivative [Line Items]    
Receivable position 225 412
(Payable) position (191) (226)
Carrying Value | Interest Rate Swap    
Derivative [Line Items]    
Receivable position 0 0
(Payable) position (153) (156)
Carrying Value | Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 574 558
Carrying Value | Other    
Derivative [Line Items]    
Long-term Investment Securities: 225 208
Fair Value    
Derivative [Line Items]    
Total Long-term Debt (16,555) (16,313)
Fair Value | Foreign Exchange Forward    
Derivative [Line Items]    
Receivable position 225 412
(Payable) position (191) (226)
Fair Value | Interest Rate Swap    
Derivative [Line Items]    
Receivable position 0 0
(Payable) position (153) (156)
Fair Value | Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 574 558
Fair Value | Other    
Derivative [Line Items]    
Long-term Investment Securities: $ 225 $ 208
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Quoted Prices in Active Markets    
Assets, at Fair Value    
Equity securities $ 315 $ 307
Foreign currency forward exchange contracts 0 0
Total Assets 315 307
Liabilities, at Fair Value    
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 0 0
Total Liabilities 0 0
Significant Other Observable Inputs    
Assets, at Fair Value    
Equity securities 0 0
Foreign currency forward exchange contracts 225 412
Total Assets 225 412
Liabilities, at Fair Value    
Fair value of hedged long-term debt 2,697 2,691
Interest rate swap derivative financial instruments 153 156
Foreign currency forward exchange contracts 191 226
Contingent consideration related to business combinations 0 0
Total Liabilities 3,041 3,073
Significant Unobservable Inputs    
Assets, at Fair Value    
Equity securities 0 0
Foreign currency forward exchange contracts 0 0
Total Assets 0 0
Liabilities, at Fair Value    
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 84 130
Total Liabilities 84 130
Outstanding Balances    
Assets, at Fair Value    
Equity securities 315 307
Foreign currency forward exchange contracts 225 412
Total Assets 540 719
Liabilities, at Fair Value    
Fair value of hedged long-term debt 2,697 2,691
Interest rate swap derivative financial instruments 153 156
Foreign currency forward exchange contracts 191 226
Contingent consideration related to business combinations 84 130
Total Liabilities $ 3,125 $ 3,203
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Litigation and Environmental Matters (Details)
$ in Millions
Jun. 30, 2023
USD ($)
Loss Contingencies [Line Items]  
Maximum expected cleanup exposure for individual site $ 4
Maximum expected cleanup exposure in aggregate 10
Legal proceedings and environmental exposures  
Loss Contingencies [Line Items]  
Recorded accrual balance for legal proceedings and exposures 30
Legal proceedings and environmental exposures | Minimum  
Loss Contingencies [Line Items]  
Estimation of possible loss 25
Legal proceedings and environmental exposures | Maximum  
Loss Contingencies [Line Items]  
Estimation of possible loss $ 35
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Defined Benefit Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost - benefits earned during the period $ 58 $ 94 $ 118 $ 190
Interest cost on projected benefit obligations 114 75 228 151
Expected return on plan assets (243) (234) (485) (470)
Curtailment gain (14) 0 (14) 0
Net amortization of:        
Actuarial loss, net 3 57 6 116
Prior service cost (credit) 0 1 0 1
Net cost (credit) (82) (7) (147) (12)
Medical and Dental Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost - benefits earned during the period 10 12 19 25
Interest cost on projected benefit obligations 16 8 30 18
Expected return on plan assets (6) (8) (12) (15)
Curtailment gain 0 0 0 0
Net amortization of:        
Actuarial loss, net (1) 1 (1) 6
Prior service cost (credit) (4) (6) (7) (12)
Net cost (credit) $ 15 $ 7 $ 29 $ 22
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Post-Employment Benefits - Narrative (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Defined Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 290 $ 348
Medical and Dental Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 28 $ 28
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.23.2
Taxes on Earnings (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]    
Excess tax benefits associated with share-based compensation $ 9 $ 32
Tax expense from prior year tax positions 62 $ 27
Decrease reasonably possible in gross unrecognized tax benefits $ 100  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting Information [Line Items]        
Net Sales to External Customers $ 9,978 $ 11,257 $ 19,725 $ 23,152
Operating Earnings 1,542 2,376 3,051 5,288
Amortization of intangible assets (498) (507) (989) (1,019)
Earnings before taxes $ 1,636 $ 2,352 $ 3,198 $ 5,228
Annual share-based awards recognized in first quarter (as a percent) 45.00% 45.00% 45.00% 45.00%
Nutritional Products        
Segment Reporting Information [Line Items]        
Inventory recall expense   $ 42   $ 162
Operating Segments        
Segment Reporting Information [Line Items]        
Net Sales to External Customers $ 9,975 11,255 $ 19,719 23,147
Operating Earnings 2,437 3,353 4,846 7,493
Operating Segments | Established Pharmaceutical Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 1,287 1,223 2,476 2,370
Operating Earnings 307 258 607 500
Operating Segments | Nutritional Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,076 1,953 4,043 3,847
Operating Earnings 308 230 688 481
Operating Segments | Diagnostic Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,317 4,294 5,005 9,551
Operating Earnings 437 1,705 1,088 4,269
Operating Segments | Medical Devices        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 4,295 3,785 8,195 7,379
Operating Earnings 1,385 1,160 2,463 2,243
Other        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 3 2 6 5
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Corporate functions and benefit plan costs (71) (123) (148) (237)
Net interest expense (61) (106) (113) (223)
Share-based compensation (132) (142) (413) (447)
Amortization of intangible assets (498) (507) (989) (1,019)
Other, net $ (39) $ (123) $ 15 $ (339)
XML 71 abt-20230630_htm.xml IDEA: XBRL DOCUMENT 0000001800 2023-01-01 2023-06-30 0000001800 exch:XCHI 2023-01-01 2023-06-30 0000001800 exch:XNYS 2023-01-01 2023-06-30 0000001800 2023-06-30 0000001800 2023-04-01 2023-06-30 0000001800 2022-04-01 2022-06-30 0000001800 2022-01-01 2022-06-30 0000001800 2022-12-31 0000001800 us-gaap:CommonStockMember 2023-03-31 0000001800 us-gaap:CommonStockMember 2022-03-31 0000001800 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000001800 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000001800 us-gaap:CommonStockMember 2023-06-30 0000001800 us-gaap:CommonStockMember 2022-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2023-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2022-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2023-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-06-30 0000001800 us-gaap:RetainedEarningsMember 2023-03-31 0000001800 us-gaap:RetainedEarningsMember 2022-03-31 0000001800 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000001800 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000001800 us-gaap:RetainedEarningsMember 2023-06-30 0000001800 us-gaap:RetainedEarningsMember 2022-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2023-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2022-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2023-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-06-30 0000001800 us-gaap:CommonStockMember 2022-12-31 0000001800 us-gaap:CommonStockMember 2021-12-31 0000001800 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000001800 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2021-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0000001800 us-gaap:RetainedEarningsMember 2022-12-31 0000001800 us-gaap:RetainedEarningsMember 2021-12-31 0000001800 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000001800 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2021-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0000001800 2021-12-31 0000001800 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2022-04-01 2022-06-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2023-04-01 2023-06-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0000001800 us-gaap:CorporateNonSegmentMember 2023-04-01 2023-06-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2022-04-01 2022-06-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000001800 us-gaap:CorporateNonSegmentMember 2022-04-01 2022-06-30 0000001800 country:US 2023-04-01 2023-06-30 0000001800 us-gaap:NonUsMember 2023-04-01 2023-06-30 0000001800 country:US 2022-04-01 2022-06-30 0000001800 us-gaap:NonUsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2022-01-01 2022-06-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2023-01-01 2023-06-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0000001800 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-06-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-06-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000001800 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-06-30 0000001800 country:US 2023-01-01 2023-06-30 0000001800 us-gaap:NonUsMember 2023-01-01 2023-06-30 0000001800 country:US 2022-01-01 2022-06-30 0000001800 us-gaap:NonUsMember 2022-01-01 2022-06-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-04-01 2022-06-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-04-01 2022-06-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-06-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-06-30 0000001800 abt:DiagnosticProductsMember 2023-06-30 0000001800 abt:MedicalDevicesMember 2023-06-30 0000001800 2023-07-01 2023-01-01 2023-06-30 0000001800 2023-07-01 2023-06-30 0000001800 2025-07-01 2023-01-01 2023-06-30 0000001800 2025-07-01 2023-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-06-30 0000001800 us-gaap:EquitySecuritiesMember 2023-06-30 0000001800 us-gaap:EquitySecuritiesMember 2022-12-31 0000001800 us-gaap:OtherInvestmentsMember 2023-06-30 0000001800 us-gaap:OtherInvestmentsMember 2022-12-31 0000001800 abt:StJudeMedicalMember us-gaap:EquitySecuritiesMember 2023-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 2023-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-04-01 2022-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-01 2023-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-06-30 0000001800 abt:CardiovascularSystemsIncMember 2023-04-27 0000001800 abt:CardiovascularSystemsIncMember 2023-04-27 2023-04-27 0000001800 abt:CardiovascularSystemsIncMember 2023-01-01 2023-06-30 0000001800 abt:EstablishedPharmaceuticalProductsMember 2023-06-30 0000001800 abt:NutritionalProductsMember 2023-06-30 0000001800 abt:CardiovascularSystemsIncMember 2023-04-01 2023-06-30 0000001800 abt:MedicalDevicesMember 2023-04-01 2023-06-30 0000001800 abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-06-30 0000001800 abt:CostOfGoodsAndServicesSoldMember abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-06-30 0000001800 us-gaap:ResearchAndDevelopmentExpenseMember abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-06-30 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-06-30 0000001800 abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2022-12-31 0000001800 abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-06-30 0000001800 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000001800 abt:RestrictedStockAwardsMember 2023-01-01 2023-06-30 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0000001800 us-gaap:EmployeeStockOptionMember 2023-06-30 0000001800 abt:A255LongTermNotesDue2022Member 2022-03-15 2022-03-15 0000001800 abt:A255LongTermNotesDue2022Member 2022-03-15 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-12-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-06-30 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:PrepaidExpensesAndOtherReceivablesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-06-30 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-06-30 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-12-31 0000001800 abt:LongTermDebtExcludingCurrentMaturitiesMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000001800 abt:LongTermDebtExcludingCurrentMaturitiesMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2023-04-01 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2022-04-01 2022-06-30 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2023-01-01 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2022-01-01 2022-06-30 0000001800 us-gaap:DebtMember 2023-04-01 2023-06-30 0000001800 us-gaap:DebtMember 2022-04-01 2022-06-30 0000001800 us-gaap:DebtMember 2023-01-01 2023-06-30 0000001800 us-gaap:DebtMember 2022-01-01 2022-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2023-04-01 2023-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2022-04-01 2022-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2023-01-01 2023-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2022-01-01 2022-06-30 0000001800 us-gaap:ForeignExchangeForwardMember 2023-04-01 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember 2022-04-01 2022-06-30 0000001800 us-gaap:ForeignExchangeForwardMember 2023-01-01 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-06-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2023-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2023-06-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2022-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2022-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2023-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2023-06-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2022-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2022-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000001800 us-gaap:FairValueInputsLevel1Member 2023-06-30 0000001800 us-gaap:FairValueInputsLevel2Member 2023-06-30 0000001800 us-gaap:FairValueInputsLevel3Member 2023-06-30 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000001800 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000001800 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000001800 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000001800 srt:MinimumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2023-06-30 0000001800 srt:MaximumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2023-06-30 0000001800 abt:LegalProceedingsAndEnvironmentalExposuresMember 2023-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2023-04-01 2023-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2022-04-01 2022-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-04-01 2023-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-04-01 2022-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000001800 us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000001800 us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2023-04-01 2023-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2022-04-01 2022-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-06-30 0000001800 abt:NutritionalProductsMember 2022-04-01 2022-06-30 0000001800 abt:NutritionalProductsMember 2022-01-01 2022-06-30 0000001800 abt:AndreaFWainerMember 2023-01-01 2023-06-30 0000001800 abt:AndreaFWainerMember 2023-04-01 2023-06-30 0000001800 abt:AndreaFWainerMember abt:AndreaFWainerTradingArrangementCommonStockMember 2023-06-30 0000001800 abt:AndreaFWainerMember abt:AndreaFWainerTradingArrangementStockOptionsMember 2023-06-30 shares iso4217:USD iso4217:USD shares abt:segment pure 0000001800 --12-31 2023 Q2 false P12M P426D 10-Q true 2023-06-30 false 1-2189 ABBOTT LABORATORIES IL 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 Common Shares, Without Par Value Common Shares, Without Par Value ABT ABT NYSE CHX Yes Yes Large Accelerated Filer false false false 1735357980 9978000000 11257000000 19725000000 23152000000 4483000000 4933000000 8814000000 9920000000 498000000 507000000 989000000 1019000000 715000000 684000000 1369000000 1381000000 2740000000 2757000000 5502000000 5544000000 8436000000 8881000000 16674000000 17864000000 1542000000 2376000000 3051000000 5288000000 159000000 132000000 312000000 263000000 98000000 26000000 199000000 40000000 -21000000 0 -27000000 3000000 176000000 82000000 287000000 160000000 1636000000 2352000000 3198000000 5228000000 261000000 334000000 505000000 763000000 1375000000 2018000000 2693000000 4465000000 0.79 1.15 1.54 2.53 0.78 1.14 1.53 2.51 1740359000 1753865000 1741051000 1757858000 9889000 11598000 9933000 12115000 1750248000 1765463000 1750984000 1769973000 5474000 5419000 5474000 2655000 1375000000 2018000000 2693000000 4465000000 -52000000 -315000000 87000000 -421000000 -3000000 -3000000 12000000 25000000 6000000 -54000000 4000000 -116000000 4000000 -54000000 61000000 46000000 26000000 29000000 -103000000 -27000000 -32000000 -232000000 -20000000 -332000000 1343000000 1786000000 2673000000 4133000000 -6646000000 -6733000000 1497000000 1493000000 72000000 175000000 -8071000000 -8051000000 7835000000 9882000000 320000000 288000000 485000000 500000000 6172000000 6218000000 4004000000 3805000000 845000000 680000000 2022000000 1688000000 6871000000 6173000000 2307000000 2663000000 23505000000 25224000000 799000000 766000000 20926000000 20212000000 11477000000 11050000000 9449000000 9162000000 9834000000 10454000000 23258000000 22799000000 6509000000 6033000000 73354000000 74438000000 4211000000 4607000000 1362000000 1556000000 5334000000 5845000000 886000000 887000000 273000000 343000000 2284000000 2251000000 14350000000 15489000000 14562000000 14522000000 7038000000 7522000000 1 1 1000000 1000000 0 0 0 0 2400000000 2400000000 1987181491 1986519278 24612000000 24709000000 251823511 248724257 15722000000 15229000000 36355000000 35257000000 -8071000000 -8051000000 37174000000 36686000000 230000000 219000000 37404000000 36905000000 73354000000 74438000000 1986904170 1985525053 24488000000 24304000000 277321 151682 14000000 10000000 119000000 125000000 -9000000 -10000000 1987181491 1985676735 24612000000 24429000000 247957371 234582764 -15307000000 -13726000000 157305 135663 10000000 7000000 4023445 9891 425000000 1000000 251823511 234456992 -15722000000 -13720000000 35868000000 33295000000 1375000000 2018000000 0.51 0.47 889000000 827000000 -1000000 -1000000 36355000000 34487000000 -8039000000 -8474000000 -32000000 -232000000 -8071000000 -8706000000 222000000 230000000 8000000 -4000000 230000000 226000000 1986519278 1985273421 24709000000 24470000000 662213 403314 30000000 24000000 415000000 449000000 -542000000 -514000000 1987181491 1985676735 24612000000 24429000000 248724257 221191228 -15229000000 -11822000000 4090470 4280139 252000000 230000000 7189724 17545903 745000000 2128000000 251823511 234456992 -15722000000 -13720000000 35257000000 31528000000 2693000000 4465000000 1.02 0.94 1779000000 1653000000 -184000000 -147000000 36355000000 34487000000 -8051000000 -8374000000 -20000000 -332000000 -8071000000 -8706000000 219000000 222000000 11000000 4000000 230000000 226000000 2693000000 4465000000 617000000 626000000 989000000 1019000000 413000000 447000000 -37000000 939000000 667000000 1030000000 1736000000 113000000 2346000000 4475000000 887000000 700000000 826000000 0 40000000 48000000 7000000 -18000000 -5000000 -10000000 -1675000000 -624000000 -29000000 13000000 1000000 6000000 2000000 752000000 966000000 2312000000 77000000 69000000 1780000000 1660000000 -2699000000 -4636000000 -19000000 -77000000 -2047000000 -862000000 9882000000 9799000000 7835000000 8937000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1 — Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2 — New Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Recently Adopted Accounting Standards</span></div>In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements. Recently Adopted Accounting StandardsIn September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3 — Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,076 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,953 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,356 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,317 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,853 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,294 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,257 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,847 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,709 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,398 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,072 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,233 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,686 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,725 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,323 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $28 million of sales in the second quarter of 2022 and $57 million in the first six months of 2022 were moved from Rapid Diagnostics to Heart Failure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.2 billion in the Diagnostics segment and approximately $475 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contract Assets and Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4 4 4 4 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,076 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,953 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,356 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,317 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,853 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,294 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,257 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,043 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,847 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,709 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,398 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,072 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,233 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,686 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,039 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,725 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,323 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $28 million of sales in the second quarter of 2022 and $57 million in the first six months of 2022 were moved from Rapid Diagnostics to Heart Failure.</span></div> 0 990000000 990000000 0 946000000 946000000 0 297000000 297000000 0 277000000 277000000 0 1287000000 1287000000 0 1223000000 1223000000 507000000 517000000 1024000000 413000000 512000000 925000000 374000000 678000000 1052000000 348000000 680000000 1028000000 881000000 1195000000 2076000000 761000000 1192000000 1953000000 311000000 982000000 1293000000 287000000 934000000 1221000000 43000000 98000000 141000000 71000000 141000000 212000000 99000000 43000000 142000000 101000000 38000000 139000000 508000000 233000000 741000000 1982000000 740000000 2722000000 961000000 1356000000 2317000000 2441000000 1853000000 4294000000 269000000 314000000 583000000 264000000 284000000 548000000 245000000 308000000 553000000 226000000 260000000 486000000 226000000 69000000 295000000 207000000 62000000 269000000 264000000 451000000 715000000 228000000 425000000 653000000 219000000 279000000 498000000 207000000 233000000 440000000 185000000 42000000 227000000 157000000 40000000 197000000 505000000 919000000 1424000000 399000000 793000000 1192000000 1913000000 2382000000 4295000000 1688000000 2097000000 3785000000 3000000 0 3000000 2000000 0 2000000 3758000000 6220000000 9978000000 4892000000 6365000000 11257000000 0 1902000000 1902000000 0 1852000000 1852000000 0 574000000 574000000 0 518000000 518000000 0 2476000000 2476000000 0 2370000000 2370000000 966000000 982000000 1948000000 751000000 1021000000 1772000000 727000000 1368000000 2095000000 687000000 1388000000 2075000000 1693000000 2350000000 4043000000 1438000000 2409000000 3847000000 600000000 1875000000 2475000000 555000000 1850000000 2405000000 90000000 198000000 288000000 243000000 389000000 632000000 192000000 84000000 276000000 192000000 75000000 267000000 1414000000 552000000 1966000000 4163000000 2084000000 6247000000 2296000000 2709000000 5005000000 5153000000 4398000000 9551000000 529000000 581000000 1110000000 512000000 560000000 1072000000 483000000 575000000 1058000000 442000000 529000000 971000000 444000000 132000000 576000000 403000000 116000000 519000000 482000000 850000000 1332000000 437000000 835000000 1272000000 429000000 530000000 959000000 397000000 454000000 851000000 340000000 83000000 423000000 300000000 76000000 376000000 984000000 1753000000 2737000000 742000000 1576000000 2318000000 3691000000 4504000000 8195000000 3233000000 4146000000 7379000000 6000000 0 6000000 5000000 0 5000000 7686000000 12039000000 19725000000 9829000000 13323000000 23152000000 28000000 -28000000 -57000000 57000000 4200000000 475000000 0.59 P24M 0.17 P12M <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 500000000 243000000 192000000 551000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 4 — Supplemental Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended June 30, 2023 and 2022 were $1.370 billion and $2.009 billion, respectively, and for the six months ended June 30, 2023 and 2022 were $2.682 billion and $4.447 billion, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2023 includes $290 million of pension contributions and the payment of cash taxes of approximately $837 million. The first six months of 2022 includes $348 million of pension contributions and the payment of cash taxes of approximately $657 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first six months of 2023 related to the allowance for doubtful accounts as of June 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of June 30, 2023 and December 31, 2022 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Abbott’s long-term investments as of June 30, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s equity securities as of June 30, 2023 include $305 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott also holds certain investments as of June 30, 2023 with a carrying value of $164 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $95 million that do not have a readily determinable fair value.</span></div> 1370000000 2009000000.000 2682000000 4447000000 290000000 837000000 348000000 657000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first six months of 2023 related to the allowance for doubtful accounts as of June 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 262000000 16000000 12000000 266000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of June 30, 2023 and December 31, 2022 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 574000000 558000000 225000000 208000000 799000000 766000000 305000000 164000000 95000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,594)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,646)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,646)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,594)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,646)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,646)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -6594000000 -5945000000 -1491000000 -2608000000 46000000 79000000 -52000000 -315000000 1000000 13000000 80000000 45000000 0 0 7000000 -41000000 54000000 16000000 -52000000 -315000000 -6000000 54000000 26000000 29000000 -6646000000 -6260000000 -1497000000 -2554000000 72000000 108000000 -6733000000 -5839000000 -1493000000 -2670000000 175000000 135000000 87000000 -421000000 3000000 30000000 38000000 11000000 0 0 7000000 -86000000 141000000 38000000 87000000 -421000000 -4000000 116000000 -103000000 -27000000 -6646000000 -6260000000 -1497000000 -2554000000 72000000 108000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note 6 — Business Acquisition </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc (CSI) for $20 per common share, which equated to a purchase price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complimentary technologies to Abbott's portfolio of vascular device offerings. </span></div>The preliminary allocation of the purchase price of the acquisition resulted in the recording of a non-deductible developed technology intangible asset of $290 million; non-deductible in-process research and development of $60 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $340 million; net deferred tax assets of approximately $18 million and other net assets of approximately $143 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts. 20 851000000 290000000 60000000 340000000 18000000 143000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 7 — Goodwill and Intangible Assets </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of goodwill reported was $23.3 billion at June 30, 2023 and $22.8 billion at December 31, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of CSI increased goodwill by approximately $340 million and f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oreign currency translation adjustments increased goodwill by approximately $120 million in the first six months of 2023. The amount of goodwill related to reportable segments at June 30, 2023 was $2.7 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.7 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first six months of 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.7 billion and $27.2 billion as of June 30, 2023 and December 31, 2022, respectively.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The gross amount of amortizable intangible assets increased by $290 million due to the CSI acquisition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization was $18.7 billion and $17.6 billion as of June 30, 2023 and December 31, 2022, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments increased intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by $47 million in the first six months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026 and $1.3 billion in 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which relate to in-process research and development (IPR&amp;D) acquired in a business combination, were approximately $822 million as of June 30, 2023 and $807 million as of December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the second quarter of 2023, the acquisition of CSI increased IPR&amp;D by $60 million. This increase was partially offset by $45 million of charges recorded on the Research and development line of the Condensed Consolidated Statement of Earnings for the impairment of certain indefinite-lived intangible assets related to the Medical Devices reportable segment.</span></div> 23300000000 22800000000 340000000 120000000 2700000000 286000000 3500000000 16700000000 0 27700000000 27200000000 290000000 18700000000 17600000000 47000000 2000000000 1900000000 1700000000 1600000000 1300000000 822000000 807000000 60000000 45000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8 — Restructuring Plans </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the six months ended June 30, 2023, Abbott recorded employee related severance and other charges of approximately $49 million, of which approximately $17 million was recorded in Cost of products sold, approximately $5 million was recorded in Research and development, and approximately $27 million was recorded in Selling, general and administrative expenses. In addition, Abbott recognized fixed asset impairment charges of approximately $17 million related to these restructuring plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to these restructuring actions and the status of the related accruals as of June 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 49000000 17000000 5000000 27000000 17000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to these restructuring actions and the status of the related accruals as of June 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 228000000 49000000 120000000 157000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 — Incentive Stock Programs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first six months of 2023, Abbott granted 1,973,371 stock options, 460,447 restricted stock awards and 4,854,027 restricted stock units under its incentive stock program. At June 30, 2023, approximately 74 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at June 30, 2023 is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,508,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,819,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized share-based compensation cost at June 30, 2023 amounted to approximately $660 million which is expected to be recognized over the next three years.</span></div> 1973371 460447 4854027 74000000 Information regarding the number of options outstanding and exercisable at June 30, 2023 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,508,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,819,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 29508026 24819977 P5Y2M12D P4Y6M 73.66 66.04 1107000000 1101000000 660000000 P3Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 10 — Debt and Lines of Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.</span></div> 750000000 0.0255 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 11 — Financial Instruments, Derivatives and Fair Value Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.1 billion at June 30, 2023 and $7.7 billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next <span style="-sec-ix-hidden:f-829">twelve</span> to eighteen months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At June 30, 2023 and December 31, 2022, Abbott held the gross notional amounts of $12.3 billion and $12.0 billion, respectively, of such foreign currency forward exchange contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $446 million as of June 30, 2023 and December 31, 2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.9 billion at June 30, 2023 and December 31, 2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2023 and December 31, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains of $39 million and $303 million were recognized in the three months ended June 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. A loss of $64 million and a gain of $252 million were recognized in the first six months ended June 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of June 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt was determined based on significant other observable inputs, including current interest rates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The change in fair value from December 31, 2022 reflects changes in the projected timelines for events that will trigger payment of contingent consideration. 7100000000 7700000000 P18M 12300000000 12000000000 P5Y P5Y 413000000 446000000 2900000000 2900000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2023 and December 31, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 0 0 142000000 136000000 0 0 11000000 20000000 147000000 304000000 129000000 96000000 78000000 108000000 62000000 130000000 413000000 446000000 225000000 412000000 757000000 828000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div> 90000000 141000000 27000000 92000000 63000000 43000000 189000000 70000000 38000000 54000000 33000000 84000000 -6000000 -47000000 3000000 -168000000 39000000 303000000 -64000000 252000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of June 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 574000000 574000000 558000000 558000000 225000000 225000000 208000000 208000000 16846000000 16555000000 16773000000 16313000000 225000000 225000000 412000000 412000000 191000000 191000000 226000000 226000000 0 0 0 0 153000000 153000000 156000000 156000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 315000000 315000000 0 0 225000000 0 225000000 0 540000000 315000000 225000000 0 2697000000 0 2697000000 0 153000000 0 153000000 0 191000000 0 191000000 0 84000000 0 0 84000000 3125000000 0 3041000000 84000000 307000000 307000000 0 0 412000000 0 412000000 0 719000000 307000000 412000000 0 2691000000 0 2691000000 0 156000000 156000000 226000000 0 226000000 0 130000000 0 0 130000000 3203000000 0 3073000000 130000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12 — Litigation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $25 million to $35 million. The recorded accrual balance at June 30, 2023 for these proceedings and exposures was approximately $30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.</span></div> 4000000 10000000 25000000 35000000 30000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13 — Post-Employment Benefits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months <br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months <br/>Ended June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailment gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first six months of 2023 and 2022, $290 million and $348 million, respectively, were contributed to defined benefit plans. In the first six months of 2023 and 2022, $28 million was contributed, in each year, to the post-employment medical and dental plans.</span></div> Net cost recognized for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months <br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months <br/>Ended June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailment gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 58000000 94000000 118000000 190000000 10000000 12000000 19000000 25000000 114000000 75000000 228000000 151000000 16000000 8000000 30000000 18000000 243000000 234000000 485000000 470000000 6000000 8000000 12000000 15000000 14000000 0 14000000 0 0 0 0 0 -3000000 -57000000 -6000000 -116000000 1000000 -1000000 1000000 -6000000 0 1000000 0 1000000 -4000000 -6000000 -7000000 -12000000 -82000000 -7000000 -147000000 -12000000 15000000 7000000 29000000 22000000 290000000 348000000 28000000 28000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 14 — Taxes on Earnings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2023 and 2022, taxes on earnings include approximately $9 million and $32 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of 2023 and 2022, taxes on earnings also include approximately $62 million and $27 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.</span></div> 9000000 32000000 62000000 27000000 100000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 15 — Segment Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s reportable segments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Established Pharmaceutical Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— International sales of a broad line of branded generic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nutritional Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of a broad line of adult and pediatric nutritional products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three and six months ended June 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net for the three and six months ended June 30, 2023 includes costs associated with the acquisition of CSI, charges related to restructurings, and income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and six months ended June 30, 2022 includes $42 million and $162 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment as well as integration costs related to the acquisition of Alere Inc. </span></div></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>Ended June 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,228 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three and six months ended June 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net for the three and six months ended June 30, 2023 includes costs associated with the acquisition of CSI, charges related to restructurings, and income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and six months ended June 30, 2022 includes $42 million and $162 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment as well as integration costs related to the acquisition of Alere Inc. </span></div></td></tr></table></div> 1287000000 1223000000 2476000000 2370000000 307000000 258000000 607000000 500000000 2076000000 1953000000 4043000000 3847000000 308000000 230000000 688000000 481000000 2317000000 4294000000 5005000000 9551000000 437000000 1705000000 1088000000 4269000000 4295000000 3785000000 8195000000 7379000000 1385000000 1160000000 2463000000 2243000000 9975000000 11255000000 19719000000 23147000000 2437000000 3353000000 4846000000 7493000000 3000000 2000000 6000000 5000000 9978000000 11257000000 19725000000 23152000000 71000000 123000000 148000000 237000000 -61000000 -106000000 -113000000 -223000000 132000000 142000000 413000000 447000000 498000000 507000000 989000000 1019000000 39000000 123000000 -15000000 339000000 1636000000 2352000000 3198000000 5228000000 0.45 0.45 0.45 0.45 42000000 162000000 On May 1, 2023, Andrea F. Wainer, Executive Vice President, Rapid and Molecular Diagnostics, adopted a plan for the sale of securities of Abbott that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Ms. Wainer's Rule 10b5-1 plan provides for the sale of 5,400 shares and the exercise of up to 111,606 stock options until June 30, 2024. May 1, 2023 Andrea F. Wainer Executive Vice President, Rapid and Molecular Diagnostics true false false false 5400 111606 EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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˜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

8ZB3.3_=4DF6N2S#-$UB@%=&H+Z_2NM=M MI#XC?@3D6X]_ D66L_IM%:!^DQI(*.)LMXTF+&RW#00",?Z%0?/G#KLE;F1 M;P?Y$^_\=7(5,!P2\5XK%UYZ=-8:"%357F3Q>EF:6E&M%?5JS9ZORPI1^]&? M(E6C!M0JJ08#AQ-5IPZ%.I369AKVN^D'*2^02]=/0N#*;BD/.PUU/]6WMA.C M;*Y1-L\46[,HM:N&;VNKH5%?;93--TL:@44<+J?TU?&N##36V=ZRFH(V9JAEH0P:MMX5FJ&E'!FJ'#4U; M;*@QO2W%&DQ+L@:CK@Q/"^HJ>^VPX?=;;'C1/Z\O0]S+$*\7TA18>VQHQF1# MHR[;*)MKE,TSQ=;\$[0VVLB(T49M^WNM^,JU!J-:SU?0>!I,A\]&M<]&1GTV M:MO?:_57K XS5N5J,*H%U6&Z+"BJS38R8+9+CL8_0R-59ANC6FT-!*DO21U& M%6F?;7G$F.WRO28N9:2)*/[*KJY6^UFW^2Z.WE(K3239 MM2NX^@]02P,$% @ [( #5[J>/P/# @ 3@D !D !X;"]W;W)K&ULM591;]HP$/XK5E9-K;0V:4*!=1"I0*MU&A-JU>UA MVH-)#K#JV)GM0/OO=W9"!BV@5P&???7??9SOGWDJJ1[T ,.0IXT+WO84Q M^:7OZV0!&=5G,@>!*S.I,FK05'-?YPIHZH(R[H=!T/8SRH07]]S<1,4]61C. M!$P4T4664?4\ "Y7?>_<6T_NSB^'7>OO'+XS6.F-,;%,IE(^6N,V[7N!+0@X),8B4/Q;PA XMT!8QN\* MTZM3VL#-\1K]QG%'+E.J82CY#Y::1=_K>B2%&2VXN9.KSU#QN;!XB>3:_9)5 MZ=O!C$FACS :>.BD0T3=A?OC<)5AG$FGDAM3J^SG,MGW!M#!B!@QHPFI^0; M58I:D\CAYI(N"8R" \"?BG$&8F"#R0,PFA'/<-_#P\/E!/5ND8. MK[4';X0J"DC7>I()I[ME.@AC[_"ESFD"?0\OJ0:U!"]^_^Z\'7S:Q;$AL"W& MK9IQRZ%';V!,1DPG7.I" ?GY%9?)K8%,_]HE1*M)(1H"VQ+BHA;BXN#6#V66 M4_%,$CS@BDT+L^^&E#!M!V._MLLX_!CT_.4FD=<^4:M;^VS5UZ[K:Q^L;PPI M2R@G5*1DA'<>AWM/YT&DMVY*0V!;I#LUZ9T]E] M?3J[+P[G09>R.G^C-66@YJYC:\Q>"%-^W.O9^E%PY7KAB_D!/A;*WOX7IGQI MC*F:,Z$)AQE"!F<=O#.J[-ZE863N&N!4&FRG;KC !P\HZX#K,RG-VK )ZB=4 M_ =02P,$% @ [( #5QT/L[_= @ :@< !D !X;"]W;W)K&ULK551;],P$/XKIS"A(;$E3=L,1AMI78<8TJ1I8_" >'"3 M:V+-L8/MM!V_GG/2AJY+*Y!X27SVW7??=[;/HZ72CR9'M+ JA#1C+[>V//=] MD^18,'.J2I2T,E>Z8)9,G?FFU,C2.J@0?A@$D5\P+KUX5,_=ZGBD*BNXQ%L- MIBH*II\F*-1R[/6\S<0=SW+K)OQX5+(,[]$^E+>:++]%27F!TG E0>-\[%WT MSB\CYU\[?.6X-%MC<$IF2CTZXSH=>X$CA (3ZQ 8_19XB4(X(*+Q&KSL??.@Q3GK!+V3BT_X5K/T.$E2ICZ"\O&-QIX MD%3&JF(=3 P*+IL_6ZWKL!5 .-T!X3H@W W8EZ&_#NC70AMFM:PILRP>:;4$ M[;P)S0WJVM31I(9+MXOW5M,JIS@;?V$K-$#UO&):!&29L;N)(IIL_C?2+W0Y#>H%>O'K5[TH^- E]S^!/1,_ M:,4/#J''5ZL$C0%+XF_;!U>:9AV&H8'M3@=@Y7CA;"7*L"2LV5AB=D MNA96*L/MOK/?0 ^WZ$3A#N/A"\;A63?CJ&4<'60\Q82:-M%U7R793#PYEH;/ M!+K+FFDRH)(:$Y5)_HL*O[U#73JB%R1[0; CY""I?SUH_E;;*E!G=3T,ZV#\9%W2=WYB?TD#1]_P],\PK=,)UQ:4#@G""#TS/:"=UT]L:PJJR; MXTQ9:K7U,*?'$+5SH/6Y4G9CN 3M\QK_!E!+ P04 " #L@ -74H)/UL@' M !>-@ &0 'AL+W=OBD[38CQ\E.Y9%7C%V1K_$ M'SD\U.$EK^\1J;'BN?S/K"B7 M3,B/Y7Q8K4K.IDVC938DCN,/ERS-!Z/+YKO;6*S?D=%Y]7MZ7\--RQ3-,ESZNTR%')9U>##_@B M<9L&#>+/E#]6>^]1+>6^*+[4'ZZG5P.GOB*>\8FH*9A\>>!CGF4UD[R.KUO2 MP:[/NN'^^V?VGQOQ4LP]J_BXR/Y*IV)Q-0@':,IG;)V)3\7C+WPKR*OY)D56 M-7_1XP;K1P,T65>B6&X;RRM8IOGFE3UM!V*O@>2!&Y!M Z(V<'L:T&T#>F@/ M[K:!>V@/WK9!(WVXT=X,7,P$&UV6Q2,J:[1DJ]\TH]^TEN.5YO5$N1.E_&\J MVXG1'9_+L MTG6\F71V\MS$7+,VJ=^@,?;Z+T=LW[] ;E.;H)LTR":@NAT)V M71,,)]MN/FZZ(3W=4'13Y&)1H22?\BG0/C:W]PWMAU+R3C=YUOV1& E_7>?G MB#KO$7$(!:YG?'AS LGY?[TGK^Z],QAT-PEHPT=?F 2?^*HH19K/.]/A[]\D M'%T+OJS^@2*_X79A[CK1750K-N%7 YG)*EX^\,'HQQ^P[_P$#;M-LM@F66*) MK!,@=Q<@U\0^^EW^8MRQC%=(%"AY$KS,68;&37K@);@>-X1^0UC_6CR,HB@( M+X,PO]8\9(U,S)A92Y? M0:T;#F__ CV7*%IU$*&!KTC50=3QL*)4!WDD#&&A_DZH;Q3Z85FOO.^;%5?, M9+85+)^G]QE'K*JX '7[VH6L0@S) MA3"1.?H=-#2;7L.]:W7.765]C@\!Q8> DA= G:&)=D,3F3/<6I1I/?GE^-R6 MQ70]@:>\D>78'QN;9+%-LL0262<4V&EK0N>$]<"6W%*,K++%5MD26VS=,.V5 M[MBX9J[S!QFEHOQ6IP^698@_2?]8<3 H1JJC@X*U[*C^WL96>TR 'K'?4UQ@ MTHX@.;"\V$YYV-H828X>.YMLL56VQ!9;-QRM#<&G]"'8JA&QRA9;94MLL77# MU)H1;-V-8-".J"7*%M4IY*4?48L4@$P:$JR6JP";="1NT),T6DN";7@2#/@- MEP:J8L!P4(^J@G64&[J^JE='!6Y$>^2VQ@2;G8F>(]&_**D$N\_2:B$+UEM9 MSB[E;%N+=/)"]6;NZN@E:I,MMLJ6V&+K!JTU53@X928U6K:CPV23+;;*EMAB MZX:I]8/8; A?DTE#/4>24,LK$(IH>45'$5>])Y) *!HX/7FE-7S8[/@.3*,1 M<$=&4ZN#B!>J8G60KS(E ,AS>J22UD\1HQ& 4^BACM?,?>QBM,H66V5+;+%U MH]3:*8)/F#.)58-EE2VVRI;88NN&J?5LQ.S97I$SMXR=_."H>6X,H'"DU6( MRG52'ZIU2 .2&N$=J M:S*(V62 .3-.V3PO*EEHFE.FD?KHM6B3+;;*EMABZP:IM4+$.V7*-/JLH\-D MDRVVRI;88NN&J;5PQ&SA7I,R]:9[5P@M N21RU2RBHV11I>XJ *C(\_KR M2.N$B'E_Z<"4&>A"-+,.@'"@ZH@AE*,G3:!#XO?LI9'64!"SH0"SY@V?-LX\ MY@_I!-Y<,],>O11MLL56V1);;-T M:Z'1*?,F%:WOZRRQ5;9$EMLW?,PK6.C M9L?VBHRY951RH7J+$T#1(%1S"( *L/[-[ ,WN";13;/O0UI%1Z]L^5-^"H6J& '9IU/2@0]1[E "D MYT *;_SM--R4N23-&LF9CT-0:56O8Q5MM@J6V*+K1N5ULM0_Y3)PNH& ME%6VV"I;8HNM&Z;6=E&S[1H7I8P/$QS-UGGS3$"%6#Y%]SSGLU2@5<9R-"DJ M^ 8.U=W168#5S & L+;' :)FH71&EGC2"4JXN&4'TW9=W6*[AFK_"JH[NN7KL#9WU"^X+=J&NG]^CG M0IWYNZXQ&JDP I*]D (6U0^A0=U35.-Q[7D:6+O/F M0:5*SMAU+C9/3>R^W3T,]:%Y!$CY_B.^&&/@^QA?))M'G5KZS9-7-ZR P 2!$ T !X;"]S='EL97,N>&UL MW5A=3]LP%/TKD1D32!-I&QJ:T5;:*B%-VB8D>-@;38F>.REE\_7SM- M/_!%C(<-EJK$OL?GW&/[!D<=UF8MV,V",1.M2B'K$5D84WV,XWJV8"6MSU3% MI$4*I4MJ;%?/X[K2C.8UD$H1]SJ=-"XIEV0\E,ORJC1U-%-+:4;DO U%_O8E M'Y%N>DXB+S=1.1N1NY/W/Y?*7+Z+_/WHP]%1Y^[T\C!^XH!3$@=%^\\0/>O@ MNA;#I--]:3?\V IYXC%&NPC0;)8M$SJ.'#?K-AX62FZ7+R$^8-5IR:)[*D9D M0@6?:@ZL@I9%2/W@X:[OP98V.B672KO\0'QL.*&L.TO+(=-]@%'T%1T[Y=5];A7--UM]O]1 M[&FOBIU]Z\"NR;9I#35-+^,[H+^KYK5W93LOTHTJ?J_,YZ6=CG1]*%!VK5G! M5ZZ_*EH#F'H75Z=5)=:?!)_+DOG)/SOA>$@WO&BA-'^PV:!49C; -(GNF39\ MMAOYI6EURU9F4TZK O?<>X.>_^XZSYEDFHI=T[;V7_,JO]AQ& M@QZ;0^RUF^R_!9/I6S#Y.FLR;HZ=G;-M[V1KHQ&\08S(=W@?$=NDT73)A>&R MZ2UXGC/YZ("S\H9.[6OBGKX=G[."+H6Y;<$1V;:_L9PORZP==0T+T8S:MK_" M]+II^_IBN&=F&S=I<0#A$KMP51C".Q\((8%@>S '&\2PL MS_\TGP$Z'X]AW@9!9(!R!BC'LT+(Q'VP/&%.9J_P3+,L2=(46]')).A@@JU; MFL(WK(9Y P:6!S+]V5KCNXU7R--U@.WI4Q6"S12O1&RF^%H#$EXW8&19>+>Q M/,# =@&K'<@?S@,U%>8D">PJY@U[@G$DRS $:C%1AS!'( '#$D2=PX>G$?QYIR*M[^=C'\#4$L#!!0 ( .R M U>7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 470 273 1 false 79 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://www.abbott.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited Condensed Consolidated Statement of Earnings (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited Condensed Consolidated Statement of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited Condensed Consolidated Balance Sheet (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/BasisofPresentation Basis of Presentation Notes 10 false false R11.htm 0000011 - Disclosure - New Accounting Standards Sheet http://www.abbott.com/role/NewAccountingStandards New Accounting Standards Notes 11 false false R12.htm 0000012 - Disclosure - Revenue Sheet http://www.abbott.com/role/Revenue Revenue Notes 12 false false R13.htm 0000013 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/SupplementalFinancialInformation Supplemental Financial Information Notes 13 false false R14.htm 0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss Changes In Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 0000015 - Disclosure - Business Acquisition Sheet http://www.abbott.com/role/BusinessAcquisition Business Acquisition Notes 15 false false R16.htm 0000016 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 16 false false R17.htm 0000017 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/RestructuringPlans Restructuring Plans Notes 17 false false R18.htm 0000018 - Disclosure - Incentive Stock Programs Sheet http://www.abbott.com/role/IncentiveStockPrograms Incentive Stock Programs Notes 18 false false R19.htm 0000019 - Disclosure - Debt and Lines of Credit Sheet http://www.abbott.com/role/DebtandLinesofCredit Debt and Lines of Credit Notes 19 false false R20.htm 0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 20 false false R21.htm 0000021 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/LitigationandEnvironmentalMatters Litigation and Environmental Matters Notes 21 false false R22.htm 0000022 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/PostEmploymentBenefits Post-Employment Benefits Notes 22 false false R23.htm 0000023 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/TaxesonEarnings Taxes on Earnings Notes 23 false false R24.htm 0000024 - Disclosure - Segment Information Sheet http://www.abbott.com/role/SegmentInformation Segment Information Notes 24 false false R25.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 9954701 - Disclosure - New Accounting Standards (Policies) Sheet http://www.abbott.com/role/NewAccountingStandardsPolicies New Accounting Standards (Policies) Policies http://www.abbott.com/role/NewAccountingStandards 27 false false R28.htm 9954702 - Disclosure - Revenue (Tables) Sheet http://www.abbott.com/role/RevenueTables Revenue (Tables) Tables http://www.abbott.com/role/Revenue 28 false false R29.htm 9954703 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/SupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/SupplementalFinancialInformation 29 false false R30.htm 9954704 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables Changes In Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss 30 false false R31.htm 9954705 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/RestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/RestructuringPlans 31 false false R32.htm 9954706 - Disclosure - Incentive Stock Programs (Tables) Sheet http://www.abbott.com/role/IncentiveStockProgramsTables Incentive Stock Programs (Tables) Tables http://www.abbott.com/role/IncentiveStockPrograms 32 false false R33.htm 9954707 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures 33 false false R34.htm 9954708 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/PostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/PostEmploymentBenefits 34 false false R35.htm 9954709 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/SegmentInformation 35 false false R36.htm 9954710 - Disclosure - Revenue - Narrative (Details) Sheet http://www.abbott.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 36 false false R37.htm 9954711 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details) Sheet http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails Revenue - Summary of Revenue by Sales Category (Details) Details 37 false false R38.htm 9954712 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details) Sheet http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails Revenue - Schedule of Changes in Contract Liabilities (Details) Details 38 false false R39.htm 9954713 - Disclosure - Supplemental Financial Information - Narrative (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails Supplemental Financial Information - Narrative (Details) Details 39 false false R40.htm 9954714 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Details 40 false false R41.htm 9954715 - Disclosure - Supplemental Financial Information - Investments (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails Supplemental Financial Information - Investments (Details) Details 41 false false R42.htm 9954716 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails Changes In Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables 42 false false R43.htm 9954717 - Disclosure - Business Acquisition (Details) Sheet http://www.abbott.com/role/BusinessAcquisitionDetails Business Acquisition (Details) Details http://www.abbott.com/role/BusinessAcquisition 43 false false R44.htm 9954718 - Disclosure - Goodwill and Intangible Assets (Details) Sheet http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails Goodwill and Intangible Assets (Details) Details http://www.abbott.com/role/GoodwillandIntangibleAssets 44 false false R45.htm 9954719 - Disclosure - Restructuring Plans - Narrative (Details) Sheet http://www.abbott.com/role/RestructuringPlansNarrativeDetails Restructuring Plans - Narrative (Details) Details 45 false false R46.htm 9954720 - Disclosure - Restructuring Plans - Restructuring Activity and Related Accruals (Details) Sheet http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails Restructuring Plans - Restructuring Activity and Related Accruals (Details) Details 46 false false R47.htm 9954721 - Disclosure - Incentive Stock Programs - Narrative (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails Incentive Stock Programs - Narrative (Details) Details 47 false false R48.htm 9954722 - Disclosure - Incentive Stock Programs - Options (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails Incentive Stock Programs - Options (Details) Details 48 false false R49.htm 9954723 - Disclosure - Debt and Lines of Credit (Details) Sheet http://www.abbott.com/role/DebtandLinesofCreditDetails Debt and Lines of Credit (Details) Details http://www.abbott.com/role/DebtandLinesofCredit 49 false false R50.htm 9954724 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) Details http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables 50 false false R51.htm 9954725 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) Details 51 false false R52.htm 9954726 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) Details 52 false false R53.htm 9954727 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Details 53 false false R54.htm 9954728 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Details 54 false false R55.htm 9954729 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/LitigationandEnvironmentalMatters 55 false false R56.htm 9954730 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) Details 56 false false R57.htm 9954731 - Disclosure - Post-Employment Benefits - Narrative (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails Post-Employment Benefits - Narrative (Details) Details 57 false false R58.htm 9954732 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/TaxesonEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/TaxesonEarnings 58 false false R59.htm 9954733 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/SegmentInformationTables 59 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: abt:MinimumLengthOfTimeHedgedInCashFlowHedge, ecd:TrdArrDuration - abt-20230630.htm 4 abt-20230630.htm abt-20230630.xsd abt-20230630_cal.xml abt-20230630_def.xml abt-20230630_lab.xml abt-20230630_pre.xml amendmentno1fiveyearcredit.htm q2202310qex311.htm q2202310qex312.htm q2202310qex321.htm q2202310qex322.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abt-20230630.htm": { "axisCustom": 0, "axisStandard": 26, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1042, "http://xbrl.sec.gov/dei/2023": 32, "http://xbrl.sec.gov/ecd/2023": 11 }, "contextCount": 470, "dts": { "calculationLink": { "local": [ "abt-20230630_cal.xml" ] }, "definitionLink": { "local": [ "abt-20230630_def.xml" ] }, "inline": { "local": [ "abt-20230630.htm" ] }, "labelLink": { "local": [ "abt-20230630_lab.xml" ] }, "presentationLink": { "local": [ "abt-20230630_pre.xml" ] }, "schema": { "local": [ "abt-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd" ] } }, "elementCount": 552, "entityCount": 1, "hidden": { "http://www.abbott.com/20230630": 1, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 1, "total": 7 }, "keyCustom": 19, "keyStandard": 254, "memberCustom": 36, "memberStandard": 43, "nsprefix": "abt", "nsuri": "http://www.abbott.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "10", "role": "http://www.abbott.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - New Accounting Standards", "menuCat": "Notes", "order": "11", "role": "http://www.abbott.com/role/NewAccountingStandards", "shortName": "New Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Revenue", "menuCat": "Notes", "order": "12", "role": "http://www.abbott.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Supplemental Financial Information", "menuCat": "Notes", "order": "13", "role": "http://www.abbott.com/role/SupplementalFinancialInformation", "shortName": "Supplemental Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss)", "menuCat": "Notes", "order": "14", "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Business Acquisition", "menuCat": "Notes", "order": "15", "role": "http://www.abbott.com/role/BusinessAcquisition", "shortName": "Business Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Goodwill and Intangible Assets", "menuCat": "Notes", "order": "16", "role": "http://www.abbott.com/role/GoodwillandIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Restructuring Plans", "menuCat": "Notes", "order": "17", "role": "http://www.abbott.com/role/RestructuringPlans", "shortName": "Restructuring Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Incentive Stock Programs", "menuCat": "Notes", "order": "18", "role": "http://www.abbott.com/role/IncentiveStockPrograms", "shortName": "Incentive Stock Programs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Debt and Lines of Credit", "menuCat": "Notes", "order": "19", "role": "http://www.abbott.com/role/DebtandLinesofCredit", "shortName": "Debt and Lines of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "shortName": "Condensed Consolidated Statement of Earnings (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures", "menuCat": "Notes", "order": "20", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures", "shortName": "Financial Instruments, Derivatives and Fair Value Measures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Litigation and Environmental Matters", "menuCat": "Notes", "order": "21", "role": "http://www.abbott.com/role/LitigationandEnvironmentalMatters", "shortName": "Litigation and Environmental Matters", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Post-Employment Benefits", "menuCat": "Notes", "order": "22", "role": "http://www.abbott.com/role/PostEmploymentBenefits", "shortName": "Post-Employment Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Taxes on Earnings", "menuCat": "Notes", "order": "23", "role": "http://www.abbott.com/role/TaxesonEarnings", "shortName": "Taxes on Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Segment Information", "menuCat": "Notes", "order": "24", "role": "http://www.abbott.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Notes", "order": "25", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "ecd:MtrlTermsOfTrdArrTextBlock", "span", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:NonRule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995445 - Disclosure - Insider Trading Arrangements", "menuCat": "Notes", "order": "26", "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "shortName": "Insider Trading Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ecd:MtrlTermsOfTrdArrTextBlock", "span", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:NonRule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - New Accounting Standards (Policies)", "menuCat": "Policies", "order": "27", "role": "http://www.abbott.com/role/NewAccountingStandardsPolicies", "shortName": "New Accounting Standards (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.abbott.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Supplemental Financial Information (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.abbott.com/role/SupplementalFinancialInformationTables", "shortName": "Supplemental Financial Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "menuCat": "Statements", "order": "3", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Restructuring Plans (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.abbott.com/role/RestructuringPlansTables", "shortName": "Restructuring Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Incentive Stock Programs (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.abbott.com/role/IncentiveStockProgramsTables", "shortName": "Incentive Stock Programs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables", "shortName": "Financial Instruments, Derivatives and Fair Value Measures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Post-Employment Benefits (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.abbott.com/role/PostEmploymentBenefitsTables", "shortName": "Post-Employment Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Segment Information (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.abbott.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Revenue - Narrative (Details)", "menuCat": "Details", "order": "36", "role": "http://www.abbott.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details)", "menuCat": "Details", "order": "37", "role": "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "shortName": "Revenue - Summary of Revenue by Sales Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-181", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details)", "menuCat": "Details", "order": "38", "role": "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails", "shortName": "Revenue - Schedule of Changes in Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Supplemental Financial Information - Narrative (Details)", "menuCat": "Details", "order": "39", "role": "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails", "shortName": "Supplemental Financial Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "menuCat": "Details", "order": "40", "role": "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails", "shortName": "Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Supplemental Financial Information - Investments (Details)", "menuCat": "Details", "order": "41", "role": "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "shortName": "Supplemental Financial Information - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-323", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details)", "menuCat": "Details", "order": "42", "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-326", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Business Acquisition (Details)", "menuCat": "Details", "order": "43", "role": "http://www.abbott.com/role/BusinessAcquisitionDetails", "shortName": "Business Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-356", "decimals": "INF", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Goodwill and Intangible Assets (Details)", "menuCat": "Details", "order": "44", "role": "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-363", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Restructuring Plans - Narrative (Details)", "menuCat": "Details", "order": "45", "role": "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "shortName": "Restructuring Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-363", "decimals": "-6", "lang": "en-US", "name": "us-gaap:TangibleAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-367", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Restructuring Plans - Restructuring Activity and Related Accruals (Details)", "menuCat": "Details", "order": "46", "role": "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails", "shortName": "Restructuring Plans - Restructuring Activity and Related Accruals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-367", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Incentive Stock Programs - Narrative (Details)", "menuCat": "Details", "order": "47", "role": "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "shortName": "Incentive Stock Programs - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-372", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Incentive Stock Programs - Options (Details)", "menuCat": "Details", "order": "48", "role": "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails", "shortName": "Incentive Stock Programs - Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-372", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-373", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - Debt and Lines of Credit (Details)", "menuCat": "Details", "order": "49", "role": "http://www.abbott.com/role/DebtandLinesofCreditDetails", "shortName": "Debt and Lines of Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-373", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "shortName": "Condensed Consolidated Balance Sheet (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details)", "menuCat": "Details", "order": "50", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtInstrumentTerm", "span", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-381", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details)", "menuCat": "Details", "order": "51", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-386", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-404", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details)", "menuCat": "Details", "order": "52", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-404", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954727 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "menuCat": "Details", "order": "53", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-428", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-441", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954728 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "menuCat": "Details", "order": "54", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-441", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954729 - Disclosure - Litigation and Environmental Matters (Details)", "menuCat": "Details", "order": "55", "role": "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "shortName": "Litigation and Environmental Matters (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-451", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954730 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details)", "menuCat": "Details", "order": "56", "role": "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "shortName": "Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-451", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-319", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954731 - Disclosure - Post-Employment Benefits - Narrative (Details)", "menuCat": "Details", "order": "57", "role": "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "shortName": "Post-Employment Benefits - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-455", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:ExcessTaxBenefitFromShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954732 - Disclosure - Taxes on Earnings (Details)", "menuCat": "Details", "order": "58", "role": "http://www.abbott.com/role/TaxesonEarningsDetails", "shortName": "Taxes on Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:ExcessTaxBenefitFromShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954733 - Disclosure - Segment Information (Details)", "menuCat": "Details", "order": "59", "role": "http://www.abbott.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-5", "decimals": "2", "lang": "en-US", "name": "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-4", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-9", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-8", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-9", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "9", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 79, "tag": { "abt_A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entity's 2022 and 2023 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses.", "label": "2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses [Member]", "terseLabel": "2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses" } } }, "localname": "A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "domainItemType" }, "abt_A255LongTermNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.55% Long-term Notes Due 2022", "label": "2.55% Long-term Notes Due 2022 [Member]", "terseLabel": "2.55% Long-term Notes Due 2022" } } }, "localname": "A255LongTermNotesDue2022Member", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "domainItemType" }, "abt_AdultNutritionalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the adult nutritionals, segment of the entity.", "label": "Adult Nutritionals [Member]", "terseLabel": "Adult Nutritionals" } } }, "localname": "AdultNutritionalsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_AndreaFWainerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Andrea F. Wainer", "label": "Andrea F. Wainer [Member]" } } }, "localname": "AndreaFWainerMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "abt_AndreaFWainerTradingArrangementCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Andrea F. Wainer Trading Arrangement, Common Stock", "label": "Andrea F. Wainer Trading Arrangement, Common Stock [Member]" } } }, "localname": "AndreaFWainerTradingArrangementCommonStockMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "abt_AndreaFWainerTradingArrangementStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Andrea F. Wainer Trading Arrangement, Stock Options", "label": "Andrea F. Wainer Trading Arrangement, Stock Options [Member]" } } }, "localname": "AndreaFWainerTradingArrangementStockOptionsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter.", "label": "Annual Share Based Awards Recognized in First Quarter Percent", "terseLabel": "Annual share-based awards recognized in first quarter (as a percent)" } } }, "localname": "AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "percentItemType" }, "abt_CardiovascularSystemsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardiovascular Systems, Inc.", "label": "Cardiovascular Systems, Inc. [Member]", "terseLabel": "CSI" } } }, "localname": "CardiovascularSystemsIncMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails", "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abt_ContractLiabilitiesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Liabilities", "label": "Contract Liabilities [Roll Forward]", "terseLabel": "Contract Liabilities:" } } }, "localname": "ContractLiabilitiesRollForward", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in cash received to be satisfied.", "label": "Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized", "terseLabel": "Unearned revenue from cash received during the period" } } }, "localname": "ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abt_CoreLaboratoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the core laboratory, segment of the entity.", "label": "Core Laboratory [Member]", "terseLabel": "Core Laboratory" } } }, "localname": "CoreLaboratoryMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_CorporateAndBenefitPlanCosts": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs.", "label": "Corporate and Benefit Plan Costs", "negatedLabel": "Corporate functions and benefit plan costs" } } }, "localname": "CorporateAndBenefitPlanCosts", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "abt_CostOfGoodsAndServicesSoldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of Goods and Services Sold", "label": "Cost of Goods and Services Sold [Member]", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSoldMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "abt_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included.", "label": "Deferred Income Taxes and Other Assets, Noncurrent [Member]", "terseLabel": "Deferred income taxes and other assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_DefinedBenefitPlanNetAmortizationCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Defined Benefit Plan Net Amortization Costs [Abstract]", "terseLabel": "Net amortization of:" } } }, "localname": "DefinedBenefitPlanNetAmortizationCostsAbstract", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "abt_DiabetesCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the Diabetes Care, segment of the entity.", "label": "Diabetes Care [Member]", "terseLabel": "Diabetes Care" } } }, "localname": "DiabetesCareMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_DiagnosticProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The diagnostics products segment of the entity.", "label": "Diagnostic Products [Member]", "terseLabel": "Diagnostics", "verboseLabel": "Diagnostic Products" } } }, "localname": "DiagnosticProductsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_EffectOfCommonAndTreasuryShareTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the effect on retained earning due to common and treasury stock transactions.", "label": "Effect of Common and Treasury Share Transactions", "negatedLabel": "Effect of common and treasury share transactions" } } }, "localname": "EffectOfCommonAndTreasuryShareTransactions", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_ElectrophysiologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the electrophysiology, segment of the entity.", "label": "Electrophysiology [Member]", "terseLabel": "Electrophysiology" } } }, "localname": "ElectrophysiologyMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_EstablishedPharmaceuticalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Established Pharmaceutical Products, segment of the entity.", "label": "Established Pharmaceutical Products [Member]", "terseLabel": "Established Pharmaceutical Products" } } }, "localname": "EstablishedPharmaceuticalProductsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_ExcessTaxBenefitFromShareBasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation", "terseLabel": "Excess tax benefits associated with share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensation", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "monetaryItemType" }, "abt_FiveYearTermLoanDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Year Term Loan due 2024", "label": "Five Year Term Loan due 2024 [Member]", "terseLabel": "Five Year Term Loan due 2024" } } }, "localname": "FiveYearTermLoanDue2024Member", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "abt_GoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets [Line Items]", "terseLabel": "Goodwill and Intangible Assets [Line Items]" } } }, "localname": "GoodwillAndIntangibleAssetsLineItems", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "abt_HeartFailureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the Heart Failure, segment of the entity.", "label": "Heart Failure [Member]", "terseLabel": "Heart Failure" } } }, "localname": "HeartFailureMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_KeyEmergingMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the key emerging markets, segment of the entity.", "label": "Key Emerging Markets [Member]", "terseLabel": "Key Emerging Markets" } } }, "localname": "KeyEmergingMarketsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_LegalProceedingsAndEnvironmentalExposuresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss contingencies related to legal proceedings and environmental exposures.", "label": "Legal proceedings and environmental exposures [Member]", "terseLabel": "Legal proceedings and environmental exposures" } } }, "localname": "LegalProceedingsAndEnvironmentalExposuresMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "abt_LongTermDebtExcludingCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Excluding Current Maturities", "label": "Long-Term Debt, Excluding Current Maturities [Member]", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtExcludingCurrentMaturitiesMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico.", "label": "Loss Contingency Range of Possible Loss, Maximum Aggregate Sites", "terseLabel": "Maximum expected cleanup exposure in aggregate" } } }, "localname": "LossContingencyRangeOfPossibleLossMaximumAggregateSites", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico.", "label": "Loss Contingency Range of Possible Loss, Maximum Individual Site", "terseLabel": "Maximum expected cleanup exposure for individual site" } } }, "localname": "LossContingencyRangeOfPossibleLossMaximumIndividualSite", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "abt_MedicalDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The medical devices segment of the entity.", "label": "Medical Devices [Member]", "terseLabel": "Medical Devices" } } }, "localname": "MedicalDevicesMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_MinimumLengthOfTimeHedgedInCashFlowHedge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Minimum Length Of Time Hedged In Cash Flow Hedge", "terseLabel": "Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold" } } }, "localname": "MinimumLengthOfTimeHedgedInCashFlowHedge", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "durationItemType" }, "abt_MolecularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the molecular, segment of the entity.", "label": "Molecular [Member]", "terseLabel": "Molecular" } } }, "localname": "MolecularMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_NeuromodulationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the neuromodulation, segment of the entity.", "label": "Neuromodulation [Member]", "terseLabel": "Neuromodulation" } } }, "localname": "NeuromodulationMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations.", "label": "Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations", "terseLabel": "Noncontrolling Interests\u2019 share of income, business combinations, net of distributions and share repurchases" } } }, "localname": "NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_NutritionalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The nutritional products segment of the entity.", "label": "Nutritional Products [Member]", "terseLabel": "Nutritionals", "verboseLabel": "Nutritional Products" } } }, "localname": "NutritionalProductsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_OtherAccruedLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Accrued Liabilities, Current", "label": "Other Accrued Liabilities, Current [Member]", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrentMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_OtherComprehensiveIncomeLossFairValueHedgeGainLossReclassificationBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax", "label": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges" } } }, "localname": "OtherComprehensiveIncomeLossFairValueHedgeGainLossReclassificationBeforeTax", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "abt_OtherCostAndExpenseOperatingAndNonoperating": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses.", "label": "Other Cost and Expense, Operating and Nonoperating", "negatedLabel": "Other, net" } } }, "localname": "OtherCostAndExpenseOperatingAndNonoperating", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "abt_OtherEmergingMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Emerging Markets", "label": "Other Emerging Markets [Member]", "terseLabel": "Other" } } }, "localname": "OtherEmergingMarketsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets.", "label": "Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process", "negatedLabel": "Acquisitions of businesses and technologies, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_PediatricNutritionalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the pediatric nutritionals, segment of the entity.", "label": "Pediatric Nutritionals [Member]", "terseLabel": "Pediatric Nutritionals" } } }, "localname": "PediatricNutritionalsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_PointOfCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the point of care, segment of the entity.", "label": "Point of Care [Member]", "terseLabel": "Point of Care" } } }, "localname": "PointOfCareMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities", "verboseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities" } } }, "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities [Member]", "terseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities" } } }, "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_PrepaidExpenseAndOtherReceivables": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Receivables", "verboseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpenseAndOtherReceivables", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_PrepaidExpenseAndOtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Other Prepaid Expenses and Receivables line item in the statement of financial position in which the amounts are included.", "label": "Prepaid Expense and Other Receivables [Member]", "terseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpenseAndOtherReceivablesMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_PrepaidExpensesAndOtherReceivablesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses and Other Receivables, Current", "label": "Prepaid Expenses and Other Receivables, Current [Member]", "terseLabel": "Prepaid expenses and other receivables, current" } } }, "localname": "PrepaidExpensesAndOtherReceivablesCurrentMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_RapidDiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the rapid diagnostics, segment of the entity.", "label": "Rapid Diagnostics [Member]", "terseLabel": "Rapid Diagnostics" } } }, "localname": "RapidDiagnosticsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_RestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock awards.", "label": "Restricted stock awards [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockAwardsMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "abt_RestructuringReservePeriodCashSettledAndOtherAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.", "label": "Restructuring Reserve Period Cash Settled and Other Adjustments", "negatedTerseLabel": "Payments and other adjustments" } } }, "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of revenue recognized for remaining performance obligations.", "label": "Revenue Remaining Performance Obligation Expected Timing Percentage", "terseLabel": "Percentage of remaining performance obligation expected to be recognized in period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingPercentage", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "abt_RhythmManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the rhythm management, segment of the entity.", "label": "Rhythm Management [Member]", "terseLabel": "Rhythm Management" } } }, "localname": "RhythmManagementMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_ScheduleOfGoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Goodwill and Intangible Assets", "label": "Schedule of Goodwill and Intangible Assets [Table]", "terseLabel": "Schedule of Goodwill and Intangible Assets [Table]" } } }, "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "abt_ScheduleOfLongTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Schedule of Long Term Investments [Table Text Block]", "terseLabel": "Schedule of Long-term Investments" } } }, "localname": "ScheduleOfLongTermInvestmentsTableTextBlock", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "abt_StJudeMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to acquisition of St. Jude Medical, Inc.", "label": "St Jude Medical [Member]", "terseLabel": "St. Jude Medical" } } }, "localname": "StJudeMedicalMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Incentive Stock Programs", "label": "Stock Issued During Period, Shares, Incentive Stock Programs", "terseLabel": "Issued under incentive stock programs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIncentiveStockPrograms", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "abt_StockIssuedDuringPeriodValueIncentiveStockPrograms": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Incentive Stock Programs", "label": "Stock Issued During Period, Value, Incentive Stock Programs", "terseLabel": "Issued under incentive stock programs" } } }, "localname": "StockIssuedDuringPeriodValueIncentiveStockPrograms", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_StructuralHeartMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the structural heart, segment of the entity.", "label": "Structural Heart [Member]", "terseLabel": "Structural Heart" } } }, "localname": "StructuralHeartMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "abt_VascularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the vascular products, segment of the entity.", "label": "Vascular [Member]", "terseLabel": "Vascular" } } }, "localname": "VascularMember", "nsuri": "http://www.abbott.com/20230630", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document and Entity Information" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r858" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r897" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r822" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r859" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r830", "r841", "r851", "r876" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r833", "r844", "r854", "r879" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r872" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r837", "r845", "r855", "r872", "r880", "r884", "r892" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r890" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r887" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r888" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r886" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r885" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r884" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r884" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r863" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r869" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r868" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r870" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r866" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r830", "r841", "r851", "r876" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r827", "r838", "r848", "r873" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r872" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r834", "r845", "r855", "r880" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r834", "r845", "r855", "r880" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r834", "r845", "r855", "r880" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r834", "r845", "r855", "r880" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r834", "r845", "r855", "r880" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r837", "r845", "r855", "r872", "r880", "r884", "r892" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r890" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r826", "r896" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r826", "r896" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r826", "r896" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r891" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r834", "r845", "r855", "r872", "r880" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r862" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r861" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r872" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r891" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r891" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r832", "r843", "r853", "r878" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r835", "r846", "r856", "r881" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r835", "r846", "r856", "r881" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r860" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r863" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r863" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r862" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r872" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r861" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r860" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r860" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r827", "r838", "r848", "r873" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r828", "r839", "r849", "r874" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r829", "r840", "r850", "r875" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r836", "r847", "r857", "r882" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r891" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r891" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r831", "r842", "r852", "r877" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r871" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r863" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r870" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r890" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r892" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r894" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r892" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r892" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r895" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r889" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NYSE CHICAGO, INC. [Member]", "terseLabel": "CHICAGO STOCK EXCHANGE, INC" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2023", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "srt_CondensedCashFlowStatementTable": { "auth_ref": [ "r230", "r899" ], "lang": { "en-us": { "role": { "label": "Condensed Cash Flow Statement [Table]", "terseLabel": "Condensed Cash Flow Statement [Table]" } } }, "localname": "CondensedCashFlowStatementTable", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "auth_ref": [ "r230", "r899" ], "lang": { "en-us": { "role": { "label": "Condensed Cash Flow Statements, Captions [Line Items]", "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]" } } }, "localname": "CondensedCashFlowStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r230", "r273", "r284", "r285", "r286", "r287", "r288", "r290", "r294", "r354", "r355", "r356", "r357", "r359", "r360", "r362", "r364", "r365", "r929", "r930" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r230", "r273", "r284", "r285", "r286", "r287", "r288", "r290", "r294", "r354", "r355", "r356", "r357", "r359", "r360", "r362", "r364", "r365", "r929", "r930" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r348", "r349", "r350", "r351", "r478", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r931", "r944", "r945", "r946", "r947", "r948", "r949" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r348", "r349", "r350", "r351", "r478", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r931", "r944", "r945", "r946", "r947", "r948", "r949" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r348", "r349", "r350", "r351", "r438", "r478", "r507", "r508", "r509", "r603", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r808", "r925", "r931", "r945", "r946", "r947", "r948", "r949" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r348", "r349", "r350", "r351", "r438", "r478", "r507", "r508", "r509", "r603", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r808", "r925", "r931", "r945", "r946", "r947", "r948", "r949" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r182", "r231", "r232", "r233", "r236", "r237", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r265", "r310", "r311", "r527", "r559", "r561", "r562", "r563", "r594", "r597", "r598", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r182", "r231", "r232", "r233", "r236", "r237", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r265", "r310", "r311", "r527", "r559", "r561", "r562", "r563", "r594", "r597", "r598", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Reclassification, Adjustment" } } }, "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r298", "r299", "r668", "r672", "r674", "r735", "r737", "r742", "r752", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r772", "r791", "r808", "r933", "r953" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r298", "r299", "r668", "r672", "r674", "r735", "r737", "r742", "r752", "r758", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r772", "r791", "r808", "r933", "r953" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Changes in accumulated other comprehensive income (loss), net of income taxes" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r33", "r34" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r920" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Summary of Allowance for Doubtful Accounts Activity" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r301", "r302" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Trade receivables, less allowances of $485 in 2023 and $500 in 2022" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r117", "r162" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r7", "r20", "r44", "r905", "r906", "r907" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Net Actuarial (Losses) and Prior Service (Costs) and Credits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r61", "r192", "r624" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r209", "r217", "r218", "r541", "r780", "r905" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r8", "r44", "r934" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Net actuarial (losses) and prior service (costs) and credits" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r204", "r206", "r208", "r209", "r576" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Cumulative foreign currency translation (loss) adjustments" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r216", "r217", "r586", "r587", "r588", "r589", "r590", "r591" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r43", "r44", "r126", "r199", "r620", "r649", "r653" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "totalLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r216", "r217", "r586", "r587", "r588", "r589", "r590", "r591" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r5", "r20", "r44", "r552", "r555", "r598", "r644", "r645", "r905", "r906", "r907", "r913", "r914", "r915" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r6", "r20", "r44", "r217", "r218", "r587", "r588", "r589", "r590", "r591", "r905" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Cumulative Foreign Currency Translation (Loss) Adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental Financial Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities \u2014" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r511", "r519" ], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "negatedLabel": "Share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r200", "r303", "r313", "r314", "r317", "r952" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r200", "r303", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Trade receivables, allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedLabel": "Amounts charged off and other deductions" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r14", "r57", "r59" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of intangible assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Outstanding Common Stock Options Having No Dilutive Effect (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r206" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "verboseLabel": "Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r160", "r195", "r228", "r271", "r286", "r292", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r539", "r542", "r578", "r616", "r701", "r804", "r821", "r929", "r930", "r942" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r187", "r202", "r228", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r539", "r542", "r578", "r804", "r929", "r930", "r942" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r104" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets, at Fair Value" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r91", "r96" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r536", "r796", "r799" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails", "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r76", "r77", "r536", "r796", "r799" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails", "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Acquisition share price (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r1", "r2", "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Acquisition purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r3", "r80", "r538" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration related to business combinations" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r156", "r537" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Net deferred tax assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "In-process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r78", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Developed technology intangible asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r49", "r189", "r773" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r49", "r136", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "periodStartLabel": "Cash and Cash Equivalents, Beginning of Year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r4", "r136" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r111", "r617", "r688" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r147", "r345", "r346", "r759", "r926" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Litigation and Environmental Matters" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared on common shares (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r806", "r807", "r808", "r810", "r811", "r812", "r815", "r913", "r914", "r937", "r954", "r956" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r119", "r689" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesHeldInEmployeeTrust": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.", "label": "Common Stock, Shares Held in Employee Trust", "terseLabel": "Securities in mutual funds held in a rabbi trust" } } }, "localname": "CommonStockSharesHeldInEmployeeTrust", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r119", "r689", "r707", "r956", "r957" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r119", "r619", "r804" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common shares, without par value Authorized \u2014 2,400,000,000 shares Issued at stated capital amount \u2014 Shares: 2023: 1,987,181,491; 2022: 1,986,519,278" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r213", "r215", "r221", "r612", "r629" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r125", "r220", "r611", "r628" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Changes In Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r932" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Changes in Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r397", "r398", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedTerseLabel": "Revenue recognized related to contract liability balance" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r27", "r285", "r286", "r287", "r288", "r294", "r917" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r130", "r605" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold, excluding amortization of intangible assets" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r129" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating cost and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r148", "r227", "r367", "r373", "r374", "r375", "r376", "r377", "r378", "r383", "r390", "r391", "r393" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Lines of Credit" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r32", "r116", "r117", "r161", "r163", "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r593", "r785", "r786", "r787", "r788", "r789", "r911" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r37", "r369" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r392", "r593", "r785", "r786", "r787", "r788", "r789", "r911" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r38", "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r593", "r785", "r786", "r787", "r788", "r789", "r911" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r38", "r64", "r65", "r107", "r108", "r110", "r112", "r149", "r150", "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r392", "r593", "r785", "r786", "r787", "r788", "r789", "r911" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "Debt [Member]", "terseLabel": "Debt" } } }, "localname": "DebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease reasonably possible in gross unrecognized tax benefits" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Deferred income taxes and other assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r416", "r453", "r469", "r794", "r795" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Actuarial loss, net" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r416", "r454", "r470", "r794", "r795" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "verboseLabel": "Prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r431", "r440", "r473", "r792", "r793", "r794", "r795" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Company contributions", "verboseLabel": "Pension contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r416", "r452", "r468", "r794", "r795" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r416", "r420", "r451", "r467", "r794", "r795" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost on projected benefit obligations" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r449", "r465", "r794", "r795" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net cost (credit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r415", "r456", "r472" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedTerseLabel": "Curtailment gain" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r418", "r450", "r466", "r794", "r795" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost - benefits earned during the period" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r14", "r60" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r676", "r679", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r717", "r718", "r719", "r720", "r723", "r724", "r725", "r726", "r743", "r744", "r747", "r748", "r806", "r808" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r29", "r94", "r124", "r203", "r779" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Fair Value - Assets", "verboseLabel": "Receivable position" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r29", "r94", "r124", "r203", "r779" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "negatedTerseLabel": "(Payable) position", "terseLabel": "Fair Value - Liabilities", "verboseLabel": "Yen-denominated term loan" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r92", "r95", "r97", "r99", "r676", "r679", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r717", "r718", "r719", "r720", "r723", "r724", "r725", "r726", "r743", "r744", "r747", "r748", "r779", "r806", "r808" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r159", "r549", "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Financial Instruments, Derivatives and Fair Value Measures" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r22", "r92", "r97" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r22", "r92", "r97", "r99", "r102", "r103", "r547" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r98", "r901" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Gain (loss) from foreign currency forward exchange contracts not designated as hedges" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r935", "r936" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r22", "r84", "r85", "r86", "r90", "r93", "r97", "r100", "r101", "r103", "r558" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r933" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Revenue by Sales Category" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r480", "r484", "r512", "r513", "r515", "r803" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Incentive Stock Programs" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockPrograms" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]", "terseLabel": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common shares" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r222", "r240", "r241", "r243", "r244", "r246", "r252", "r255", "r261", "r262", "r263", "r265", "r562", "r563", "r613", "r630", "r781" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic Earnings Per Common Share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r222", "r240", "r241", "r243", "r244", "r246", "r255", "r261", "r262", "r263", "r265", "r562", "r563", "r613", "r630", "r781" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted Earnings Per Common Share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r939" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Salaries, wages and commissions" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Total unrecognized compensation cost, recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r21", "r181", "r216", "r217", "r218", "r231", "r232", "r233", "r237", "r247", "r249", "r266", "r307", "r312", "r396", "r516", "r517", "r518", "r526", "r527", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r586", "r587", "r588", "r589", "r590", "r591", "r598", "r644", "r645", "r646", "r664", "r730" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r281", "r305", "r903", "r918" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments carrying value" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r196", "r574", "r775" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r54", "r816", "r817", "r818", "r959" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investment without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r381", "r577", "r786", "r787" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r568", "r569", "r572" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r568", "r569", "r572" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r104", "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Carrying Values and Fair Values of Financial Instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r381", "r440", "r441", "r442", "r443", "r444", "r445", "r569", "r600", "r601", "r602", "r786", "r787", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r30", "r104", "r381", "r786", "r787" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r568", "r569", "r570", "r571", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r381", "r786", "r787" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r381", "r440", "r445", "r569", "r600", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r381", "r440", "r445", "r569", "r601", "r786", "r787", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r381", "r440", "r441", "r442", "r443", "r444", "r445", "r569", "r602", "r786", "r787", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r381", "r440", "r441", "r442", "r443", "r444", "r445", "r600", "r601", "r602", "r786", "r787", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r567", "r573" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Outstanding Balances" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r194", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Estimated annual amortization expense, intangible assets, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Estimated annual amortization expense, intangible assets, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Estimated annual amortization expense, intangible assets, 2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Estimated annual amortization expense, intangible assets, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Estimated annual amortization expense, intangible assets, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Increase in intangible assets due to foreign currency translation adjustments" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r142", "r609" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross amount of amortizable intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Increase in amortizable intangible assets due to acquisition" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "verboseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "verboseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r582", "r583", "r584", "r585", "r727" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "negatedLabel": "Net foreign exchange (gain) loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [ "r695", "r699", "r704", "r719", "r725", "r745", "r746", "r747", "r808" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r193", "r318", "r610", "r784", "r804", "r922", "r923" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails", "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Increase in goodwill due to foreign currency translation adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r14", "r319", "r325", "r329", "r784" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Amount of reductions of goodwill relating to impairments" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r921" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Increase in goodwill due to acquisition" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r548" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Fair value of hedged long-term debt" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r22", "r547" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r910", "r924" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment of indefinite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r127", "r168", "r271", "r285", "r291", "r294", "r614", "r626", "r782" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r331", "r337", "r713" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r337", "r713" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r229", "r521", "r523", "r524", "r525", "r531", "r533", "r534", "r535", "r661" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Earnings" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/TaxesonEarnings" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r172", "r178", "r248", "r249", "r279", "r522", "r532", "r631" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on earnings" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r13" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r13" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r13" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Investment" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r256", "r257", "r258", "r263", "r483" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive Common Stock Options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets related to in-process R&D acquired in a business combination" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Increase in in-process R&D due to acquisition" } } }, "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r56", "r58" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net of amortization" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r109", "r171", "r219", "r275", "r592", "r714", "r819", "r955" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r170" ], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Net interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Interest rate swap derivative financial instruments" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r771", "r813", "r814" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r140", "r776" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r201", "r774", "r804" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r140", "r778" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRecallExpense": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.", "label": "Inventory Recall Expense", "terseLabel": "Inventory recall expense" } } }, "localname": "InventoryRecallExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r140", "r777" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r133", "r274" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest (income)" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r667", "r669", "r670", "r673", "r677", "r733", "r735", "r737", "r741", "r742", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r808" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r667", "r669", "r670", "r673", "r677", "r733", "r735", "r737", "r741", "r742", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r808" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r123", "r165", "r623", "r804", "r912", "r919", "r938" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders' Investment" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Investment" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36", "r188", "r228", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r540", "r542", "r543", "r578", "r804", "r929", "r942", "r943" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r104" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities, at Fair Value" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r32", "r163", "r380", "r394", "r786", "r787", "r951" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "negatedTerseLabel": "Total Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r197" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r198" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r190" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-Term Investments", "terseLabel": "Investments", "verboseLabel": "Long-term Investment Securities:" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r347", "r348", "r349", "r353", "r927", "r928" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [ "r347", "r348", "r349", "r353", "r927", "r928" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r347", "r348", "r349", "r353", "r927", "r928" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r347", "r898" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Recorded accrual balance for legal proceedings and exposures" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r348", "r349", "r352", "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Estimation of possible loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r347", "r348", "r349", "r353", "r927", "r928" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "terseLabel": "Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold" } } }, "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r42", "r164", "r228", "r306", "r354", "r357", "r358", "r359", "r365", "r366", "r578", "r622", "r691" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.", "label": "Equity, Attributable to Noncontrolling Interest", "verboseLabel": "Noncontrolling Interests in Subsidiaries" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "Allowance for Doubtful Accounts:" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r225" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash From (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r225" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash From (Used in) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r136", "r137", "r138" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r128", "r138", "r169", "r186", "r211", "r214", "r218", "r228", "r236", "r240", "r241", "r243", "r244", "r248", "r249", "r259", "r271", "r285", "r291", "r294", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r563", "r578", "r627", "r709", "r728", "r729", "r782", "r819", "r929" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net earnings", "totalLabel": "Net Earnings", "verboseLabel": "Net Earnings" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r224", "r240", "r241", "r243", "r244", "r252", "r253", "r260", "r263", "r271", "r285", "r291", "r294", "r782" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net earnings allocated to common shares" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r176", "r177", "r179", "r183", "r234", "r235", "r238", "r239", "r250", "r251", "r308", "r309", "r528", "r529", "r530", "r556", "r560", "r564", "r565", "r566", "r579", "r580", "r581", "r595", "r596", "r599", "r606", "r607", "r608", "r648", "r649", "r650", "r651", "r653" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/NewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/NewAccountingStandardsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [ "r958", "r960", "r961", "r962" ], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r81", "r396", "r913", "r914", "r915", "r956" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests in Subsidiaries" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r916" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r271", "r285", "r291", "r294", "r782" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Earnings", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r294" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r114", "r157", "r654", "r655" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAggregatedInvestmentsMember": { "auth_ref": [ "r669", "r670", "r740" ], "lang": { "en-us": { "role": { "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.", "label": "Other Security Investments [Member]", "terseLabel": "Other" } } }, "localname": "OtherAggregatedInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r8", "r19", "r126", "r158" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(3) and $(3) in 2023 and $12 and $25 in 2022" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r11", "r19", "r158" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation gain (loss) adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r31", "r44", "r217", "r586", "r588", "r591", "r905" ], "calculation": { "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r206" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $4 and $(54) in 2023 and $61 and $46 in 2022" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r205", "r206", "r544", "r545", "r550" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r175", "r206", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r546" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r11", "r19", "r158", "r212", "r215" ], "calculation": { "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r8", "r9", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "terseLabel": "Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "verboseLabel": "Other" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r134" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r794", "r795", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Medical and Dental Plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForOtherTaxes": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for taxes classified as other.", "label": "Payments for Other Taxes", "terseLabel": "Payment of cash taxes" } } }, "localname": "PaymentsForOtherTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Payments for (Proceeds from) Investments", "negatedLabel": "Sales (purchases) of other investment securities, net" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r900", "r908" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r47" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of common shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r47" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r135" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r479", "r794", "r795", "r799", "r800", "r801" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Defined Benefit Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Postemployment Benefits [Abstract]", "terseLabel": "Postemployment Benefits [Abstract]" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "auth_ref": [ "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.", "label": "Postemployment Benefits Disclosure [Text Block]", "terseLabel": "Post-Employment Benefits" } } }, "localname": "PostemploymentBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r118", "r395" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred shares, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r118", "r689" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r118", "r395" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred shares, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r118", "r618", "r804" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred shares, one dollar par value Authorized \u2014 1,000,000 shares, none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r46", "r658" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-Term Debt", "verboseLabel": "Net borrowings (repayments) of short-term debt and other" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r900" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "terseLabel": "Proceeds from business dispositions" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r10", "r26" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r145", "r191", "r625" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r615", "r625", "r804" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r223", "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provisions/charges to income" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r31", "r44", "r217", "r586", "r590", "r591", "r905" ], "calculation": { "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Amounts reclassified from accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r909" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "Repayments of Debt", "verboseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r48", "r659" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r113", "r520", "r950" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r333", "r334", "r336", "r339", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Plans" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [ "r335", "r336", "r337", "r338", "r341", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r336", "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Accrued balance at end of the period", "periodStartLabel": "Accrued balance at beginning of the period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r120", "r151", "r621", "r648", "r653", "r660", "r690", "r804" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Earnings employed in the business" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r181", "r231", "r232", "r233", "r237", "r247", "r249", "r307", "r312", "r516", "r517", "r518", "r526", "r527", "r551", "r553", "r554", "r557", "r561", "r644", "r646", "r664", "r956" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Earnings Employed in the Business" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r272", "r273", "r284", "r289", "r290", "r296", "r298", "r300", "r407", "r408", "r605" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net Sales to External Customers" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r180", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r411" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Expected timing of satisfaction period (in months)" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r44", "r940", "r941" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r76", "r77", "r536" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r16", "r68", "r69", "r70", "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r92", "r97", "r547" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivatives Gain (Loss) in OCI and Income (Expense)" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Amounts and Location of Derivative Financial Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Periodic Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r335", "r336", "r337", "r338", "r341", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Restructuring Activity and Related Accruals" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r50", "r51", "r52", "r55" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r50", "r51", "r52", "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r481", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r24", "r25", "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Options Outstanding and Exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r268", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r300", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r338", "r343", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r784", "r902", "r953" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r283", "r288", "r292", "r293", "r294", "r295", "r296", "r297", "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r132" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Restructuring charges in 2023", "verboseLabel": "Restructuring charges" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r13" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock awards granted during the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r481", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Restricted stock units granted during period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Incentive stock program, shares reserved for future grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable options, number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable options, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock options granted during the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "Stock options outstanding, number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Stock options outstanding, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value of options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable options, weighted-average remaining life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options outstanding, weighted-average remaining life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r166", "r167", "r904" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r185", "r268", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r300", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r332", "r338", "r343", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r784", "r902", "r953" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r40", "r181", "r216", "r217", "r218", "r231", "r232", "r233", "r237", "r247", "r249", "r266", "r307", "r312", "r396", "r516", "r517", "r518", "r526", "r527", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r586", "r587", "r588", "r589", "r590", "r591", "r598", "r644", "r645", "r646", "r664", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r231", "r232", "r233", "r266", "r605", "r657", "r665", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r706", "r708", "r711", "r712", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r730", "r809" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r231", "r232", "r233", "r266", "r605", "r657", "r665", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r706", "r708", "r711", "r712", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r730", "r809" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r21", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r74", "r118", "r119", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r119", "r121", "r122", "r139", "r691", "r707", "r731", "r732", "r804", "r821", "r912", "r919", "r938", "r956" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "End of the period", "periodStartLabel": "Beginning of the period", "totalLabel": "Total Abbott Shareholders\u2019 Investment" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r81", "r82", "r83", "r181", "r182", "r217", "r231", "r232", "r233", "r237", "r247", "r307", "r312", "r396", "r516", "r517", "r518", "r526", "r527", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r586", "r587", "r591", "r598", "r645", "r646", "r663", "r691", "r707", "r731", "r732", "r757", "r820", "r912", "r919", "r938", "r956" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Shareholders\u2019 Investment" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 Investment:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "auth_ref": [ "r662", "r666", "r667", "r668", "r669", "r670", "r671", "r673", "r674", "r675", "r676", "r677", "r680", "r681", "r710", "r808" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary of Investment Holdings [Line Items]", "terseLabel": "Summary of Investment Holdings [Line Items]" } } }, "localname": "SummaryOfInvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "auth_ref": [ "r662", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r680", "r681", "r710", "r808" ], "lang": { "en-us": { "role": { "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period.", "label": "Summary of Investment Holdings [Table]", "terseLabel": "Summary of Investment Holdings [Table]" } } }, "localname": "SummaryOfInvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r115", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Fixed asset impairment charges" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r154", "r155" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "Tax expense from prior year tax positions" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Common Shares Held in Treasury" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Ending balance, treasury stock, common (in shares)", "periodStartLabel": "Beginning balance, treasury stock, common (in shares)", "terseLabel": "Common shares held in treasury (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r41", "r66", "r67" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Common shares held in treasury, at cost \u2014 Shares: 2023: 251,823,511; 2022: 248,724,257" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r21", "r119", "r151" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r21", "r66", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r254", "r263" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r252", "r263" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org//220/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org//350/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org//815/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org//420/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org//712/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "712", "URI": "https://asc.fasb.org//1943274/2147481565/712-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column G))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column I))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column K))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(g)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(g)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r822": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r823": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r824": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r825": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r826": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r827": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r828": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r829": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r831": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r832": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r833": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r834": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r835": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r836": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r837": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r838": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r839": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r841": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r842": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r843": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r844": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r845": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r846": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r847": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r848": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r849": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r851": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r852": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r853": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r854": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r855": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r856": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r857": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r858": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r859": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r861": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r862": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r863": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r864": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r865": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r866": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r867": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r868": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r869": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r871": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r872": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r873": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r874": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r875": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r876": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r877": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r878": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r879": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r881": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r882": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r883": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r884": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r885": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r886": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r887": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r888": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r889": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r891": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r892": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r893": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r894": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r895": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r896": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r897": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 79 0001628280-23-027203-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-027203-xbrl.zip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�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�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

<']DPD?VD*V %=INZE ![EB%, MVU)2PX<@CT$N:.F\%>QOP%D=Z")S_E@^,YVE@V,YE)T^S!;TEMMX!F>K#*H4 MT:L&G %(E(L9 *\N/BS2!@#8J7AZN*$)B*P& 2%@T!Q/]7KAG$IZ^*B$G-R? M'@B>1[/ FEWJ4X[S3"5#/J>X/:?F)F^RE7, W=9:)1&F$].J%.74^^)B1;FM^"A\!_B3:]6WT@XL80?8/VBI3"&[__?CS7PW8U*I2V"GT+#DM^01)#"%E9AQA:R-NG-0@7Q423BP\4-23B38< M;MSN7:/>1AXW _J H W^V0.TY?T)X[PTP\0.$J0:X=8N=C 3]L[ 1+!^AEO( M+N(S4[+SVC!)7?]YPY!1F?=<(6.3(;)W$]XLT[EUZ'0NS%3D95BS/3T]Q;BR M:#)$TTWD/9G:)G:,FH@Y"+V94DHZ*?+IE N%R[Q>V3;ZW.U"ZRY&'!=^X8Z8 MV$,QF\/$0V\K:!(Y[V.5J@?7CK3ID@G! M(W9R[8YXKJL&M9W[_+OFWW\ZQ/S[+6T06N3SBVS^"8,DJ<9'RN7@6Q*2ABV> MY^5;!*!"-D?-J/M&L1^&?YP^C;T0193+R%@?R1LRNX,6>D6(XL%KK>&BS/NE M;DG\?/8&EAOSYEOZ0*QE7'OY\6[57B"?0OVEU[WO< ^@">-A%W3JM06M;US! MD.B-,S38+85KT2??&#Q\3>P@]!U!QR:^(R%P;+4=P;CMW@5* @>(K(00M'C: M';Q-!NB>NBKS^60%L?2YN_@IG ] YX,^,,A_9H!RF+FSQGFB52,9;O:I849 M#\F]T*E$[,R5P4X+^WH"Y/-&] MRXZ_K&='%XSN4P\R4;Q*\3>NHS MU@0Z=R'-PJ23>$[V??IKVD'%E7-<)5Z4;*Q<]U<1>NJ[@/X/8BB>07@ MQU07;6P3POZ#%0"Y'5S -$MI'P!9)65E 'D=_+N5%\=->DR8/S ;4TPEU38 MO\@ N5C)F48(9 O5#L[;\=SX+OE2R#J[&]8+OP4IU+\T;0N\?KDB8P=8Z<@. MU,%X>K<=E3%"/?74J8%L(YS(N5>D*) >6407HODNE&W[?A3SZ4V+& M5;X:88MI1&W4;&8/$"/=2!> /W5[,PQCAR_K$Y*(N%SXVSU3^"1NA'DM#5

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end